US20190290617A1 - Novel use of sesquiterpene derivative - Google Patents
Novel use of sesquiterpene derivative Download PDFInfo
- Publication number
- US20190290617A1 US20190290617A1 US16/301,583 US201616301583A US2019290617A1 US 20190290617 A1 US20190290617 A1 US 20190290617A1 US 201616301583 A US201616301583 A US 201616301583A US 2019290617 A1 US2019290617 A1 US 2019290617A1
- Authority
- US
- United States
- Prior art keywords
- bond
- methyl
- compound
- preparation example
- trimethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229930004725 sesquiterpene Natural products 0.000 title abstract description 25
- 150000004354 sesquiterpene derivatives Chemical class 0.000 title abstract description 25
- 150000001875 compounds Chemical class 0.000 claims abstract description 172
- 239000000203 mixture Substances 0.000 claims abstract description 40
- 239000000126 substance Substances 0.000 claims abstract description 38
- 230000002792 vascular Effects 0.000 claims abstract description 35
- 201000010230 macular retinal edema Diseases 0.000 claims abstract description 34
- 208000001344 Macular Edema Diseases 0.000 claims abstract description 33
- 206010025415 Macular oedema Diseases 0.000 claims abstract description 33
- 208000002780 macular degeneration Diseases 0.000 claims abstract description 26
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 110
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 230000002401 inhibitory effect Effects 0.000 claims description 19
- 125000000524 functional group Chemical group 0.000 claims description 17
- -1 ethoxy, methoxy Chemical group 0.000 claims description 13
- 125000005605 benzo group Chemical group 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 9
- KHYSBNREYPBDKG-KKPDNJFZSA-N 3-[[(1S,2R,4aR,8aR)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-5-ethoxy-2-hydroxycyclohexa-2,5-diene-1,4-dione Chemical compound C[C@@]1([C@@H](CC[C@]2(C(CCC[C@H]12)=C)C)C)CC1=C(C(C=C(C1=O)OCC)=O)O KHYSBNREYPBDKG-KKPDNJFZSA-N 0.000 claims description 6
- OIQROOMINSFFMF-JEDUBMGFSA-N 3-[[(1r,2s,4as,8as)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2h-naphthalen-1-yl]methyl]-4-hydroxy-5-(2-phenylethylamino)cyclohexa-3,5-diene-1,2-dione Chemical compound C([C@@]1(C)[C@H]2[C@](C(CCC2)=C)(C)CC[C@@H]1C)C(C(C(=O)C=1)=O)=C(O)C=1NCCC1=CC=CC=C1 OIQROOMINSFFMF-JEDUBMGFSA-N 0.000 claims description 6
- JJWITJNSXCXULM-YVUMSICPSA-N Ilimaquinone Chemical compound O=C1C(OC)=CC(=O)C(O)=C1C[C@@]1(C)[C@H](CCCC2=C)[C@]2(C)CC[C@@H]1C JJWITJNSXCXULM-YVUMSICPSA-N 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000003889 eye drop Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 229940126701 oral medication Drugs 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 9
- 238000007912 intraperitoneal administration Methods 0.000 abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 203
- 238000002360 preparation method Methods 0.000 description 202
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 90
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 66
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 48
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 45
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 44
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- 238000005160 1H NMR spectroscopy Methods 0.000 description 33
- 241000243142 Porifera Species 0.000 description 29
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 26
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 25
- 229910052799 carbon Inorganic materials 0.000 description 21
- 102000015735 Beta-catenin Human genes 0.000 description 20
- 108060000903 Beta-catenin Proteins 0.000 description 20
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 20
- 239000000284 extract Substances 0.000 description 20
- 239000007787 solid Substances 0.000 description 20
- 229910002651 NO3 Inorganic materials 0.000 description 19
- 235000019439 ethyl acetate Nutrition 0.000 description 19
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 18
- 239000000741 silica gel Substances 0.000 description 18
- 229910002027 silica gel Inorganic materials 0.000 description 18
- 239000011734 sodium Substances 0.000 description 18
- 238000004128 high performance liquid chromatography Methods 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- 102000013814 Wnt Human genes 0.000 description 15
- 108050003627 Wnt Proteins 0.000 description 15
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 14
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 14
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 13
- 230000037361 pathway Effects 0.000 description 13
- 238000000825 ultraviolet detection Methods 0.000 description 13
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- 239000003480 eluent Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 0 *c1(*)cCCC2([H])C(C)(C[3*])C(C)Ccc2-1[1*].C.C.C.C.C.C Chemical compound *c1(*)cCCC2([H])C(C)(C[3*])C(C)Ccc2-1[1*].C.C.C.C.C.C 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 9
- 239000012091 fetal bovine serum Substances 0.000 description 9
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 7
- 235000019253 formic acid Nutrition 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 238000012014 optical coherence tomography Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 210000001525 retina Anatomy 0.000 description 6
- 238000004809 thin layer chromatography Methods 0.000 description 6
- UAKYMONZPZNHHU-UHFFFAOYSA-N CC(C)(C)NC(CO)C(=O)O.CC(C)CCNC(C)C.CC(C)CNC(C)C.CC(C)NCC(=O)O.CC(C)NCCC(=O)O.CC(C)NCCC1=CC=CC=C1.CC(C)NCCS(=O)(=O)O.CC(O)C(NC(C)(C)C)C(=O)O.CCC(C)CNC(C)C.[H]C(NC(C)(C)C)C(=O)O Chemical compound CC(C)(C)NC(CO)C(=O)O.CC(C)CCNC(C)C.CC(C)CNC(C)C.CC(C)NCC(=O)O.CC(C)NCCC(=O)O.CC(C)NCCC1=CC=CC=C1.CC(C)NCCS(=O)(=O)O.CC(O)C(NC(C)(C)C)C(=O)O.CCC(C)CNC(C)C.[H]C(NC(C)(C)C)C(=O)O UAKYMONZPZNHHU-UHFFFAOYSA-N 0.000 description 5
- 241000858091 Smenospongia Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 238000013534 fluorescein angiography Methods 0.000 description 5
- 238000002000 high resolution fast-atom bombardment mass spectrometry Methods 0.000 description 5
- 238000001819 mass spectrum Methods 0.000 description 5
- 239000000401 methanolic extract Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000004007 reversed phase HPLC Methods 0.000 description 5
- JSPUCPNQXKTYRO-LWILDLIXSA-N 2-[[(1r,2s,4as,8as)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]benzene-1,4-diol Chemical compound C([C@@]1(C)[C@H]2[C@](C(=CCC2)C)(C)CC[C@@H]1C)C1=CC(O)=CC=C1O JSPUCPNQXKTYRO-LWILDLIXSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 4
- OPDQOKREXYCJHD-YUMYIRISSA-N [(1r,4ar,5r,8ar)-4a-formyl-5-[2-(furan-3-yl)ethyl]-1-methyl-6-methylidene-3,4,5,7,8,8a-hexahydro-2h-naphthalen-1-yl]methyl acetate Chemical compound C([C@H]1[C@]2(C=O)CCC[C@@]([C@H]2CCC1=C)(C)COC(=O)C)CC=1C=COC=1 OPDQOKREXYCJHD-YUMYIRISSA-N 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000469 ethanolic extract Substances 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 230000002207 retinal effect Effects 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 238000003817 vacuum liquid chromatography Methods 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 241000098128 Dactylospongia elegans Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 241000264873 Spongiidae Species 0.000 description 3
- 229920002472 Starch Chemical class 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 229920002678 cellulose Chemical class 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 238000000451 chemical ionisation Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000003818 flash chromatography Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 210000002189 macula lutea Anatomy 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 229920001592 potato starch Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- LYXDEFOUSRLPID-PSPKEWGOSA-N (2S)-2-[[5-[[(1R,2S,4aS,8aS)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]-6-hydroxy-3,4-dioxocyclohexa-1,5-dien-1-yl]amino]-3-hydroxybutanoic acid Chemical compound CC(O)[C@H](NC1=CC(=O)C(=O)C(C[C@]2(C)[C@@H](C)CC[C@@]3(C)[C@H]2CCC=C3C)=C1O)C(O)=O LYXDEFOUSRLPID-PSPKEWGOSA-N 0.000 description 2
- VPRHEJGLNUDEEH-LWILDLIXSA-N 2-[[(1r,2s,4as,8as)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]cyclohexa-2,5-diene-1,4-dione Chemical compound C([C@@]1(C)[C@H]2[C@](C(=CCC2)C)(C)CC[C@@H]1C)C1=CC(=O)C=CC1=O VPRHEJGLNUDEEH-LWILDLIXSA-N 0.000 description 2
- LJQRQVMBMCUGBH-LAHPKLRZSA-N 2-[[5-[[(1r,2s,4as,8as)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2h-naphthalen-1-yl]methyl]-6-hydroxy-3,4-dioxocyclohexa-1,5-dien-1-yl]amino]acetic acid Chemical compound C([C@@]1(C)[C@H]2[C@](C(CCC2)=C)(C)CC[C@@H]1C)C1=C(O)C(NCC(O)=O)=CC(=O)C1=O LJQRQVMBMCUGBH-LAHPKLRZSA-N 0.000 description 2
- YXMANDRSLJYXOW-DWJYJAETSA-N 2-hydroxy-5-methoxy-3-[[(1r,2s)-1,2,5,5-tetramethyl-2,3,6,7,8,8a-hexahydronaphthalen-1-yl]methyl]cyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C(OC)=CC(=O)C(O)=C1C[C@@]1(C)C(CCCC2(C)C)C2=CC[C@@H]1C YXMANDRSLJYXOW-DWJYJAETSA-N 0.000 description 2
- XLTLVXMWNFXHCA-WAAJQORZSA-N 3-[[(1S,2R,4aR,8aR)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-2,5-dihydroxycyclohexa-2,5-diene-1,4-dione Chemical compound C[C@@]1([C@@H](CC[C@]2(C(CCC[C@H]12)=C)C)C)CC1=C(C(C=C(C1=O)O)=O)O XLTLVXMWNFXHCA-WAAJQORZSA-N 0.000 description 2
- LPRRMKKQWCVICH-CMEURUHUSA-N 3-[[(1r,2s,4as,8as)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]-4-hydroxy-5-(2-methylpropylamino)cyclohexa-3,5-diene-1,2-dione Chemical compound CC(C)CNC1=CC(=O)C(=O)C(C[C@@]2(C)[C@H]3[C@](C(=CCC3)C)(C)CC[C@@H]2C)=C1O LPRRMKKQWCVICH-CMEURUHUSA-N 0.000 description 2
- SCHSMVYQHXLOTA-JEDUBMGFSA-N 3-[[(1r,2s,4as,8as)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]-4-hydroxy-5-(2-phenylethylamino)cyclohexa-3,5-diene-1,2-dione Chemical compound C([C@@]1(C)[C@H]2[C@](C(=CCC2)C)(C)CC[C@@H]1C)C(C(C(=O)C=1)=O)=C(O)C=1NCCC1=CC=CC=C1 SCHSMVYQHXLOTA-JEDUBMGFSA-N 0.000 description 2
- OXKKAOLBCWPDIX-DVBYZVISSA-N 3-[[(1r,2s,4as,8as)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]-4-hydroxy-5-(3-methylbutylamino)cyclohexa-3,5-diene-1,2-dione Chemical compound CC(C)CCNC1=CC(=O)C(=O)C(C[C@@]2(C)[C@H]3[C@](C(=CCC3)C)(C)CC[C@@H]2C)=C1O OXKKAOLBCWPDIX-DVBYZVISSA-N 0.000 description 2
- GCPDAWCLXMGGSH-AZDFDGHFSA-N 3-[[(1r,2s,4as,8as)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]-4-hydroxy-5-[[(2s)-2-methylbutyl]amino]cyclohexa-3,5-diene-1,2-dione Chemical compound CC[C@H](C)CNC1=CC(=O)C(=O)C(C[C@@]2(C)[C@H]3[C@](C(=CCC3)C)(C)CC[C@@H]2C)=C1O GCPDAWCLXMGGSH-AZDFDGHFSA-N 0.000 description 2
- WKSGRDQDEVFYDC-AZDFDGHFSA-N 3-[[(1r,2s,4as,8as)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2h-naphthalen-1-yl]methyl]-4-hydroxy-5-[[(2s)-2-methylbutyl]amino]cyclohexa-3,5-diene-1,2-dione Chemical compound CC[C@H](C)CNC1=CC(=O)C(=O)C(C[C@@]2(C)[C@H]3[C@](C(CCC3)=C)(C)CC[C@@H]2C)=C1O WKSGRDQDEVFYDC-AZDFDGHFSA-N 0.000 description 2
- OBQPWRJUZHGREQ-NUATZEMDSA-N 3-[[(1r,2s,4as,8as)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2h-naphthalen-1-yl]methyl]-5-amino-4-hydroxycyclohexa-3,5-diene-1,2-dione Chemical compound C([C@@]1(C)[C@H]2[C@](C(CCC2)=C)(C)CC[C@@H]1C)C1=C(O)C(N)=CC(=O)C1=O OBQPWRJUZHGREQ-NUATZEMDSA-N 0.000 description 2
- MHCOGFNVFDFUND-VNHZXFAYSA-N 3-[[(1r,2s,8as)-1,2,5,5-tetramethyl-2,3,6,7,8,8a-hexahydronaphthalen-1-yl]methyl]-4-hydroxy-5-(2-phenylethylamino)cyclohexa-3,5-diene-1,2-dione Chemical compound C([C@@]1(C)[C@H]2C(C(CCC2)(C)C)=CC[C@@H]1C)C(C(C(=O)C=1)=O)=C(O)C=1NCCC1=CC=CC=C1 MHCOGFNVFDFUND-VNHZXFAYSA-N 0.000 description 2
- ARCBBPSWKXBVGD-ADLZZSLISA-N 3-[[(1r,2s,8as)-1,2,5,5-tetramethyl-2,3,6,7,8,8a-hexahydronaphthalen-1-yl]methyl]-4-hydroxy-5-(3-methylbutylamino)cyclohexa-3,5-diene-1,2-dione Chemical compound CC(C)CCNC1=CC(=O)C(=O)C(C[C@@]2(C)[C@H]3C(C(CCC3)(C)C)=CC[C@@H]2C)=C1O ARCBBPSWKXBVGD-ADLZZSLISA-N 0.000 description 2
- XRCZPUYFOQFUIV-IIKBXZHJSA-N 3-[[(1r,2s,8as)-1,2,5,5-tetramethyl-2,3,6,7,8,8a-hexahydronaphthalen-1-yl]methyl]-4-hydroxy-5-[[(2s)-2-methylbutyl]amino]cyclohexa-3,5-diene-1,2-dione Chemical compound CC[C@H](C)CNC1=CC(=O)C(=O)C(C[C@@]2(C)[C@H]3C(C(CCC3)(C)C)=CC[C@@H]2C)=C1O XRCZPUYFOQFUIV-IIKBXZHJSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000264878 Hippospongia Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 229910004878 Na2S2O4 Inorganic materials 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000035965 Postoperative Complications Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000858093 Smenospongia aurea Species 0.000 description 2
- QAIBXYQYLGUGJG-DVBYZVISSA-N Smenospongiarine Chemical compound CC(C)CCNC1=CC(=O)C(=O)C(C[C@@]2(C)[C@H]3[C@](C(CCC3)=C)(C)CC[C@@H]2C)=C1O QAIBXYQYLGUGJG-DVBYZVISSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 2
- 241000159836 Verongula rigida Species 0.000 description 2
- LBTUMRYFDFRELU-NDHSLDTFSA-N [7-[[(1r,2s,4as,8as)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2h-naphthalen-1-yl]methyl]-6-acetyloxy-1,3-benzoxazol-5-yl] acetate Chemical compound C([C@@]1(C)[C@H]2[C@](C(CCC2)=C)(C)CC[C@@H]1C)C1=C(OC(C)=O)C(OC(C)=O)=CC2=C1OC=N2 LBTUMRYFDFRELU-NDHSLDTFSA-N 0.000 description 2
- LKNAVZKSKJJHQH-UHFFFAOYSA-N [H]C12CCC=C(C)C1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(OC)C1=O Chemical compound [H]C12CCC=C(C)C1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(OC)C1=O LKNAVZKSKJJHQH-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000004155 blood-retinal barrier Anatomy 0.000 description 2
- 230000004378 blood-retinal barrier Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001913 cellulose Chemical class 0.000 description 2
- XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 238000005100 correlation spectroscopy Methods 0.000 description 2
- 239000006059 cover glass Substances 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- LKNAVZKSKJJHQH-YVUMSICPSA-N isospongiaquinone Chemical compound O=C1C(OC)=CC(=O)C(O)=C1C[C@@]1(C)[C@H](CCC=C2C)[C@]2(C)CC[C@@H]1C LKNAVZKSKJJHQH-YVUMSICPSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000013532 laser treatment Methods 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- FMHCCRKQMUIWGQ-KKPDNJFZSA-N methyl 3-[[(1S,2R,4aR,8aR)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-4,5-dihydroxybenzoate Chemical compound COC(=O)c1cc(O)c(O)c(C[C@@]2(C)[C@H](C)CC[C@]3(C)[C@@H]2CCCC3=C)c1 FMHCCRKQMUIWGQ-KKPDNJFZSA-N 0.000 description 2
- VXQUGYOYJDITTO-KNSMUJDWSA-N methyl 3-[[(1r,2s,4ar,8as)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]-4,5-dihydroxybenzoate Chemical compound COC(=O)C1=CC(O)=C(O)C(C[C@@]2(C)[C@H]3[C@@](C(=CCC3)C)(C)CC[C@@H]2C)=C1 VXQUGYOYJDITTO-KNSMUJDWSA-N 0.000 description 2
- WNSIKCDGFAFGBP-DQOBCGMHSA-N methyl 3-[[(1r,2s,4as,8as)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2h-naphthalen-1-yl]methyl]-4-hydroxybenzoate Chemical compound COC(=O)C1=CC=C(O)C(C[C@@]2(C)[C@H]3[C@](C(CCC3)=C)(C)CC[C@@H]2C)=C1 WNSIKCDGFAFGBP-DQOBCGMHSA-N 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000649 photocoagulation Effects 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 210000001210 retinal vessel Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000007940 sugar coated tablet Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229960004791 tropicamide Drugs 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- RIHVEJOGUIBAQW-IAOVCDLUSA-N (2s)-2-[[5-[[(1r,2s,4as,8as)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]-6-hydroxy-3,4-dioxocyclohexa-1,5-dien-1-yl]amino]-3-hydroxypropanoic acid Chemical compound C([C@@]1(C)[C@H]2[C@](C(=CCC2)C)(C)CC[C@@H]1C)C1=C(O)C(N[C@@H](CO)C(O)=O)=CC(=O)C1=O RIHVEJOGUIBAQW-IAOVCDLUSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- WOAHJDHKFWSLKE-UHFFFAOYSA-N 1,2-benzoquinone Chemical compound O=C1C=CC=CC1=O WOAHJDHKFWSLKE-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- SPXOTSHWBDUUMT-UHFFFAOYSA-N 138-42-1 Chemical compound OS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1 SPXOTSHWBDUUMT-UHFFFAOYSA-N 0.000 description 1
- WDMPTRNBGBEFTI-LAHPKLRZSA-N 2-[[5-[[(1r,2s,4as,8as)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]-6-hydroxy-3,4-dioxocyclohexa-1,5-dien-1-yl]amino]acetic acid Chemical compound C([C@@]1(C)[C@H]2[C@](C(=CCC2)C)(C)CC[C@@H]1C)C1=C(O)C(NCC(O)=O)=CC(=O)C1=O WDMPTRNBGBEFTI-LAHPKLRZSA-N 0.000 description 1
- FUQZXQOTZSUCHH-OVOQHVDUSA-N 2-[[5-[[(1r,2s,4as,8as)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]-6-hydroxy-3,4-dioxocyclohexa-1,5-dien-1-yl]amino]ethanesulfonic acid Chemical compound C([C@@]1(C)[C@H]2[C@](C(=CCC2)C)(C)CC[C@@H]1C)C1=C(O)C(NCCS(O)(=O)=O)=CC(=O)C1=O FUQZXQOTZSUCHH-OVOQHVDUSA-N 0.000 description 1
- BJPBLPIJEUNNFF-ZZWUPXSGSA-N 3-[[5-[[(1r,2s,4as,8as)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2h-naphthalen-1-yl]methyl]-6-hydroxy-3,4-dioxocyclohexa-1,5-dien-1-yl]amino]propanoic acid Chemical compound C([C@@]1(C)[C@H]2[C@](C(CCC2)=C)(C)CC[C@@H]1C)C1=C(O)C(NCCC(O)=O)=CC(=O)C1=O BJPBLPIJEUNNFF-ZZWUPXSGSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- LBTUMRYFDFRELU-UHFFFAOYSA-N C=C1CCCC2C1(C)CCC(C)C2(C)CC1=C2OC=NC2=CC(OC(C)=O)=C1OC(C)=O Chemical compound C=C1CCCC2C1(C)CCC(C)C2(C)CC1=C2OC=NC2=CC(OC(C)=O)=C1OC(C)=O LBTUMRYFDFRELU-UHFFFAOYSA-N 0.000 description 1
- BVOMWOZDWVPLIR-UHFFFAOYSA-N CC1=CCCC2C1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(NC(C(=O)O)C(C)O)C1=O Chemical compound CC1=CCCC2C1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(NC(C(=O)O)C(C)O)C1=O BVOMWOZDWVPLIR-UHFFFAOYSA-N 0.000 description 1
- HLNQVQCCJZHWEH-UHFFFAOYSA-N CC1C(C)(CC(C(C(OC=C)=CC2=O)=O)=C2O)C(CCCC2)C2(C)CC1 Chemical compound CC1C(C)(CC(C(C(OC=C)=CC2=O)=O)=C2O)C(CCCC2)C2(C)CC1 HLNQVQCCJZHWEH-UHFFFAOYSA-N 0.000 description 1
- KMLXOIVDKLSQRX-UHFFFAOYSA-N CC1CCC2(C)CCCCC2C1(C)CC1=C2OC=NC2=CC(O)=C1O Chemical compound CC1CCC2(C)CCCCC2C1(C)CC1=C2OC=NC2=CC(O)=C1O KMLXOIVDKLSQRX-UHFFFAOYSA-N 0.000 description 1
- KQSFBZYEQGEWJA-UHFFFAOYSA-N COC1=C(O)C(CC2(C)C(C)CCC3(C)CCCCC32)=C2OC(C)=NC2=C1 Chemical compound COC1=C(O)C(CC2(C)C(C)CCC3(C)CCCCC32)=C2OC(C)=NC2=C1 KQSFBZYEQGEWJA-UHFFFAOYSA-N 0.000 description 1
- WROHFWFSGGRCAI-UHFFFAOYSA-N COC1=CC2=NC(C)(C)OC2=C(CC2(C)C(C)CCC3(C)CCCCC32)C1=O Chemical compound COC1=CC2=NC(C)(C)OC2=C(CC2(C)C(C)CCC3(C)CCCCC32)C1=O WROHFWFSGGRCAI-UHFFFAOYSA-N 0.000 description 1
- PUDNSLDTUHTGSL-OYJHOXBRSA-N C[C@@]1([C@@H](CC[C@]2(C(CCC[C@H]12)=C)C)C)CC=1C(C(C=C(C=1O)NCC(C)C)=O)=O Chemical compound C[C@@]1([C@@H](CC[C@]2(C(CCC[C@H]12)=C)C)C)CC=1C(C(C=C(C=1O)NCC(C)C)=O)=O PUDNSLDTUHTGSL-OYJHOXBRSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010007764 Cataract subcapsular Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 241000098129 Dactylospongia Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 1
- 102100037985 Dickkopf-related protein 3 Human genes 0.000 description 1
- 101710099550 Dickkopf-related protein 3 Proteins 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 241001409301 Dysidea Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000498041 Hyrtios Species 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- VRCMSDQYPBPHCD-YVUMSICPSA-N Nakijinol B Chemical compound C([C@@]1(C)[C@H]2[C@](C(CCC2)=C)(C)CC[C@@H]1C)C1=C(O)C(O)=CC2=C1OC=N2 VRCMSDQYPBPHCD-YVUMSICPSA-N 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 201000010183 Papilledema Diseases 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 206010038886 Retinal oedema Diseases 0.000 description 1
- 241001554848 Rhopaloeides Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 241000520664 Spongia Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 241000218220 Ulmaceae Species 0.000 description 1
- 241000858089 Verongula Species 0.000 description 1
- 101150109862 WNT-5A gene Proteins 0.000 description 1
- 102000043366 Wnt-5a Human genes 0.000 description 1
- 108700020483 Wnt-5a Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- NKOAEUZQJPBJRM-UHFFFAOYSA-N [H]C12CCC=C(C)C1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(NC(CC)C(=O)O)C1=O Chemical compound [H]C12CCC=C(C)C1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(NC(CC)C(=O)O)C1=O NKOAEUZQJPBJRM-UHFFFAOYSA-N 0.000 description 1
- SCTQYYSQPUVRHV-UHFFFAOYSA-N [H]C12CCC=C(C)C1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(NCC(=O)O)C1=O Chemical compound [H]C12CCC=C(C)C1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(NCC(=O)O)C1=O SCTQYYSQPUVRHV-UHFFFAOYSA-N 0.000 description 1
- FNCUIBSVSDQFCR-UHFFFAOYSA-N [H]C12CCC=C(C)C1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(NCC(C)C)C1=O Chemical compound [H]C12CCC=C(C)C1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(NCC(C)C)C1=O FNCUIBSVSDQFCR-UHFFFAOYSA-N 0.000 description 1
- JCVDOCLIEFORNI-UHFFFAOYSA-N [H]C12CCC=C(C)C1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(NCC(C)CC)C1=O Chemical compound [H]C12CCC=C(C)C1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(NCC(C)CC)C1=O JCVDOCLIEFORNI-UHFFFAOYSA-N 0.000 description 1
- ACOQUBGHQYPJFN-UHFFFAOYSA-N [H]C12CCC=C(C)C1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(NCCC(C)C)C1=O Chemical compound [H]C12CCC=C(C)C1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(NCCC(C)C)C1=O ACOQUBGHQYPJFN-UHFFFAOYSA-N 0.000 description 1
- ZRZRJHAYWIOCML-UHFFFAOYSA-N [H]C12CCC=C(C)C1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(NCCC2=CC=CC=C2)C1=O Chemical compound [H]C12CCC=C(C)C1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(NCCC2=CC=CC=C2)C1=O ZRZRJHAYWIOCML-UHFFFAOYSA-N 0.000 description 1
- WNWNSFOUHRBTEF-UHFFFAOYSA-N [H]C12CCC=C(C)C1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(NCCS(C)(=O)=O)C1=O Chemical compound [H]C12CCC=C(C)C1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(NCCS(C)(=O)=O)C1=O WNWNSFOUHRBTEF-UHFFFAOYSA-N 0.000 description 1
- JSPUCPNQXKTYRO-UHFFFAOYSA-N [H]C12CCC=C(C)C1(C)CCC(C)C2(C)CC1=C(O)C=CC(O)=C1 Chemical compound [H]C12CCC=C(C)C1(C)CCC(C)C2(C)CC1=C(O)C=CC(O)=C1 JSPUCPNQXKTYRO-UHFFFAOYSA-N 0.000 description 1
- BVODNHRPVLAYDD-UHFFFAOYSA-N [H]C12CCC=C(C)C1(C)CCC(C)C2(C)CC1=C(OC)C=CC(CO)=C1 Chemical compound [H]C12CCC=C(C)C1(C)CCC(C)C2(C)CC1=C(OC)C=CC(CO)=C1 BVODNHRPVLAYDD-UHFFFAOYSA-N 0.000 description 1
- VPRHEJGLNUDEEH-UHFFFAOYSA-N [H]C12CCC=C(C)C1(C)CCC(C)C2(C)CC1=CC(=O)C=CC1=O Chemical compound [H]C12CCC=C(C)C1(C)CCC(C)C2(C)CC1=CC(=O)C=CC1=O VPRHEJGLNUDEEH-UHFFFAOYSA-N 0.000 description 1
- VXQUGYOYJDITTO-UHFFFAOYSA-N [H]C12CCC=C(C)C1(C)CCC(C)C2(C)CC1=CC(C(=O)OC)=CC(O)=C1O Chemical compound [H]C12CCC=C(C)C1(C)CCC(C)C2(C)CC1=CC(C(=O)OC)=CC(O)=C1O VXQUGYOYJDITTO-UHFFFAOYSA-N 0.000 description 1
- NAXWCXIIGZMBKS-UHFFFAOYSA-N [H]C12CCCC(C)(C)C1=CCC(C)C2(C)CC1=C(O)C(=O)C=C(NCC(C)CC)C1=O Chemical compound [H]C12CCCC(C)(C)C1=CCC(C)C2(C)CC1=C(O)C(=O)C=C(NCC(C)CC)C1=O NAXWCXIIGZMBKS-UHFFFAOYSA-N 0.000 description 1
- PCPNXIVFZOIXJX-UHFFFAOYSA-N [H]C12CCCC(C)(C)C1=CCC(C)C2(C)CC1=C(O)C(=O)C=C(NCCC(C)C)C1=O Chemical compound [H]C12CCCC(C)(C)C1=CCC(C)C2(C)CC1=C(O)C(=O)C=C(NCCC(C)C)C1=O PCPNXIVFZOIXJX-UHFFFAOYSA-N 0.000 description 1
- XPBBMGKNBSHXLB-UHFFFAOYSA-N [H]C12CCCC(C)(C)C1=CCC(C)C2(C)CC1=C(O)C(=O)C=C(NCCC2=CC=CC=C2)C1=O Chemical compound [H]C12CCCC(C)(C)C1=CCC(C)C2(C)CC1=C(O)C(=O)C=C(NCCC2=CC=CC=C2)C1=O XPBBMGKNBSHXLB-UHFFFAOYSA-N 0.000 description 1
- YXMANDRSLJYXOW-UHFFFAOYSA-N [H]C12CCCC(C)(C)C1=CCC(C)C2(C)CC1=C(O)C(=O)C=C(OC)C1=O Chemical compound [H]C12CCCC(C)(C)C1=CCC(C)C2(C)CC1=C(O)C(=O)C=C(OC)C1=O YXMANDRSLJYXOW-UHFFFAOYSA-N 0.000 description 1
- BZGOZXVJVQDKFR-UHFFFAOYSA-N [H]C12CCCCC1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(N)C1=O Chemical compound [H]C12CCCCC1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(N)C1=O BZGOZXVJVQDKFR-UHFFFAOYSA-N 0.000 description 1
- KABOFZNOTWGXRE-UHFFFAOYSA-N [H]C12CCCCC1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(NCC(=O)O)C1=O Chemical compound [H]C12CCCCC1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(NCC(=O)O)C1=O KABOFZNOTWGXRE-UHFFFAOYSA-N 0.000 description 1
- FLVFGYVNBRSDOK-UHFFFAOYSA-N [H]C12CCCCC1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(NCC(C)C)C1=O Chemical compound [H]C12CCCCC1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(NCC(C)C)C1=O FLVFGYVNBRSDOK-UHFFFAOYSA-N 0.000 description 1
- CKJUOUUEJXWCCT-UHFFFAOYSA-N [H]C12CCCCC1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(NCC(C)CC)C1=O Chemical compound [H]C12CCCCC1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(NCC(C)CC)C1=O CKJUOUUEJXWCCT-UHFFFAOYSA-N 0.000 description 1
- LOFGMIMRGONLDC-UHFFFAOYSA-N [H]C12CCCCC1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(NCCC(=O)O)C1=O Chemical compound [H]C12CCCCC1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(NCCC(=O)O)C1=O LOFGMIMRGONLDC-UHFFFAOYSA-N 0.000 description 1
- HXINNHCRQZYYLZ-UHFFFAOYSA-N [H]C12CCCCC1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(NCCC(C)C)C1=O Chemical compound [H]C12CCCCC1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(NCCC(C)C)C1=O HXINNHCRQZYYLZ-UHFFFAOYSA-N 0.000 description 1
- QEXOHLBIEAUQMB-UHFFFAOYSA-N [H]C12CCCCC1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(NCCC2=CC=CC=C2)C1=O Chemical compound [H]C12CCCCC1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(NCCC2=CC=CC=C2)C1=O QEXOHLBIEAUQMB-UHFFFAOYSA-N 0.000 description 1
- INURPKLFEQLLMU-UHFFFAOYSA-N [H]C12CCCCC1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(O)C1=O Chemical compound [H]C12CCCCC1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(O)C1=O INURPKLFEQLLMU-UHFFFAOYSA-N 0.000 description 1
- VUZIPRBZIKFCHJ-UHFFFAOYSA-N [H]C12CCCCC1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(OC)C1=O Chemical compound [H]C12CCCCC1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(OC)C1=O VUZIPRBZIKFCHJ-UHFFFAOYSA-N 0.000 description 1
- DBSUSJSKXZMXKF-UHFFFAOYSA-N [H]C12CCCCC1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(OCC)C1=O Chemical compound [H]C12CCCCC1(C)CCC(C)C2(C)CC1=C(O)C(=O)C=C(OCC)C1=O DBSUSJSKXZMXKF-UHFFFAOYSA-N 0.000 description 1
- SWQQVCJRIDUIHY-UHFFFAOYSA-N [H]C12CCCCC1(C)CCC(C)C2(C)CC1=C(OC)C=CC(CO)=C1 Chemical compound [H]C12CCCCC1(C)CCC(C)C2(C)CC1=C(OC)C=CC(CO)=C1 SWQQVCJRIDUIHY-UHFFFAOYSA-N 0.000 description 1
- HKHITUSVYGXANR-UHFFFAOYSA-N [H]C12CCCCC1(C)CCC(C)C2(C)CC1=CC(C(=O)OC)=CC(O)=C1O Chemical compound [H]C12CCCCC1(C)CCC(C)C2(C)CC1=CC(C(=O)OC)=CC(O)=C1O HKHITUSVYGXANR-UHFFFAOYSA-N 0.000 description 1
- ACRQPEGTUXNRDI-UHFFFAOYSA-N [H]C12CCCCC1(C)CCC(C)C2(C)CC1=CC(C(=O)OC)=CC=C1O Chemical compound [H]C12CCCCC1(C)CCC(C)C2(C)CC1=CC(C(=O)OC)=CC=C1O ACRQPEGTUXNRDI-UHFFFAOYSA-N 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 235000013409 condiments Nutrition 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000011190 diabetic macular edema Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000002196 fr. b Anatomy 0.000 description 1
- 210000003918 fraction a Anatomy 0.000 description 1
- 235000013611 frozen food Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008202 granule composition Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 125000005446 heptyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 238000001052 heteronuclear multiple bond coherence spectrum Methods 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- NIQQIJXGUZVEBB-UHFFFAOYSA-N methanol;propan-2-one Chemical compound OC.CC(C)=O NIQQIJXGUZVEBB-UHFFFAOYSA-N 0.000 description 1
- 239000002032 methanolic fraction Substances 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000005447 octyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- FHHJDRFHHWUPDG-UHFFFAOYSA-N peroxysulfuric acid Chemical compound OOS(O)(=O)=O FHHJDRFHHWUPDG-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000012063 pure reaction product Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 201000011195 retinal edema Diseases 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000008107 starch Chemical class 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 201000005428 steroid-induced glaucoma Diseases 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960002898 threonine Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- HSSMNYDDDSNUKH-UHFFFAOYSA-K trichlororhodium;hydrate Chemical compound O.Cl[Rh](Cl)Cl HSSMNYDDDSNUKH-UHFFFAOYSA-K 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
Definitions
- the present disclosure relates to a novel use of a sesquiterpene derivative, more particularly to a composition for preventing, improving or treating macular degeneration or macular edema caused by vascular leakage in the eye, the composition containing a sesquiterpene derivative compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
- Macular edema refers to the swelling of the macula lutea.
- the edema is caused by fluid leaking from the retinal blood vessel. Blood is leaked from weak blood vessel walls and flown into the macula lutea packed with retinal cones which sense color and are responsible for vision during the day. Then, images are blurred at the center or right side of the central region. The vision worsens gradually over several months. All age-related macular degeneration (AMD) is associated with macular edema.
- AMD age-related macular degeneration
- Vascular leakage in the eye occurs due to various causes. For example, continued increase in blood pressure in in hypertensive patients causes breakdown of the blood-retinal barrier and the damage to the blood-retinal barrier causes retinal edema due to vascular leakage.
- the macula lutea is often damaged by macula tumentia following the removal of the eye lens for treatment of cataract.
- Laser photocoagulation alleviates macula tumentia by blocking the blood vessels where fluid leakage occurs.
- care should be taken to avoid the fovea when irradiating laser because it is extremely vulnerable. If the fovea is damaged during the operation, the central vision may be impaired.
- more than one laser treatments are often necessary to remove the swelling.
- Vitrectomy is employed when the laser treatment is ineffective, but this method is often associated with the high risk of tissue invasion which causes postoperative complications.
- the intravitreal administration of steroids may cause ocular hypertension, steroid-induced glaucoma and posterior subcapsular cataract. In addition, the intravitreal administration of steroids often cause postoperative complications.
- the inventors of the present disclosure have researched to develop a medication exhibiting an excellent therapeutic effect for macular edema or macular degeneration related thereto, which reduces the inconvenience of administration and can be administered for a long time. In doing so, they have identified that a compound represented by Chemical Formula 1 exhibits therapeutic effect in a macular edema or macular degeneration animal model by effectively preventing vascular leakage in the eye and that the compound is targeted to the eye even when it is administered orally.
- the present disclosure is directed to providing a pharmaceutical composition for preventing or treating macular degeneration or macular edema caused by vascular leakage in the eye.
- the present disclosure is also directed to providing a food composition for preventing or improving macular degeneration or macular edema caused by vascular leakage in the eye.
- the present disclosure provides a pharmaceutical composition for preventing or treating macular degeneration or macular edema, which contains a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient:
- R 1 is H or CH 3 ,
- R 3 is a functional group selected from a group consisting of R 3a through R 3d ,
- each of R 4 and R 7 is OH or OCH 3 and R 5 , R 6 and R 8 are H; or
- R 5 is COOCH 3 , R 7 is H or OH, R 8 is OH and R 4 and R are H,
- R 9 is a functional group selected from a group consisting of H, NH 2 , C 1 -C 8 alkoxy and R 9a through R 9j and R 10 is H or OH,
- each of R 11 and R 12 is OH or OAc and R 13 is H; or
- each of R 11 and R 12 is OH or OCH 3 and R 13 is CH 3 and
- R 14 is OCH 3 and R 15 and R 16 are CH 3 .
- the present disclosure also provides a pharmaceutical composition for inhibiting vascular leakage in the eye, which contains the compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient
- the present disclosure also provides a food composition for preventing or improving macular degeneration or macular edema, which contains the compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
- FIG. 1 shows a result of investigating the inhibitory effect of a compound of the present disclosure (Preparation Example 30 or Preparation Example 31) on 3-catenin expression in HEK293 cells, in which the Wnt/ ⁇ -catenin pathway is activated by treating with Wnt-3a CM, by western blot.
- FIG. 2 shows a result of investigating the inhibitory effect of a compound of the present disclosure (Preparation Example 32) on 3-catenin expression in HEK293 cells, in which the Wnt/ ⁇ -catenin pathway is activated by treating with Wnt-3a CM, by western blot.
- FIG. 3 shows a result of investigating the inhibitory effect of a compound of the present disclosure (Preparation Example 33 or Preparation Example 34) on 3-catenin expression in human retinal epithelial cells, in which the Wnt/3-catenin pathway is activated by treating with Wnt-3a CM, by western blot.
- FIG. 4 shows a result of investigating the inhibitory effect of intravitreal administration of a compound of the present disclosure (Preparation Example 33) on vascular leakage in a macular edema mouse model by fluorescein angiography and optical coherence tomography (A and B are images for a control group (compound-untreated) obtained after DMSO injection and C and D are images for a test group (Preparation Example 33) obtained after injection.
- the arrows indicate blood vessels).
- FIG. 5 shows a result of investigating the inhibitory effect of intraperitoneal injection of a compound of the present disclosure (Preparation Example 33) on vascular leakage in a macular edema mouse model by optical coherence tomography (A: vehicle-administered group, B: Preparation Example 33 compound 1 mg/kg administered group).
- FIG. 6 shows a result of orally administering a compound of the present disclosure (Preparation Example 33) to an ICR mouse and measuring distribution of the compound in target tissues (particularly, eye).
- the inventors of the present disclosure have researched to develop a medication exhibiting an excellent therapeutic effect for macular edema or macular degeneration related thereto, which reduces the inconvenience of administration and can be administered for a long time. In doing so, they have identified that a compound represented by Chemical Formula 1 exhibits therapeutic effect for macular edema or macular degeneration diseases by effectively preventing vascular leakage in the eye, particularly in the retina.
- the present disclosure relates to a pharmaceutical composition for preventing or treating macular degeneration or macular edema, which contains a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
- R 1 is H or CH 3 ,
- R 3 is a functional group selected from a group consisting of R 3a through R 3d ,
- each of R 4 and R 7 is OH or OCH 3 and R 5 , R 6 and R 8 are H; or
- R 5 is COOCH 3 , R 7 is H or OH, R 8 is OH and R 4 and R 6 are H,
- R 9 is a functional group selected from a group consisting of H, NH 2 , C 1 -C 8 alkoxy and R 9a through R 9j and R 10 is H or OH,
- each of R 11 and R 12 is OH or OAc and R 13 is H; or
- each of R 11 and R 12 is OH or OCH 3 and R 13 is CH 3 and
- R 14 is OCH 3 and R 15 and R 16 are CH 3 .
- the term alkoxy group refers to an alkyl group bonded to oxygen (O-alkyl group).
- the alkoxy group may be a C 1 -C 8 alkoxy group selected from a group consisting of a methoxy group (C 1 ), an ethoxy group (C 2 ), a propoxy group (C 3 ), a butoxy group (C 4 ), a pentyloxy group (C 5 ), a hexyloxy group (C 6 ), a heptyloxy group (C 7 ) and an octyloxy group (C 8 ), although not being limited thereto.
- the alkoxy group of the present disclosure may be a methoxy group or an ethoxy group.
- the compound of the present disclosure of Chemical Formula 1 may be the compounds described in [Table 1], although not being limited thereto.
- the sesquiterpene derivative compound of the present disclosure may be one wherein, in Chemical Formula 1, if the bond between C-3 and C-4 and the bond between C-5 and C-6 are single bonds, R 2b is nonexistent, R 2a is CH 2 and R 3 is a functional group selected from a group consisting of R 3b through R 3d .
- R 9 may be selected from a group consisting of ethoxy, methoxy and R 9a .
- R 11 may be OH
- R 12 may be OCH 3
- R 13 may be CH 3 .
- R 14 may be OCH 3 and R 15 and R 16 may be CH 3 .
- the compound of Chemical Formula 1 of the present disclosure may be a compound selected from a group consisting of:
- the compound of Chemical Formula 1 of the present disclosure may be extracted from sponge.
- the compound of Chemical Formula 1 for preventing or treating macular degeneration or macular edema caused by vascular leakage in the eye may be obtained by a method including a step of extracting one or more sponge selected from a group consisting of Rhopaloeides sp., Spongia sp., Smenospongia sp., Hippospongia sp., Dactylospongia sp., Verongula sp., Dysidea sp., sponge SS-1047, sponge SS-265 and sponge SS-1208 by adding a C 1 -C 6 organic solvent.
- the C 1 -C 6 organic solvent may be selected from a group consisting of a C 1 -C 6 alcohol (methanol, ethanol, propanol, butanol, pentanol, hexanol), acetone, an ether, benzene, chloroform, ethyl acetate, methylene chloride, hexane, cyclohexane, acetonitrile, dichloromethane and petroleum ether.
- a C 1 -C 6 alcohol methanol, ethanol, propanol, butanol, pentanol, hexanol
- acetone an ether
- benzene chloroform
- ethyl acetate methylene chloride
- hexane hexane
- cyclohexane acetonitrile
- dichloromethane and petroleum ether.
- the compound of the present disclosure of Chemical Formula 1 may be obtained by a method including: a step of extracting sponge by adding water, a C 1 -C 4 alcohol or a mixture thereof as a solvent, thereby preparing a sponge extract; and a step of fractionating the extract by adding a second solvent and separating the same through chromatography.
- any one known to those skilled in the art can be used without limitation, including silica gel column chromatography, LH-20 column chromatography, ion-exchange chromatography, medium pressure liquid chromatography, thin-layer chromatography (TLC), silica gel vacuum liquid chromatography, high-performance liquid chromatography, etc.
- the C 1 -C 4 alcohol used to prepare the sponge extract may be selected from a group consisting of methanol, ethanol, propanol, isopropanol, butanol and isobutanol.
- a C 1 -C 4 alcohol n-hexane, methylene chloride, acetone, chloroform, dichloromethane, ethyl acetate, acetonitrile or a mixture thereof may be used.
- the compound of the present disclosure of Chemical Formula 1 includes a pharmaceutically acceptable salt thereof.
- pharmaceutically acceptable means being physiologically acceptable and not causing allergic reactions such as gastroenteric trouble, dizziness, etc. or similar reactions when administered to human.
- the pharmaceutically acceptable salt includes an acid addition salt with an inorganic acid or an organic acid.
- an acid addition salt formed by a pharmaceutically acceptable free acid is useful.
- an inorganic acid or an organic acid may be used.
- the inorganic acid hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, etc. may be used.
- organic acid citric acid, acetic acid, lactic acid, tartaric acid, fumaric acid, formic acid, propionic acid, oxalic acid, trifluoroacetic acid, methanesulfonic acid, benzenesulfonic acid, maleic acid, benzoic acid, gluconic acid, glycolic acid, succinic acid, 4-morpholinoethanesulfonic acid, camphorsulfonic acid, 4-nitrobenzenesulfonic acid, hydroxy-O-sulfonic acid, 4-toluenesulfonic acid, galacturonic acid, embonic acid, glutamic acid, aspartic acid, etc.
- organic acid citric acid, acetic acid, lactic acid, tartaric acid, fumaric acid, formic acid, propionic acid, oxalic acid, trifluoroacetic acid, methanesulfonic acid, benzenesulfonic acid, maleic acid, benzoic acid, gluconic acid,
- the compound of the present disclosure of Chemical Formula 1 inhibits ⁇ -catenin in vitro, suggesting that it can inhibit vascular leakage by inhibiting the Wnt/0-catenin mechanism.
- the present disclosure compound exhibits therapeutic effect by inhibiting vascular leakage in a macular edema animal model in vivo.
- the present disclosure relates to a pharmaceutical composition for inhibiting vascular leakage in the eye, which contains the compound of Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
- vascular leakage refers to the leakage of body fluid or blood plasma due to damage to the integrity of blood vessels.
- the vascular leakage in the eye constitutes the major pathological conditions of various eye diseases.
- vascular leakage in the eye refers to vascular leakage in various tissues (choroid, retina, etc.) constituting the eye. Specifically, it may refer to vascular leakage in the retina, although not being limited thereto.
- the pharmaceutical composition of the present disclosure has preventive or therapeutic effect for a disease caused by vascular leakage in the eye.
- the disease caused by vascular leakage in the eye may be any one known in the art. For example, it include retinal degeneration, macular degeneration, retinal edema and macular edema.
- the disease caused by vascular leakage in the eye may be macular degeneration or macular edema.
- the pharmaceutical composition according to the present disclosure may contain only the sesquiterpene derivative compound of Chemical Formula 1 or a pharmaceutically acceptable salt thereof or may further contain one or more pharmaceutically acceptable carrier, excipient or diluent.
- the pharmaceutically acceptable carrier may further contain, for example, a carrier for oral administration or a carrier for parenteral administration.
- the carrier for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, etc.
- the carrier for parenteral administration may include water, suitable oils, physiological saline, water-soluble glucose, glycol, etc.
- the pharmaceutical composition of the present disclosure may further contain a stabilizer and a preservative.
- a suitable stabilizer includes sodium bisulfite, sodium sulfite or an antioxidant such as ascorbic acid.
- a suitable preservative includes benzalkonium chloride, methyl- or propylparaben and chlorobutanol.
- the pharmaceutical composition of the present disclosure may further contain a lubricant, a humectant, a sweetener, a flavorant, an emulsifier, a suspending agent, etc.
- a lubricant for other pharmaceutically acceptable carriers, reference can be made to the literature (Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, Pa., 1995).
- composition of the present disclosure may be administered to mammals including human by any means.
- it may be administered orally or parenterally.
- the parenteral administration method may include intravenous, intramuscular, intraarterial, intramedullary, intradural, intracardiac, intraocular, intravitreal, transdermal, subcutaneous, intraabdominal, intranasal, intraintestinal, topical, sublingual or intrarectal administration, although not being limited thereto.
- the pharmaceutical composition of the present disclosure may be prepared into a formulation for oral administration or parenteral administration depending on the administration routes.
- the composition of the present disclosure may be formulated into a powder, a granule, a tablet, a pill, a sugar-coated tablet, a capsule, a solution, a gel, a syrup, a slurry, a suspension, etc. using the method known in the art.
- a tablet or a sugar-coated tablet may be prepared by mixing the active ingredient with a solid excipient, pulverizing the mixture, adding a suitable adjuvant and then processing into a granule mixture.
- the suitable excipient may include sugars including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, etc., a starches including corn starch, wheat starch, rice starch, potato starch, etc., celluloses including cellulose, methyl cellulose, sodium carboxymethyl cellulose, hydroxypropylmethyl cellulose, etc. and fillers such as gelatin, polyvinylpyrrolidone, etc. If necessary, crosslinked polyvinylpyrrolidone, agar, alginic acid, sodium alginate, etc. may be added as a disintegrant.
- the pharmaceutical composition of the present disclosure may further contain an antiagglomerant, a lubricant, a humectant, a flavor, an emulsifier, an antiseptic, etc.
- the composition may be formulated into an injection, an eye drop, an ointment, a cream, a lotion, an oil, a gel, an aerosol or a nasal inhaler using the method known in the art.
- formulations are described in the literature generally known in the field of pharmaceutical chemistry (Remington's Pharmaceutical Science, 15th Edition, 1975. Mack Publishing Company, Easton, Pa. 18042, Chapter 87: Blaug, Seymour).
- the pharmaceutical composition of the present disclosure may be prepared into a formulation selected from a group consisting of an oral medication, an injection, an eye drop and an ointment.
- the total effective amount of the sesquiterpene derivative compound of the present disclosure or a pharmaceutically acceptable salt thereof may be administered to a patient with a single dose or a multiple dose according to the fractionated treatment protocol for long-term administration.
- the content of the active ingredient of the pharmaceutical composition of the present disclosure may vary depending on the severity of a disease.
- the effective administration dosage of the compound or a pharmaceutically acceptable salt thereof is determined in consideration of various factors including the route and number of administration of the pharmaceutical composition, the age, body weight, health condition and sex of a patient, the severity of a disease, diet, excretion rate, etc.
- the pharmaceutical composition according to the present disclosure is not specially limited in formulation, administration route and administration method as long as the effect of the present disclosure can be achieved.
- the present disclosure relates to a food composition for preventing or improving macular degeneration or macular edema, which contains the compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
- the food composition of the present disclosure includes all forms such as a functional food, a nutritional supplement, a health food, a food additive, a feed, etc. and is provided for animals including human or livestock.
- the food composition may be prepared into various forms according to the method known in the art.
- the health food may be prepared by preparing the sesquiterpene derivative of the present disclosure or a sponge extract containing the sesquiterpene into tea, juice or a drink for drinking or into a granule, a capsule or a powder.
- a composition may be prepared by mixing the sesquiterpene derivative of the present disclosure or a sponge extract containing the sesquiterpene with an active ingredient known to be effective in improving and preventing macular edema or macular degeneration.
- the functional food be prepared by adding the sesquiterpene derivative of the present disclosure or a sponge extract containing the sesquiterpene to beverages (including alcoholic beverage, fruit or processed fruit (e.g., canned fruit, bottling, jam, marmalade, etc.), fish, meat or processed foodstuffs thereof (e.g., ham, sausage corn beef, etc.), bread or noodles (e.g., udon, buckwheat noodle, instant noodle, spaghetti, macaroni, etc.), fruit juice, drinks, cookies, taffy, dairy products (e.g., butter, cheese, etc.), vegetable fats and oils, margarine, vegetable proteins, retort foods, frozen foods, condiments (e.g., soybean paste, soy sauce, etc.), etc.
- beverages including alcoholic beverage, fruit or processed fruit (e.g., canned fruit, bottling, jam, marmalade, etc.), fish, meat or processed foodstuffs thereof (e.g., ham, sausage corn
- sesquiterpene derivative of the present disclosure or a sponge extract containing the sesquiterpene may be prepared into a powder or a concentrate for use as a food additive.
- the obtained compound of Preparation Example 1 had the following physicochemical properties and was identified as ‘methyl 3-[[(1R,2S,4aR,8aS)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]-4,5-dihydroxybenzoate’.
- the obtained compound of Preparation Example 2 had the following physicochemical properties and was identified as ‘3-[[(1S,2R,4aR,8aR)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-2,5-dihydroxycyclohexa-2,5-diene-1,4-dione’.
- the obtained compound of Preparation Example 3 had the following physicochemical properties and was identified as ‘3-[[(1R,2S,4aS,8aS)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-4-hydroxy-5-(3-methylbutylamino)cyclohexa-3,5-diene-1,2-dione’.
- a compound of Preparation Example 4 was prepared in the same manner as in Preparation Example 3.
- the obtained compound (Preparation Example 4) had the following physicochemical properties and was identified as ‘3-[[(1S,2R,4aR,8aR)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-4-hydroxy-5-(2-methylpropylamino)cyclohexa-3,5-diene-1,2-dione’.
- MeOH and DCM crude extracts of Hippospongia sp. were combined and fractionated with MeOH, DCM, hexane and BuOH. Among them, the hexane, DCM and MeOH fractions were subjected to flash column chromatography and semi-preparative RP-HPLC to obtain a compound of Preparation Example 5.
- the obtained compound had the following physicochemical properties and was identified as ‘3-[[(1R,2S,4aS,8aS)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-5-amino-4-hydroxycyclohexa-3,5-diene-1,2-dione’.
- the prepared Preparation Example 6 compound had the following physicochemical properties and was identified as ‘2-[[5-[[(1R,2S,4aS,8aS)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-6-hydroxy-3,4-dioxocyclohexa-1,5-dien-1-yl]amino]acetic acid’.
- a compound of Preparation Example 7 was prepared in the same manner as in Preparation Example 6.
- the prepared compound (Preparation Example 7) had the following physicochemical properties and was identified as ‘3-[[5-[[(1R,2S,4aS,8aS)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-6-hydroxy-3,4-dioxocyclohexa-1,5-dien-1-yl]amino]propanoic acid’.
- a compound of Preparation Example 8 was prepared in the same manner as in Preparation Example 6.
- the prepared compound (Preparation Example 8) had the following physicochemical properties and was identified as ‘7-[[(1R,2S,4aS,8aS)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-1,3-benzoxazole-5,6-diol’.
- the obtained compound of Preparation Example 9 (2.3 mg, 0.007%) had the following physicochemical properties and was identified as ‘[7-[[(1R,2S,4aS,8aS)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-6-acetyloxy-1,3-benzoxazol-5-yl] acetate’.
- a sponge (Spongiidae SS-1047, 0.30 kg, wet weight) was obtained as described in the literature ‘Yohei Takahashi et al., 2010’ and extracted. Briefly, EtOAc-soluble substances (1.2 g) were fractionated using a silica gel column (n-hexane/EtOAc) and a fraction 1, a fraction 2 and a fraction 3 of low polarity and a polar fraction 4 were prepared.
- the fraction 3 was fractionated and purified by C 18 column (MeOH/H 2 O) and C 18 HPLC (Luna 5u Phenyl-Hexyl, 250 ⁇ 10 mm; eluent, MeOH/H 2 O/CF 3 CO 2 H, 85:15:0.05; flow rate, 2.5 mL/min; UV detection at 320 nm) to obtain compounds of Preparation Example 10 and Preparation Example 11.
- the obtained Preparation Example 10 compound had the following physicochemical properties and was identified as ‘3-[[(1R,2S,4aS,8aS)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]-2-hydroxy-5-methoxycyclohexa-2,5-diene-1,4-dione’.
- a compound of Preparation Example 11 was prepared in the same manner as in Preparation Example 10.
- the obtained compound (Preparation Example 11) had the following physicochemical properties and was identified as ‘2-hydroxy-5-methoxy-3-[[(1R,2S)-1,2,5,5-tetramethyl-2,3,6,7,8,8a-hexahydronaphthalen-1-yl]methyl]cyclohexa-2,5-diene-1,4-dione’.
- the fraction 1 obtained in Preparation Example 10 was refractionated by Cis column (MeOH/H 2 O) and C 18 HPLC (Wakosil-II 5C18AR, Wako Pure Chemical Industries, Ltd., 250 ⁇ 10 mm; eluent, MeCN/H 2 O/CF 3 CO 2 H, 90:10:0.05; flow rate, 2.0 mL/min; UV detection at 300 nm) to obtain a compound of Preparation Example 11 (2.8 mg, 0.00093% wet weight) and a compound of Preparation Example 12 (24.7 mg, 0.0082%).
- the obtained Preparation Example 12 compound had the following physicochemical properties and was identified as ‘3-[[(1R,2S,8aS)-1,2,5,5-tetramethyl-2,3,6,7,8,8a-hexahydronaphthalen-1-yl]methyl]-4-hydroxy-5-(2-phenylethylamino)cyclohexa-3,5-diene-1,2-dione’.
- a compound of Preparation Example 13 was prepared in the same manner as in Preparation Example 12.
- the obtained compound (Preparation Example 13) had the following physicochemical properties and was identified as ‘3-[[(1R,2S,4aS,8aS)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]-4-hydroxy-5-(2-phenylethylamino)cyclohexa-3,5-diene-1,2-dione’.
- the fraction 2 obtained in Preparation Example 10 was subjected to C 18 column (MeOH/H 2 O/CF 3 CO 2 H) and C 18 HPLC (Luna 5u Phenyl-Hexyl, Phenomenex, 250 ⁇ 10 mm; eluent, MeCN/H 2 O/CF 3 CO 2 H, 80:20:0.05; flow rate, 2.0 mL/min; UV detection at 300 nm) to obtain a compound of Preparation Example 14 (0.9 mg, 0.00030%), a fraction y and a fraction 6.
- the obtained compound of Preparation Example 14 had the following physicochemical properties and was identified as ‘3-[[(1R,2S,4aS,8aS)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]-4-hydroxy-5-(2-methylpropylamino)cyclohexa-3,5-diene-1,2-dione’.
- the fraction ⁇ obtained in Preparation Example 14 was purified by C 18 HPLC (Luna 5u C18(2), Phenomenex, 250 ⁇ 10 mm; MeOH/H 2 O/Et 2 NH, 70:30:0.1; flow rate, 2.0 mL/min; UV detection at 300 nm) to obtain a compound of Preparation Example 15 (1.4 mg, 0.00047%) and a compound of Preparation Example 16 (4.0 mg, 0.0013%).
- the compound of Preparation Example 15 had the following physicochemical properties and was identified as ‘3-[[(1R,2S,4aS,8aS)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]-4-hydroxy-5-[[(2S)-2-methylbutyl]amino]cyclohexa-3,5-diene-1,2-dione’.
- a compound of Preparation Example 16 was prepared in the same manner as in Preparation Example 15. It had the following physicochemical properties and was identified as ‘3-[[(1R,2S,4aS,8aS)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]-4-hydroxy-5-(3-methylbutylamino)cyclohexa-3,5-diene-1,2-dione’.
- the fraction 6 obtained in Preparation Example 14 was refractionated by Cis HPLC (Luna 5u Phenyl-Hexyl, 250 ⁇ 10 mm; MeOH/H 2 O/Et 2 NH, 65:35:0.1; flow rate, 2.0 mL/min; UV detection at 300 nm) to obtain a compound of Preparation Example 17 (0.7 mg, 0.00023%) and a compound of Preparation Example 18 (1.6 mg, 0.00053%).
- the obtained Preparation Example 17 compound had the following physicochemical properties and was identified as ‘3-[[(1R,2S,8aS)-1,2,5,5-tetramethyl-2,3,6,7,8,8a-hexahydronaphthalen-1-yl]methyl]-4-hydroxy-5-[[(2S)-2-methylbutyl]amino]cyclohexa-3,5-diene-1,2-dione’.
- a compound of Preparation Example 18 was prepared in the same manner as in Preparation Example 17. It had the following physicochemical properties and was identified as ‘3-[[(1R,2S,8aS)-1,2,5,5-tetramethyl-2,3,6,7,8,8a-hexahydronaphthalen-1-yl]methyl]-4-hydroxy-5-(3-methylbutylamino)cyclohexa-3,5-diene-1,2-dione’ Compound
- a sponge (Spongiidae SS-265) was obtained as described in the literature ‘Yohei Takahashi et al., 2010’ and extracted. Briefly, an extract was prepared by adding MeOH (4.3 and 3.2 L) to sponge SS-265 (1.4 kg, wet weight). The MeOH extract (68.4 g) was fractionated with CHCl 3 and H 2 O.
- the CHCl 3 -soluble substances (2.3 g) were subjected to silica gel column (n-hexane/EtOAc), C 18 column (MeOH/H 2 O), silica gel column (n-hexane/acetone) and C 18 HPLC (Wakosil-II 5C18AR, 250 ⁇ 10 mm; eluent, MeCN/H 2 O/CF 3 CO 2 H, 90:10:0.1; flow rate, 2.0 mL/min; UV detection at 300 nm and Luna 5u C18(2), 250 ⁇ 10 mm; MeOH/H 2 O/Et 2 NH, 70:30:0.1; flow rate, 2.0 mL/min; UV detection at 300 nm) repeatedly to obtain a compound of Preparation Example 19 (1.8 mg, 0.00013%).
- the obtained Preparation Example 19 compound had the following physicochemical properties and was identified as ‘3-[[(1R,2S,4aS,8aS)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-4-hydroxy-5-[[(2S)-2-methylbutyl]amino]cyclohexa-3,5-diene-1,2-dione’.
- a sponge (Spongiidae SS-1208) was obtained as described in the literature ‘Yohei Takahashi et al., 2010’ and extracted. Briefly, an extract was prepared by adding MeOH (3 ⁇ 0.8 L) and MeOH/toluene (3:1, 1 ⁇ 0.8 L) to sponge SS-1208 (0.4 kg, wet weight). The extract mixture (15.9 g) was fractionated with CHCl 3 and H 2 O (3 ⁇ 500 mL).
- the CHCl 3 -soluble fraction (2.7 g) was subjected to silica gel column (n-hexane/EtOAc and CHCl 3 /MeOH), C 18 column (MeOH/H 2 O/CF 3 CO 2 H) and C 18 HPLC (Luna 5u Phenyl-Hexyl, 250 ⁇ 10 mm; eluent, MeCN/H 2 O/CF 3 CO 2 H, 70:30:0.1; flow rate, 2.0 mL/min; UV detection at 300 nm and Wakosil-II 5C18AR, 250 ⁇ 10 mm; eluent, MeCN/H 2 O/CF 3 CO 2 H, 75:25:0.1; flow rate, 2.0 mL/min; UV detection at 300 nm) repeatedly to obtain a compound of Preparation Example 20 (0.8 mg, 0.00020%).
- the obtained Preparation Example 20 compound had the following physicochemical properties and was identified as ‘2-[[5-[[(1R,2S,4aS,8aS)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]-6-hydroxy-3,4-dioxocyclohexa-1,5-dien-1-yl]amino]ethanesulfonic acid’.
- the obtained Preparation Example 21 compound had the following physicochemical properties and was identified as ‘methyl 3-[[(1R,2S,4aS,8aS)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-4-hydroxybenzoate’.
- a compound of Preparation Example 22 was prepared in the same manner as in Preparation Example 21. It had the following physicochemical properties and was identified as ‘methyl 3-[[(1 S,2R,4aR,8aR)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-4,5-dihydroxybenzoate’.
- a heated ylide solution was added dropwise to a solution of 212 mg (0.62 mmol) of the ketone ( ⁇ )-(1R,4aS,8aS)-1 ⁇ ,2 ⁇ , 4a ⁇ -trimethyl-1 ⁇ [(2′,5′-dimethoyphenyl)methyl]-1,2,3,4,4a,5,6,7,8,8a ⁇ -decahydronaphthalen-5-one dissolved in 3 mL of benzene. After heat-treating further for 22 hours, the reaction mixture was cooled and diluted by stirring fast while sequentially adding 10 mL of ether and 3 mL of H 2 O.
- the obtained Preparation Example 23 compound had the following physicochemical properties and was identified as ‘( ⁇ )-(1R,4aS,8aS)-1 ⁇ ,2 ⁇ ,4 ⁇ ,-trimethyl-1 ⁇ [(2′,5′-dimethoxyphenyl)methyl]-5-exo-methylene-(3H)-1, 4,4a,5,6,7,8,8a ⁇ -octahydronaphthalene’.
- the obtained Preparation Example 28 compound had the following physicochemical properties and was identified as ‘(2S)-2-[[5-[[(1R,2S,4aS,8aS)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a hexahydronaphthalen-1-yl]methyl]-6-hydroxy-3,4-dioxocyclohexa-1,5-dien-1-yl]amino]-3-hydroxypropanoic acid’.
- the obtained Preparation Example 29 compound had the following physicochemical properties and was identified as ‘(2S)-2-[[5-[[(1R,2S,4aS,8aS)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]-6-hydroxy-3,4-dioxocyclohexa-1,5-dien-1-yl]amino]-3-hydroxybutanoic acid’.
- the fraction 10 (39.3 g) was fractionated further with hexane-acetone mixtures (95:5, 90:10, 85:15, 80:20), MeOH (100%) and MeOH—H 2 O (50:50) using a silica gel VLC (12 (H) ⁇ 17.5 (D) cm) into 9 fractions (Fr. 10-1 to 10-9).
- the fraction 10-7 (3.7 g) was subjected to C 18 MPLC (15.5 ⁇ 4 cm) under an isocratic condition of MeOH—H 2 O (85:15) to prepare 6 subfractions (Fr. 10-7-1 to 10-7-6).
- the fraction 10-7-3 (115.8 mg) was subjected to C 18 HPLC (250 ⁇ 21.20 mm, 10 ⁇ m) chromatography using MeOH—H 2 O (83:17) to prepare 3 fractions (Fr. 10-7-3-1 to 10-7-3-3).
- the fraction 10-7-3-2 (12.4 mg) was subjected to C 18 HPLC (250 ⁇ 4.60 mm and 150 ⁇ 4.60 mm, 5 ⁇ m, connected in line) using MeOH—H 2 O (75:25) to obtain a compound of Preparation Example 30 and an epimer mixture thereof.
- the obtained substance had the following physicochemical properties and was identified as ‘18-methoxy-22,22-dimethyl-16-[ ⁇ (5R,8S,9R,10S)-5,8,9-trimethyl-4-methylenedecahydronaphthalen-9-yl ⁇ methyl]benzo[d]-oxazol-17(2H)-one’.
- the obtained compound had the following physicochemical properties and was identified as ‘3-[[(1R,2S,4aS,8aS)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-4-hydroxy-5-(2-phenylethylamino)cyclohexa-3,5-diene-1,2-dione’.
- the compound was identified by HPLC (Agilent Technologies 1260 Infinity) using a UV spectrophotometer (203 nm) and a Bluespher AB2 (150 ⁇ 2 mm) column.
- HPLC was conducted at a flow rate of 1 mL/min and 40° C. using water-methanol (78:22) as a mobile phase and the peaks of the compound were detected at 114 minutes.
- the obtained compound had the following physicochemical properties and was identified as ‘3-[[(1R,2S,4aS,8aS)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-2-hydroxy-5-methoxycyclohexa-2,5-diene-1,4-dione’.
- the obtained final compound had the following physicochemical properties and was identified as ‘3-[[(1S,2R,4aR,8aR)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-5-ethoxy-2-hydroxycyclohexa-2,5-diene-1,4-dione’.
- HEK293 cells human embryonic kidney cells
- Wnt3a-secreting L cells were obtained from the ATCC (American Type Culture Collection, USA) and were cultured in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10% FBS (fetal bovine serum), 120 ⁇ g/mL penicillin and 200 ⁇ g/mL streptomycin.
- DMEM Dulbecco's modified Eagle's medium
- FBS fetal bovine serum
- streptomycin fetal bovine serum
- Wnt3a-CM Wnt3a-conditioned medium
- DMEM fetal bovine serum
- FBS fetal bovine serum
- the compound of Preparation Example 30 or the compound of Preparation Example 31 (10, 20 or 40 ⁇ M) for 15 hours and extracting cytoplasmic proteins from the cells
- the amount of ⁇ -catenin regulating the CRT ( ⁇ -catenin response transcription) of the Wnt/ ⁇ -catenin pathway in the cells was investigated by western blot using a ⁇ -catenin antibody (BD Transduction Laboratories, USA) and the ECL system (Santa Cruz Biotechnology). The result is shown in FIG. 1 .
- the cells treated with the Wnt3a-CM showed increased 3-catenin expression in the cytoplasm but the cells treated with the Preparation Example 30 compound or the Preparation Example 31 compound of the present disclosure showed decreased level of ⁇ -catenin.
- the Wnt/1-Catenin Pathway Inhibitory Activity of the Preparation Example 32 Compound was evaluated in the same manner as in Example ⁇ 1-1>. Briefly, after treating HEK293 cells with the Wnt3a-CM or the compound of Preparation Example 32 (10 or 20 ⁇ M) for 15 hours and extracting cytoplasmic proteins from the cells, the amount of ⁇ -catenin regulating the CRT ( ⁇ -catenin response transcription) of the Wnt/ ⁇ -catenin pathway in the cells was investigated by western blot using a ⁇ -catenin antibody (BD Transduction Laboratories, USA) and the ECL system (Santa Cruz Biotechnology). The result is shown in FIG. 2 .
- a ⁇ -catenin antibody BD Transduction Laboratories, USA
- ECL system Santa Cruz Biotechnology
- the cells treated with the Wnt3a-CM showed increased 3-catenin expression in the cytoplasm but the cells treated with the Preparation Example 32 compound of the present disclosure showed decreased level of ⁇ -catenin.
- ARPE-19 cells human retinal epithelial cells
- Wnt3a-secreting L cells were obtained from the ATCC (American Type Culture Collection, USA) and were cultured in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10% FBS, 120 ⁇ g/mL penicillin and 200 ⁇ g/mL streptomycin.
- Wnt3a-CM Wnt3a-conditioned medium
- DMEM fetal bovine serum
- FBS fetal bovine serum
- the compound of Preparation Example 33 or the compound of Preparation Example 34 (3 or 6 ⁇ M) for 24 hours and extracting cytoplasmic proteins from the cells
- the amount of ⁇ -catenin regulating the CRT ( ⁇ -catenin response transcription) of the Wnt/3-catenin pathway in the cells was investigated by western blot using a ⁇ -catenin antibody (BD Transduction Laboratories, USA) and the ECL system (Santa Cruz Biotechnology). The result is shown in FIG. 3 .
- the cells treated with the Wnt3a-CM showed increased 3-catenin expression in the cytoplasm but the cells treated with the Preparation Example 33 compound or Preparation Example 34 compound of the present disclosure showed decreased level of ⁇ -catenin, suggesting that the compounds inhibit the Wnt/0-catenin pathway in the human retinal epithelial cells. Meanwhile, this activity was not identified in the sponge ethanol extract used to isolate the compound of Preparation Example 33 (data not shown).
- Example 33 For the compound of Preparation Example 33 which showed good activity in Example 1, the inhibitory activity on vascular leakage, which is a cause of macular degeneration or macular edema, was investigated in a macular edema-induced mouse model.
- Macular edema was induced in a 10-week-old C57BL/6 mouse by irradiating a laser. After anesthetizing the mouse with ketamine (70 mg/kg) and xylazine (30 mg/kg), the pupil was dilated with 1% tropicamide. Hydroxypropylmethyl cellulose was dropped onto the eye and a microscope cover glass was used as a contact lens.
- FIG. 4 shows the images of the control group and the compound-treated group.
- test group ( FIG. 4 , C, D) showed distinctly decreased vascular leakage, which is a cause of macular degeneration or macular edema, as compared to the control group ( FIG. 4 , A, B).
- the compound of the present disclosure inhibited vascular leakage, which is a cause of macular degeneration or macular edema, even when it was injected intraperitoneally.
- mice Male ICR mice (8 weeks, 30-35 g) were purchased from Samtako Co. (Osan, Korea). The test animals were acclimatized for a week under the following conditions: temperature 23 ⁇ 2° C., relative humidity 55 ⁇ 10%, illumination intensity 150-300 lux, ventilation frequency 15-20 times/h, illumination cycle 12 h (07:00-19:00). All the animal experiments were approved by the Animal Care and Use Committee of Kyungpook National University (Study No. 2016-0043).
- mice were fasted for 12 hours before drug administration. Feed and water were supplied ad libitum.
- blood samples were taken from the abdominal artery. 50 mL of a plasma sample obtained after centrifuging the blood sample at 13,000 rpm for 5 minutes was stored at ⁇ 80° C. until use for analysis. An eye sample taken from the mouse was homogenized with 9-fold saline to obtain a 10% cell homogenate. The obtained 50-mL aliquots were stored at ⁇ 80° C. until use for analysis.
- the compound of the present disclosure In order to investigate the distribution of the compound of the present disclosure in the target tissue, the compound was orally administered at a dose of 10 mg/kg and the concentration of the compound in the blood plasma and eye was measured. The sampling times were determined as 0.5 hour and 2 hours based on the peak plasma concentration and the distribution phase. As seen from FIG. 6 , the compound of the present disclosure (particularly, the compound of Preparation Example 33) showed high permeability for the target tissue and was found to be highly targeted in the eye even when it was administered orally. Through this result, it was confirmed that the compound of Preparation Example 33 of the present disclosure can exhibit therapeutic effect even when it is administered via different administration routes (oral administration, intraperitoneal injection, intravenous injection, etc.) other than being administered directly into the vitreous cavity. That is to say, whereas the currently available eye disease-related therapeutic agents cause inconvenience, pain and side effects because they have to be administered directly into the vitreous cavity, it was confirmed that the compound of the present disclosure can be administered orally.
- This experiment was conducted to determine acute (within 24 hours) toxicity and lethality when the compound of Preparation Example 33 was administered in excessive amounts in a short period of time.
- 20 normal ICR mice were divided into a control group and a test group, with 10 mice per each.
- the control group was administered with PEG 400:Tween 80:ethanol (8:1:1, v:v:v) only and the test group was orally administered with the compound of Preparation Example 33 dissolved in PEG 400:Tween 80:ethanol (8:1:1, v:v:v).
- lethality was investigated 24 hours after the administration, all the mice in the control group and the mice in the test group administered with the Preparation Example 33 compound at a dose of 2 g/kg/day survived.
- a long-term toxicity test was conducted by administering the compound of Preparation Example 33 at different doses to C57BL/6J mice (10 mice per group) for 8 weeks.
- blood was taken from the animals of the test group to which the compound of Preparation Example 33 was administered and the control group to which only PEG 400:Tween 80:ethanol (8:1:1, v:v:v) was administered 8 weeks later and the level of GPT (glutamate-pyruvate transferase) and BUN (blood urea nitrogen) in the blood was measured using Select E (Vital Scientific NV, Netherlands).
- 200 g of the compound of the present disclosure was mixed with 175.9 g of lactose, 180 g of potato starch and 32 g of colloidal silicate. After adding a 10% gelatin solution, the mixture was pulverized and passed through a 14-mesh sieve. A mixture obtained by drying the same and adding 160 g of potato starch, 50 g of talc and 5 g of magnesium stearate thereto was prepared into a tablet.
- the present disclosure relates to a novel use of a sesquiterpene derivative, more particularly to a composition for preventing, improving or treating macular degeneration or macular edema caused by vascular leakage in the eye, which contains the sesquiterpene derivative compound represented by Chemical Formula 1 of the present disclosure or a pharmaceutically acceptable salt thereof as an active ingredient.
- the compound of the present disclosure of Chemical Formula 1 has therapeutic effect for a disease caused by vascular leakage in the eye, such as macular edema, macular degeneration, etc., by inhibiting the vascular leakage in the eye, particularly in the retina.
- vascular leakage in the eye such as macular edema, macular degeneration, etc.
- the intraocular disease-related treating agents available in the market should be injected directly into the vitreous cavity, thus causing pain and side effects
- the sesquiterpene derivative compound of the present disclosure is delivered to the target tissue (eye) via different administration routes (oral, intraperitoneal, etc.) other than the intravitreal route. Accordingly, the sesquiterpene derivative compound provides excellent therapeutic effect without being restricted by the administration routes. Accordingly, it is highly industrially applicable.
- the compound of the present disclosure of Chemical Formula 1 has therapeutic effect for a disease caused by vascular leakage in the eye, such as macular edema, macular degeneration, etc., by inhibiting the vascular leakage in the eye, particularly in the retina.
- vascular leakage in the eye such as macular edema, macular degeneration, etc.
- the intraocular disease-related treating agents available in the market should be injected directly into the vitreous cavity, thus causing pain and side effects
- the sesquiterpene derivative compound of the present disclosure is delivered to the target tissue (eye) via different administration routes (oral, intraperitoneal, etc.) other than the intravitreal route. Accordingly, the sesquiterpene derivative compound provides excellent therapeutic effect without being restricted by the administration routes.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Ophthalmology & Optometry (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
The present disclosure relates to a novel use of a sesquiterpene derivative, more particularly to a composition for preventing, improving or treating macular degeneration or macular edema caused by vascular leakage in the eye, the composition containing a sesquiterpene derivative compound represented by Chemical Formula 1 of the present disclosure or a pharmaceutically acceptable salt thereof as an active ingredient. Whereas the intraocular disease-related treating agents available in the market should be injected directly into the vitreous cavity, thus causing pain and side effects, the sesquiterpene derivative compound of the present disclosure is delivered to the target tissue (eye) via different administration routes (oral, intraperitoneal, etc.) other than the intravitreal route. Accordingly, the sesquiterpene derivative compound provides excellent therapeutic effect without being restricted by the administration routes.
Description
- The present disclosure relates to a novel use of a sesquiterpene derivative, more particularly to a composition for preventing, improving or treating macular degeneration or macular edema caused by vascular leakage in the eye, the composition containing a sesquiterpene derivative compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
- Macular edema refers to the swelling of the macula lutea. The edema is caused by fluid leaking from the retinal blood vessel. Blood is leaked from weak blood vessel walls and flown into the macula lutea packed with retinal cones which sense color and are responsible for vision during the day. Then, images are blurred at the center or right side of the central region. The vision worsens gradually over several months. All age-related macular degeneration (AMD) is associated with macular edema. Vascular leakage in the eye occurs due to various causes. For example, continued increase in blood pressure in in hypertensive patients causes breakdown of the blood-retinal barrier and the damage to the blood-retinal barrier causes retinal edema due to vascular leakage. The macula lutea is often damaged by macula tumentia following the removal of the eye lens for treatment of cataract.
- For treatment of macular edema, laser photocoagulation, vitrectomy or systemic, intravitreal or sub-Tenon of steroids, etc. have been employed. Laser photocoagulation alleviates macula tumentia by blocking the blood vessels where fluid leakage occurs. However, care should be taken to avoid the fovea when irradiating laser because it is extremely vulnerable. If the fovea is damaged during the operation, the central vision may be impaired. Also, more than one laser treatments are often necessary to remove the swelling. Vitrectomy is employed when the laser treatment is ineffective, but this method is often associated with the high risk of tissue invasion which causes postoperative complications. The intravitreal administration of steroids may cause ocular hypertension, steroid-induced glaucoma and posterior subcapsular cataract. In addition, the intravitreal administration of steroids often cause postoperative complications.
- In addition, other drugs administered directly into the vitreous cavity are known to require repeated administrations with 4-6 week intervals. The administration directly into the vitreous cavity also causes inconvenience of administration, pain and side effects.
- The inventors of the present disclosure have researched to develop a medication exhibiting an excellent therapeutic effect for macular edema or macular degeneration related thereto, which reduces the inconvenience of administration and can be administered for a long time. In doing so, they have identified that a compound represented by Chemical Formula 1 exhibits therapeutic effect in a macular edema or macular degeneration animal model by effectively preventing vascular leakage in the eye and that the compound is targeted to the eye even when it is administered orally.
-
- (Non-patent document 1) Joo-Hyun Kim et al., “Wnt5a attenuates the pathogenic effects of the Wnt/β-catenin pathway in human retinal pigment epithelial cells via down-regulating β-catenin and Snail”, BMB Rep. 2015; 48(9): 525-530.
- (Non-patent document 2) Bokjun Ji et al., “Increased Levels of Dickkopf 3 in the Aqueous Humor of Patients With Diabetic Macular Edema”, Invest Ophthalmol Vis Sci. April 2016; 57; 2296-2304.
- The present disclosure is directed to providing a pharmaceutical composition for preventing or treating macular degeneration or macular edema caused by vascular leakage in the eye.
- The present disclosure is also directed to providing a food composition for preventing or improving macular degeneration or macular edema caused by vascular leakage in the eye.
- The above objects of the present disclosure can be achieved by the present disclosure as described below.
- The present disclosure provides a pharmaceutical composition for preventing or treating macular degeneration or macular edema, which contains a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient:
- wherein
- the broken line denotes a single bond or a double bond, wherein
- i) if the bond between C-3 and C-4 and the bond between C-5 and C-6 are single bonds, R2b is nonexistent and R2a is CH2;
- ii) if the bond between C-3 and C-4 is a double bond, the bond between C-5 and C-6 is a single bond, R2b is nonexistent and R2a is CH3; or
- iii) if the bond between C-5 and C-6 is a double bond, the bond between C-3 and C-4 is a single bond and R2a and R2b are CH3,
- R1 is H or CH3,
- R3 is a functional group selected from a group consisting of R3a through R3d,
- in R3a,
- i) each of R4 and R7 is OH or OCH3 and R5, R6 and R8 are H; or
- ii) R5 is COOCH3, R7 is H or OH, R8 is OH and R4 and R are H,
- in R3b,
- R9 is a functional group selected from a group consisting of H, NH2, C1-C8 alkoxy and R9a through R9j and R10 is H or OH,
- in R3c,
- each of R11 and R12 is OH or OAc and R13 is H; or
- each of R11 and R12 is OH or OCH3 and R13 is CH3 and
- in R3d,
- R14 is OCH3 and R15 and R16 are CH3.
- The present disclosure also provides a pharmaceutical composition for inhibiting vascular leakage in the eye, which contains the compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient
- The present disclosure also provides a food composition for preventing or improving macular degeneration or macular edema, which contains the compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
-
FIG. 1 shows a result of investigating the inhibitory effect of a compound of the present disclosure (Preparation Example 30 or Preparation Example 31) on 3-catenin expression in HEK293 cells, in which the Wnt/β-catenin pathway is activated by treating with Wnt-3a CM, by western blot. -
FIG. 2 shows a result of investigating the inhibitory effect of a compound of the present disclosure (Preparation Example 32) on 3-catenin expression in HEK293 cells, in which the Wnt/β-catenin pathway is activated by treating with Wnt-3a CM, by western blot. -
FIG. 3 shows a result of investigating the inhibitory effect of a compound of the present disclosure (Preparation Example 33 or Preparation Example 34) on 3-catenin expression in human retinal epithelial cells, in which the Wnt/3-catenin pathway is activated by treating with Wnt-3a CM, by western blot. -
FIG. 4 shows a result of investigating the inhibitory effect of intravitreal administration of a compound of the present disclosure (Preparation Example 33) on vascular leakage in a macular edema mouse model by fluorescein angiography and optical coherence tomography (A and B are images for a control group (compound-untreated) obtained after DMSO injection and C and D are images for a test group (Preparation Example 33) obtained after injection. The arrows indicate blood vessels). -
FIG. 5 shows a result of investigating the inhibitory effect of intraperitoneal injection of a compound of the present disclosure (Preparation Example 33) on vascular leakage in a macular edema mouse model by optical coherence tomography (A: vehicle-administered group, B: Preparation Example 33compound 1 mg/kg administered group). -
FIG. 6 shows a result of orally administering a compound of the present disclosure (Preparation Example 33) to an ICR mouse and measuring distribution of the compound in target tissues (particularly, eye). - The inventors of the present disclosure have researched to develop a medication exhibiting an excellent therapeutic effect for macular edema or macular degeneration related thereto, which reduces the inconvenience of administration and can be administered for a long time. In doing so, they have identified that a compound represented by Chemical Formula 1 exhibits therapeutic effect for macular edema or macular degeneration diseases by effectively preventing vascular leakage in the eye, particularly in the retina.
- Accordingly, in an aspect, the present disclosure relates to a pharmaceutical composition for preventing or treating macular degeneration or macular edema, which contains a compound represented by
Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient. - the broken line denotes a single bond or a double bond, wherein
- i) if the bond between C-3 and C-4 and the bond between C-5 and C-6 are single bonds, R2b is nonexistent and R2a is CH2;
- ii) if the bond between C-3 and C-4 is a double bond, the bond between C-5 and C-6 is a single bond, R2b is nonexistent and R2a is CH3; or
- iii) if the bond between C-5 and C-6 is a double bond, the bond between C-3 and C-4 is a single bond and R2a and R2b are CH3,
- R1 is H or CH3,
- R3 is a functional group selected from a group consisting of R3a through R3d,
- in R3a,
- i) each of R4 and R7 is OH or OCH3 and R5, R6 and R8 are H; or
- ii) R5 is COOCH3, R7 is H or OH, R8 is OH and R4 and R6 are H,
- in R3b,
- R9 is a functional group selected from a group consisting of H, NH2, C1-C8 alkoxy and R9a through R9j and R10 is H or OH,
- in R3c,
- each of R11 and R12 is OH or OAc and R13 is H; or
- each of R11 and R12 is OH or OCH3 and R13 is CH3 and
- in R3d,
- R14 is OCH3 and R15 and R16 are CH3.
- In the present disclosure, the term alkoxy group refers to an alkyl group bonded to oxygen (O-alkyl group). In the present disclosure, the alkoxy group may be a C1-C8 alkoxy group selected from a group consisting of a methoxy group (C1), an ethoxy group (C2), a propoxy group (C3), a butoxy group (C4), a pentyloxy group (C5), a hexyloxy group (C6), a heptyloxy group (C7) and an octyloxy group (C8), although not being limited thereto. Specifically, the alkoxy group of the present disclosure may be a methoxy group or an ethoxy group.
- In
Chemical Formula 1, - i) the structure wherein, if the bond between C-3 and C-4 and the the bond between C-5 and C-6 are single bonds, R2b is nonexistent and R2a is CH2 may be represented by <Chemical Formula 1-1>;
- ii) the structure wherein, if the bond between C-3 and C-4 is a double bond, the bond between C-5 and C-6 is a single bond, R2b is nonexistent and R2a is CH3 may be represented by <Chemical Formula 1-2>; and
- iii) the structure wherein, if the bond between C-5 and C-6 is a double bond, the bond between C-3 and C-4 is a single bond and R2a and R2b are CH3 may be represented by <Chemical Formula 1-3>.
- Specifically, the compound of the present disclosure of
Chemical Formula 1 may be the compounds described in [Table 1], although not being limited thereto. - Specifically, the sesquiterpene derivative compound of the present disclosure may be one wherein, in
Chemical Formula 1, if the bond between C-3 and C-4 and the bond between C-5 and C-6 are single bonds, R2b is nonexistent, R2a is CH2 and R3 is a functional group selected from a group consisting of R3b through R3d. - Specifically, in R3b, R9 may be selected from a group consisting of ethoxy, methoxy and R9a.
- Specifically, in R3c, R11 may be OH, R12 may be OCH3 and R13 may be CH3.
- Specifically, in R3d, R14 may be OCH3 and R15 and R16 may be CH3.
- Most specifically, the compound of
Chemical Formula 1 of the present disclosure may be a compound selected from a group consisting of: - 3-[[(1R,2S,4aS,8aS)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-4-hydroxy-5-(2-phenylethylamino)cyclohexa-3,5-diene-1,2-dione;
- 3-[[(1R,2S,4aS,8aS)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-2-hydroxy-5-methoxycyclohexa-2,5-diene-1,4-dione;
- 3-[[(1S,2R,4aR,8aR)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-5-ethoxy-2-hydroxycyclohexa-2,5-diene-1,4-dione;
- 18-methoxy-22-methyl-16-[{(5 S,8 S,9R,10S)-5,8,9-trimethyl-4-methylenedecahydronaphthalen-9-yl}methyl]benzo[d]-oxazol-17-ol; and
- 18-methoxy-22,22-dimethyl-16-[{(5R,8 S,9R,10S)-5,8,9-trimethyl-4-methylenedecahydronaphthalen-9-yl}methyl]benzo[d]-oxazol-17(2H)-one.
- The compound of
Chemical Formula 1 of the present disclosure may be extracted from sponge. Specifically, the compound ofChemical Formula 1 for preventing or treating macular degeneration or macular edema caused by vascular leakage in the eye may be obtained by a method including a step of extracting one or more sponge selected from a group consisting of Rhopaloeides sp., Spongia sp., Smenospongia sp., Hippospongia sp., Dactylospongia sp., Verongula sp., Dysidea sp., sponge SS-1047, sponge SS-265 and sponge SS-1208 by adding a C1-C6 organic solvent. - The C1-C6 organic solvent may be selected from a group consisting of a C1-C6 alcohol (methanol, ethanol, propanol, butanol, pentanol, hexanol), acetone, an ether, benzene, chloroform, ethyl acetate, methylene chloride, hexane, cyclohexane, acetonitrile, dichloromethane and petroleum ether.
- Specifically, the compound of the present disclosure of
Chemical Formula 1 may be obtained by a method including: a step of extracting sponge by adding water, a C1-C4 alcohol or a mixture thereof as a solvent, thereby preparing a sponge extract; and a step of fractionating the extract by adding a second solvent and separating the same through chromatography. - As the chromatography, any one known to those skilled in the art can be used without limitation, including silica gel column chromatography, LH-20 column chromatography, ion-exchange chromatography, medium pressure liquid chromatography, thin-layer chromatography (TLC), silica gel vacuum liquid chromatography, high-performance liquid chromatography, etc.
- The C1-C4 alcohol used to prepare the sponge extract may be selected from a group consisting of methanol, ethanol, propanol, isopropanol, butanol and isobutanol.
- As the second solvent for fractionating the sponge extract, a C1-C4 alcohol, n-hexane, methylene chloride, acetone, chloroform, dichloromethane, ethyl acetate, acetonitrile or a mixture thereof may be used.
- The compound of the present disclosure of
Chemical Formula 1 includes a pharmaceutically acceptable salt thereof. In the present disclosure, the term ‘pharmaceutically acceptable’ means being physiologically acceptable and not causing allergic reactions such as gastroenteric trouble, dizziness, etc. or similar reactions when administered to human. - The pharmaceutically acceptable salt includes an acid addition salt with an inorganic acid or an organic acid. As the acid addition salt, an acid addition salt formed by a pharmaceutically acceptable free acid is useful. As the free acid, an inorganic acid or an organic acid may be used. As the inorganic acid, hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, etc. may be used. And, as the organic acid, citric acid, acetic acid, lactic acid, tartaric acid, fumaric acid, formic acid, propionic acid, oxalic acid, trifluoroacetic acid, methanesulfonic acid, benzenesulfonic acid, maleic acid, benzoic acid, gluconic acid, glycolic acid, succinic acid, 4-morpholinoethanesulfonic acid, camphorsulfonic acid, 4-nitrobenzenesulfonic acid, hydroxy-O-sulfonic acid, 4-toluenesulfonic acid, galacturonic acid, embonic acid, glutamic acid, aspartic acid, etc. may be used.
- In an example of the present disclosure, it was found out that the compound of the present disclosure of
Chemical Formula 1 inhibits β-catenin in vitro, suggesting that it can inhibit vascular leakage by inhibiting the Wnt/0-catenin mechanism. In another example of the present disclosure, it was confirmed that the present disclosure compound exhibits therapeutic effect by inhibiting vascular leakage in a macular edema animal model in vivo. In addition, it was confirmed that it exhibits therapeutic effect regardless of administration routes because the compound was distributed in the target tissue (eye) even when it was administered through other administration routes (oral adminstration, intraperitoneal injection, etc.) rather than directly into the vitreous cavity. - Accordingly, in another aspect, the present disclosure relates to a pharmaceutical composition for inhibiting vascular leakage in the eye, which contains the compound of
Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient. - In the present disclosure, the term ‘vascular leakage’ refers to the leakage of body fluid or blood plasma due to damage to the integrity of blood vessels. The vascular leakage in the eye constitutes the major pathological conditions of various eye diseases. In the present disclosure, the term ‘vascular leakage in the eye’ refers to vascular leakage in various tissues (choroid, retina, etc.) constituting the eye. Specifically, it may refer to vascular leakage in the retina, although not being limited thereto.
- The pharmaceutical composition of the present disclosure has preventive or therapeutic effect for a disease caused by vascular leakage in the eye. The disease caused by vascular leakage in the eye may be any one known in the art. For example, it include retinal degeneration, macular degeneration, retinal edema and macular edema. Specifically, in the present disclosure, the disease caused by vascular leakage in the eye may be macular degeneration or macular edema.
- The pharmaceutical composition according to the present disclosure may contain only the sesquiterpene derivative compound of
Chemical Formula 1 or a pharmaceutically acceptable salt thereof or may further contain one or more pharmaceutically acceptable carrier, excipient or diluent. - As the pharmaceutically acceptable carrier, it may further contain, for example, a carrier for oral administration or a carrier for parenteral administration. The carrier for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, etc. And, the carrier for parenteral administration may include water, suitable oils, physiological saline, water-soluble glucose, glycol, etc. The pharmaceutical composition of the present disclosure may further contain a stabilizer and a preservative. A suitable stabilizer includes sodium bisulfite, sodium sulfite or an antioxidant such as ascorbic acid. A suitable preservative includes benzalkonium chloride, methyl- or propylparaben and chlorobutanol. In addition to these ingredients, the pharmaceutical composition of the present disclosure may further contain a lubricant, a humectant, a sweetener, a flavorant, an emulsifier, a suspending agent, etc. For other pharmaceutically acceptable carriers, reference can be made to the literature (Remington's Pharmaceutical Sciences, 19th ed., Mack Publishing Company, Easton, Pa., 1995).
- The composition of the present disclosure may be administered to mammals including human by any means. For example, it may be administered orally or parenterally. The parenteral administration method may include intravenous, intramuscular, intraarterial, intramedullary, intradural, intracardiac, intraocular, intravitreal, transdermal, subcutaneous, intraabdominal, intranasal, intraintestinal, topical, sublingual or intrarectal administration, although not being limited thereto.
- The pharmaceutical composition of the present disclosure may be prepared into a formulation for oral administration or parenteral administration depending on the administration routes.
- For oral administration, the composition of the present disclosure may be formulated into a powder, a granule, a tablet, a pill, a sugar-coated tablet, a capsule, a solution, a gel, a syrup, a slurry, a suspension, etc. using the method known in the art. For example, as the formulation for oral administration, a tablet or a sugar-coated tablet may be prepared by mixing the active ingredient with a solid excipient, pulverizing the mixture, adding a suitable adjuvant and then processing into a granule mixture. Examples of the suitable excipient may include sugars including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, etc., a starches including corn starch, wheat starch, rice starch, potato starch, etc., celluloses including cellulose, methyl cellulose, sodium carboxymethyl cellulose, hydroxypropylmethyl cellulose, etc. and fillers such as gelatin, polyvinylpyrrolidone, etc. If necessary, crosslinked polyvinylpyrrolidone, agar, alginic acid, sodium alginate, etc. may be added as a disintegrant. In addition, the pharmaceutical composition of the present disclosure may further contain an antiagglomerant, a lubricant, a humectant, a flavor, an emulsifier, an antiseptic, etc.
- For parenteral administration, the composition may be formulated into an injection, an eye drop, an ointment, a cream, a lotion, an oil, a gel, an aerosol or a nasal inhaler using the method known in the art. These formulations are described in the literature generally known in the field of pharmaceutical chemistry (Remington's Pharmaceutical Science, 15th Edition, 1975. Mack Publishing Company, Easton, Pa. 18042, Chapter 87: Blaug, Seymour).
- Specifically, the pharmaceutical composition of the present disclosure may be prepared into a formulation selected from a group consisting of an oral medication, an injection, an eye drop and an ointment.
- The total effective amount of the sesquiterpene derivative compound of the present disclosure or a pharmaceutically acceptable salt thereof may be administered to a patient with a single dose or a multiple dose according to the fractionated treatment protocol for long-term administration. The content of the active ingredient of the pharmaceutical composition of the present disclosure may vary depending on the severity of a disease. The effective administration dosage of the compound or a pharmaceutically acceptable salt thereof is determined in consideration of various factors including the route and number of administration of the pharmaceutical composition, the age, body weight, health condition and sex of a patient, the severity of a disease, diet, excretion rate, etc. Those of ordinary skill in the art will be able to determine the adequate effective administration dosage of the sesquiterpene derivative or a pharmaceutically acceptable salt thereof for prevention or treatment of a disease caused by vascular leakage in the eye in consideration of these factors. The pharmaceutical composition according to the present disclosure is not specially limited in formulation, administration route and administration method as long as the effect of the present disclosure can be achieved.
- In another aspect, the present disclosure relates to a food composition for preventing or improving macular degeneration or macular edema, which contains the compound represented by
Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient. - The food composition of the present disclosure includes all forms such as a functional food, a nutritional supplement, a health food, a food additive, a feed, etc. and is provided for animals including human or livestock. The food composition may be prepared into various forms according to the method known in the art.
- For example, the health food may be prepared by preparing the sesquiterpene derivative of the present disclosure or a sponge extract containing the sesquiterpene into tea, juice or a drink for drinking or into a granule, a capsule or a powder. In addition, a composition may be prepared by mixing the sesquiterpene derivative of the present disclosure or a sponge extract containing the sesquiterpene with an active ingredient known to be effective in improving and preventing macular edema or macular degeneration.
- Also, the functional food be prepared by adding the sesquiterpene derivative of the present disclosure or a sponge extract containing the sesquiterpene to beverages (including alcoholic beverage, fruit or processed fruit (e.g., canned fruit, bottling, jam, marmalade, etc.), fish, meat or processed foodstuffs thereof (e.g., ham, sausage corn beef, etc.), bread or noodles (e.g., udon, buckwheat noodle, instant noodle, spaghetti, macaroni, etc.), fruit juice, drinks, cookies, taffy, dairy products (e.g., butter, cheese, etc.), vegetable fats and oils, margarine, vegetable proteins, retort foods, frozen foods, condiments (e.g., soybean paste, soy sauce, etc.), etc.
- In addition, the sesquiterpene derivative of the present disclosure or a sponge extract containing the sesquiterpene may be prepared into a powder or a concentrate for use as a food additive.
- Hereinafter, the present disclosure will be described in detail through examples. However, the following examples are for illustrative purposes only and it will be apparent to those of ordinary skill in the art that the scope of the present disclosure is not limited by the examples.
- A Hyrtios sp. (38 g dry weight) sample preserved in EtOH was extracted completely using MeOH. After evaporating the MeOH extract in vacuo, the remaining residue (15.6 g) was fractionated using water and a CH2Cl2 solvent. The organic phase was evaporated in vacuo and a gum (5.32 g) was obtained. 2.37 g of the gum was subjected to flash chromatography using a Si gel column and using hexane and EtOAc of increasing concentrations as eluents. Some of the resulting fractions were subjected to flash chromatography using a Si gel column and using hexane/EtOAc (100:0 to 50:50). Two UV-positive fractions were obtained and further purified by HPLC (UV detection at 210 nm, eluent 90:10 MeOH/H2O) to obtain a compound of Preparation Example 1 (3 mg).
- The obtained compound of Preparation Example 1 had the following physicochemical properties and was identified as ‘methyl 3-[[(1R,2S,4aR,8aS)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]-4,5-dihydroxybenzoate’.
- Amorphous Solid.
- IR (film) 3339, 1680, 1303 cm1.
- UV (CH3OH) λmax 221 (17440), 269 (7460), 305 nm (3341, sh).
- UV (CH3OH/NaOH) λmax 210 (18520), 241 (13176), 284 (4310), 322 nm (6950).
- 1H NMR (600 MHz) δ 7.49 (1H, d, 1.5), 7.45 (1H, d, 1.5), 5.32 (1H, bs), 3.87 (3H, s), 2.84 (1H, d, 14) and 2.60 (1H, d, 14) AB system, 1.64 (3H, bs), 0.98 (3H, d, 6), 0.95 (3H, s), 0.90 (3H, s).
- 13C NMR (CDCl3, 150.87 MHz): see [Table 2].
-
TABLE 2 Carbon Preparation Example 1 (δ ppm) C-1 19.7 C-2 25 C-3 124.3 C-4 140 C-5 37.7 C-6 37.8 C-7 29.5 C-8 37.6 C-9 43.9 C-10 44.9 C-11 38.1 C-12 17.3 C-13 18.4 C-14 33 C-15 20.5 C-16 126.2 C-17 149.2 C-18 143.1 C-19 114.6 C-20 121.3 C-21 128.1 C-22 168.2 C-23 52.8 - A sponge (Smenospongia sp.) sample (2 kg) was immersed in MeOH and extracted with CHCl3/MeOH (1/1 mixture). The extract was evaporated under reduced pressure and an aqueous suspension thereof was extracted with CH2Cl2 (extract A). The extract A (8 g) was subjected to silica gel (CHCl3/MeOH of increasing concentrations) chromatography. A
fraction 1 eluted with 2% MeOH (in CHCl3) and afraction 2 eluted with 5% MeOH (in CHCl3) were prepared therefrom. Thefraction 1 was eluted with 30% AcOEt (in hexane) to obtain a compound of Preparation Example 2 (20 mg). - The obtained compound of Preparation Example 2 had the following physicochemical properties and was identified as ‘3-[[(1S,2R,4aR,8aR)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-2,5-dihydroxycyclohexa-2,5-diene-1,4-dione’.
- C21H28O4.
- m.p.>350° C.
- SM m/e (%): 191 (40), 154 (12), 135 (44), 121 (65), 109 (56), 107 (87), 95 (100).
- UV (EtOH) λmax nm (c): 214, 286.
- IR (KBr) ν cm−1: 3324, 2940, 1645, 1535.
- 1H NMR (MeOD, 80 MHz) δ ppm: 5.71 (1H, s), 4.76 (2H, br s), 2.40 (2H, br s), 1.01 (3H, s), 0.92 (3H, d, J=7 HZ), 0.78 (3H, s).
- 13C NMR (δ ppm, CD3OD, 20.115 MHz): see [Table 3].
- 44 g of dried sponge (Smenospongia sp.) was extracted with CH2Cl2 and then with MeOH (extract B). The extract B (4 g) was subjected to chromatography using a silica gel column (CHCl3/increasing amounts MeOH) to obtain a fraction A eluted with 2% MeOH (in CHCl3) and a fraction B eluted with 5% MeOH (in HCl3). The faction A was purified with a Sephadex LH 20 (MeOH/CHCl3: 60/40) column to obtain a compound of Preparation Example 3 (20 mg) and a compound of Preparation Example 4 (5 mg).
- The obtained compound of Preparation Example 3 had the following physicochemical properties and was identified as ‘3-[[(1R,2S,4aS,8aS)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-4-hydroxy-5-(3-methylbutylamino)cyclohexa-3,5-diene-1,2-dione’.
- C26H39NO3.
- m.p.: 170-172° C.
- SM m/e (%): 413 (4), 311 (8), 283 (12), 223 (100), 191 (11), 167 (22), 153 (27), 149 (15), 135 (14), 121 (16), 109 (18), 107 (12), 95 (79).
- m/e 191.179, calc. 191.179 for C14H23; m/e 223.119, calc. 223.120 for C12H17NO3.
- UV (EtOH) λmax nm (c): 204 (27230), 324 (14070).
- IR (KBr) ν cm−1: 3417, 3275, 1640, 1592.
- 1H NMR (CDCl3 0.200 MHz) δ ppm: 8.41 (1H exch., s), 6.41 (1H exch., t). 5.36 (1H, s), 4.43 (br s), 3.20 (2H, dt), 2.48 (d), 2.37 (d) (AB syst.), 2.31 (dt), 2.07 (2H, m), 1.85 (1H, m), 1.80-1.05 (11H, m), 1.04 (3H, s), 0.95 (9H, 3d overlapped), 0.83 (3H, s), 0.78 (1H, dd).
- 13C NMR (δ ppm, CDCl3, 20.115 MHz): see [Table 3].
-
TABLE 3 Preparation Carbon Example 2 (δ ppm) Preparation Example 3 (δ ppm) 1 24.49 t 23.20 t 2 29.48 t 27.98 t 3 38.30 t 36.85 t 4 162.35 s 160.33 s 5 41.61 s 40.41 s 6 33.70 t 32.97 t 7 30.05 t 28.63 t 8 39.20 d 37.% d 9 43.65 s 42.89 s 10 51.46 d 50.01 d 11 102.58 t 102.39 t 12 21.06 q 20.48 q 13 18.88 q 17.80 q 14 17.85 q 17.16 q 15 33.94 t 32.57 t 16 114.45 s 113.53 s 17 188.82 s* 157.06 s 18 179.65 s* 182.77 s 19 101.79 d 91.484 d 20 174.72 s* 150.21 s 21 166.80 s* 177.97 s *may be reversed - A compound of Preparation Example 4 was prepared in the same manner as in Preparation Example 3. The obtained compound (Preparation Example 4) had the following physicochemical properties and was identified as ‘3-[[(1S,2R,4aR,8aR)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-4-hydroxy-5-(2-methylpropylamino)cyclohexa-3,5-diene-1,2-dione’.
- C25H37NO3.
- SM m/e (%): 399 (5). 209 (100). 191(17), 166 (36). 152 (18), 135 (11), 121 (15), 109 (15), 107 (12), 95 (66).
- UV (EtOH) λmax nm (c): 210 (14000), 329 (20150).
- IR (KBr) ν cm−1: 3417, 3275, 1640, 1592.
- 1H NMR (CDCl3, 200 MHz) δ ppm: 6.53 (1H, s). 5.41 (1H, s), 4.45 (2H, br s), 2.95 (2H, dt), 2.48 (1H, d), 2.45 (1H, d, J=13 Hz), 1.03 (3H, s), 0.97 (9H, 3d overlapped), 0.82 (3H, s). 0.76 (1H, dd).
- MeOH and DCM crude extracts of Hippospongia sp. were combined and fractionated with MeOH, DCM, hexane and BuOH. Among them, the hexane, DCM and MeOH fractions were subjected to flash column chromatography and semi-preparative RP-HPLC to obtain a compound of Preparation Example 5.
- The obtained compound (Preparation Example 5) had the following physicochemical properties and was identified as ‘3-[[(1R,2S,4aS,8aS)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-5-amino-4-hydroxycyclohexa-3,5-diene-1,2-dione’.
- Purple Solid.
- C21H30O3N (HRESIMS m/z 344.2295, [M+H]+).
- UV (MeOH) λmax (log ε) 315 (3.58) nm.
- IR (KBr) 3835, 3566, 1624, 1536 cm−1.
- 1H NMR (400 MHz, CD3OD) δ: 2.17/1.43 (2H, m H-1), 1.39 (2H, m, H-2), 1.50/1.38 (2H, m, H-3), 2.34/2.05 (2H, m, H-6), 1.23/1.82 (2H, m, H-7), 1.23 (1H, m, H-8), 0.82 (1H, m, H-10), 4.44 (2H, s, H-11), 1.05 (3H, s, H-12), 0.98 (3H, d, J=6.4 Hz H-13), 0.84 (3H, s, H-14), 2.47/2.40 (2H, dd, J=13.7 Hz, H-15), 5.51 (1H, s, H-19).
- 13C NMR (100 MHz, CD3OD) δ: 22.8 (t, C-1), 27.5 (t, C-2), 36.4 (t, C-3), 160.1 (s, C-4), 39.9 (s, C-5), 32.5 (t, C-6), 28.3 (t, C-7), 37.6 (d, C-8), 42.1 (s, C-9), 49.7 (d, C-10), 101.1 (t, C-11), 19.4 (q, C-12), 16.9 (q, C-13), 16.2 (q, C-14), 31.6 (t, C-15), 113.7 (s, C-16), 159.4 (s, C-17), 183.2 (s, C-18), 93.6 (d, C-19), 183.2 (s, C-21).
- After freeze-drying sponge (Dactylospongia elegans), an extract obtained by adding MeOH (3×1 L) to the freeze-dried sponge (33 g dry weight) was concentrated in vacuo and subjected to reversed-phase C18 vacuum liquid chromatography (0%, 20%, 50%, 70%, 90%, 100% MeOH in H2O and 1:1 CH2Cl2/MeOH). 20%, 50% and 70% MeOH fractions were obtained and subjected to C18 preparative HPLC (4 mL/min, gradient elution from 3:7 H2O/MeCN/0.1% formic acid to 100% MeCN/0.1% formic acid over 10 min, through a 150×10 mm, 5 m Phenomenex phenyl hexyl column). A Preparation Example 6 compound (11.7 mg, 0.035%), a Preparation Example 7 compound (1.4 mg, 0.004%) and a Preparation Example 8 compound (0.8 mg, 0.002%) were obtained therefrom.
- The prepared Preparation Example 6 compound had the following physicochemical properties and was identified as ‘2-[[5-[[(1R,2S,4aS,8aS)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-6-hydroxy-3,4-dioxocyclohexa-1,5-dien-1-yl]amino]acetic acid’.
- Amorphous, red solid;
- [α]D+94.4 (c 0.018, MeOH).
- UV (PDA, CH3CN/H2O) λmax 218, 311, 494 nm.
- IR (neat) νmax 3598, 2936, 2064, 1657 cm1′.
- 1H (300 MHz) and 13C (75 MHz) NMR (CD3OD): see [Table 4].
- HRESIMS m/z 424.2104 [M+Na]+ (calcd for C23H31NO5Na, 424.2094, Δ 1.0 mmu).
-
TABLE 4 no. δC mult δH (J in Hz) COSY gHMBC δC, mult δH (J in Hz) 1 24.2 CH2 2.19 br d(12.7) H -1, H -2, H-10 2.15 22.7, CH2 2.09, m 1.48, m H -1, H -2, H-10 1.35, m 2 29.7, CH2 1.84 dd (12.7, 3.0) H -1, H -2, H -3 28.0, CH2 1.74, m 1.23, m H -1, H -2, H -3 1.14, m 3 34.0, CH2 2.35, ddd (13.8, 5.2, 3.0) H -2, H -3, H -11 4 32.1, CH2 2.23, m 2.04, dd (13.8, 5.2) H -2, H -3 1, 2, 4, 11 1.99, m 4 161.4, C 159.3, C 5 41.3, C 39.8, C 6 37.8, CH2 1.51, m H -6, H -7 8, 10 36.4, CH2 1.43, m 1.41, m H -6 5, 7, 8, 12 1.27, m 7 28.8, CH2 1.40, m H2-6 6, 8, 9 27.6, CH2 1.32, m 1.11, m 8 38.9, CH 1.25, m H -7, H 13 7, 13 37.3, CH 1.17, m 9 43.7, C 42.2, C 10 50.9, CH 0.85, m H2-1 1, 8, 9, 12, 15 49.3, CH 0.74, m 11 103.1, CH2 4.40 br s H -3, H2-11 3, 4, 5 102.9, CH2 4.40, s 4.37, s 12 20.9, CH 1.05, s 4, 5, 6, 10 20.2, CH3 0.97, s 13 18.5, CH 0.98, d (6.3) H-8 7, 8, 9 18.1, CH3 0.92, d (6.2) 14 17.4, CH 0.84, s 8, 9, 10, 15 17.3, CH3 0.76, s 15 33.1, CH2 2.50, d (13.8) H -15 8, 9, 10, 14, 16, 17, 21 32.0, CH3 2.36, d (13.6) 2.40, d (13.8) H -15 8, 9, 10, 14, 16, 17, 21 2.27, d (13.6) 16 115.4, C 113.2, C 17 159.4, C 159.7, C 18 182.2, C 180.4, C 19 93.6, CH 5.27, s 17, 18, 21 92.9, CH 5.19, s 20 150.9, C 149.6, C 21 183.8, C 181.8, C 22 7.56, s (5.8) 23 44.7, CH2 3.94, br s 20, 24 42.1, CH3 3.88, d (5.8) 24 171.7, C 169.8, C *CD, OD, 75 MHz, 300 MHz, dHMBC correlations are from proton(s) stated to the indicated carbons, DMSO-d . indicates data missing or illegible when filed - A compound of Preparation Example 7 was prepared in the same manner as in Preparation Example 6. The prepared compound (Preparation Example 7) had the following physicochemical properties and was identified as ‘3-[[5-[[(1R,2S,4aS,8aS)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-6-hydroxy-3,4-dioxocyclohexa-1,5-dien-1-yl]amino]propanoic acid’.
- Amorphous, Red Solid.
- [α]D+13 (c 0.06, MeOH).
- UV (PDA, CH3CN/H2O) λmax 233, 314, 494 nm.
- IR (neat) λmax 3410, 2930, 1686, 1632, 1567 cm−1.
- HRESIMS m/z 438.2264 [M+Na]+ (calcd for C24H33NO5Na, 438.2251, Δ 1.3 mmu).
- 1H NMR (CD3OD, 300 MHz) δ 5.38 (1H, s, H-19), 4.40 (2H, s, H2-11), 3.45 (2H, t, J=6.8 Hz, H2-23), 2.59 (2H, t, J=6.8 Hz, H2-24), 2.47 (1H, d, J=13.6 Hz, Ha-15), 2.38 (1H, d, J=13.6 Hz, Hb-15), 2.32 (1H, m, Ha-3), 2.16 (1H, m, Ha-1), 2.04 (1H, m, Hb-3), 1.80 (1H, m, Ha-2), 1.48 (1H, m, Ha-6), 1.43 (1H, m, Hb-1), 1.41 (1H, m, Ha-7), 1.36 (1H, m, Hb-6), 1.35 (1H, m, Hb-7), 1.29 (1H, m, Hb-2), 1.21 (1H, m, H-8), 1.04 (3H, s, H3-12), 0.97 (3H, d, J=6.4 Hz, H3-13), 0.83 (3H, s, H3-14), 0.81 (1H, m, H-10).
- 13C NMR (CD3OD, 75 MHz) δ 183.4 (C, C-21), 179.6 (C, C-18), 176.0 (C, C-25), 162.9 (C, C-4), 161.1 (C, C-17), 152.0 (C, C-20), 115.5 (C, C-16), 103.3 (CH2, C-11), 92.6 (CH, C-19), 51.1 (CH, C-10), 44.0 (C, C-9), 41.8 (C, C-5), 39.9 (CH2, C-23), 39.0 (CH, C-8), 38.2 (CH2, C-6), 34.5 (CH2, C-24), 34.2 (CH2, C-3), 33.4 (CH2, C-15), 30.0 (CH2, C-2), 29.4 (CH2, C-7), 24.3 (CH2, C-1), 21.4 (CH3, C-12), 18.7 (CH3, C-13), 18.1 (CH3, C-14).
- A compound of Preparation Example 8 was prepared in the same manner as in Preparation Example 6. The prepared compound (Preparation Example 8) had the following physicochemical properties and was identified as ‘7-[[(1R,2S,4aS,8aS)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-1,3-benzoxazole-5,6-diol’.
- Colorless Solid.
- [α]D−6.7 (c 0.075, MeOH).
- UV (PDA, CH3CN/H2O) λmax 236, 297, 323 (sh) nm.
- IR (neat) νmax 3408, 2927, 1541 cm−1.
- 1H (300 MHz) and 13C (75 MHz) NMR (CD3OD): see [Table 5].
- HRESIMS m/z 378.2050 [M+Na]+ (calcd for C22H29NO3Na, 378.2040, Δ 1.0 mmu).
-
TABLE 5 no. δC, mult.a δN (J in Hz)b COSY gHMBCc 1 24.8, CH2 2.37, m Hb-1, Ha-2, H-10 2 1.55, m Ha-1, H-10 2 30.2, CH2 1.87, m Hb-2, Ha-3 1.28, m Ha-1, Ha-2, H2-3 3 34.4, CH2 2.32, m Hb-2, Hb-3 2, 4, 11 2.03, m Ha-2, Ha-3 5 4 161.8, C 5 41.8, C 6 38.3, CH2 1.45, m 8 7 29.5, CH2 1.41, m 8 38.7, CH 1.41, m H3-13 9 44.2, C 10 51.1, CH 0.94, m H2-1 5, 9, 12, 14 11 103.4, CH2 4.35, s 3, 4, 5 4.32, s 3, 4, 5 12 20.7, CH3 1.07, s 4, 5, 6, 10 13 19.2, CH3 1.08, d (6.8) H-8 7, 8, 9 14 18.3, CH3 0.95, s 8, 9, 10, 15 15 35.8, CH2 2.94, d (13.9) Hb-15 8, 9, 10, 14, 16, 17, 21 2.86, d (13.9) Ha-15 8, 9, 10, 14, 16, 17, 21 16 111.0, C 17 146.7, C 18 145.2, C 19 102.6, CH 6.96, s 17, 18, 20, 21 20 131.7, C 21 146.7, C 22 153.2, CH 8.20, s 20, 21 a75 MHz, b300 MHz, cHMBC correlations are from proton(s) stated to the indicated carbons. - As in Preparation Example 5, after freeze-drying sponge (Dactylospongia elegans), an extract was prepared by adding MeOH (3×1 L) to the freeze-dried sponge (33 g dry weight).
- The substance insoluble in MeOH (120 mg) was added to pyridine (0.5 mL) and stirred at room temperature for 12 hours after treating with (CH3CO)2O (0.5 mL). The obtained substance was concentrated in vacuo and subjected to sequential reversed-phase HPLC separation (A: H2O/MeCN+0.1% formic acid (3:7) to 100% MeCN+0.1% formic acid over 10 min at 4 mL/min and held for an additional 10 min on a 150×10 mm, 5 μm Phenomenex Luna C18 column; B: H2O/MeOH with 0.1% formic acid (3:7) to 100% MeOH with 0.1% formic acid for 10 min at 4 mL/min and held for an additional 5 min on a 150×10 mm, 5 μm Phenomenex Luna phenyl hexyl column). The obtained compound of Preparation Example 9 (2.3 mg, 0.007%) had the following physicochemical properties and was identified as ‘[7-[[(1R,2S,4aS,8aS)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-6-acetyloxy-1,3-benzoxazol-5-yl] acetate’.
- Colorless Oil.
- [α]D−170 (c 0.003, CHCl3).
- UV (PDA, CH3CN/H2O) λmax 233, 278, 284, 300 (sh) nm.
- IR (neat) νmax 3488, 2927, 1775, 1630, 1458 cm−1.
- HRESIMS m/z 462.2250 [M+Na]+ (calcd for C26H33NO5Na, 462.2251, Δ 0.1 mmu).
- 1H NMR (CDCl3, 300 MHz) δ 8.07 (1H, s, H-22), 7.54 (1H, s, H-19), 4.42 (1H, d, J=1.6 Hz, Ha-11), 4.38 (1H, d, J=1.6 Hz, Hb-11), 2.83 (1H, d, J=14.2 Hz, Ha-15), 2.76 (1H, d, J=14.2 Hz, Hb-15), 2.35 (1H, m, Ha-3), 2.34 (s, a-OCOCH3), 2.30 (s, b-OCOCH3), 2.08 (1H, m, Hb-3), 1.92 (1H, m, Ha-2), 1.58 (1H, m, Ha-1), 1.49 (1H, m, Ha-6), 1.45 (1H, m, Hb-1), 1.43 (1H, m, H-8), 1.42 (2H, m, H2-7), 1.28 (1H, m, Hb-6), 1.26 (1H, m, Hb-2), 1.07 (3H, s, H3-12), 0.97 (3H, d, J=5.6 Hz, H3-13), 0.94 (3H, s, H3-14), 0.92 (1H, m, H-10).
- 13C NMR (CDCl3, 150 MHz) δ168.1 (C, a-OCOCH3), 167.9 (C, b-OCOCH3), 159.1 (C, C-4), 152.7 (CH, C-22), 147.9 (C, C-21), 140.4 (C, C-17), 137.4 (C, C-18), 136.6 (C, C-20), 118.3 (C, C-16), 111.9 (CH, C-19), 102.2 (CH2, C-11), 50.1 (CH, C-10), 43.0 (C, C-9), 40.3 (C, C-5), 37.6 (CH, C-8), 36.2 (CH2, C-6), 35.6 (CH2, C-15), 32.6 (CH2, C-3), 28.3 (CH2, C-2), 27.7 (CH2, C-7), 23.1 (CH2, C-1), 20.1 (2×CH3, —OCOCH3), 19.9 (CH3, C-12), 18.1 (CH3, C-13), 16.8 (CH3, C-14).
- A sponge (Spongiidae SS-1047, 0.30 kg, wet weight) was obtained as described in the literature ‘Yohei Takahashi et al., 2010’ and extracted. Briefly, EtOAc-soluble substances (1.2 g) were fractionated using a silica gel column (n-hexane/EtOAc) and a
fraction 1, afraction 2 and afraction 3 of low polarity and a polar fraction 4 were prepared. Thefraction 3 was fractionated and purified by C18 column (MeOH/H2O) and C18 HPLC (Luna 5u Phenyl-Hexyl, 250×10 mm; eluent, MeOH/H2O/CF3CO2H, 85:15:0.05; flow rate, 2.5 mL/min; UV detection at 320 nm) to obtain compounds of Preparation Example 10 and Preparation Example 11. - The obtained Preparation Example 10 compound had the following physicochemical properties and was identified as ‘3-[[(1R,2S,4aS,8aS)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]-2-hydroxy-5-methoxycyclohexa-2,5-diene-1,4-dione’.
- m.p.: 95-98° C.
- [α]20 579+64.4° (c 0.27 CHCl3).
- IR (film) 3341, 1652, 1645, 1609, 1243 cm1′.
- UV(CH3OH) λmax 213 (9600), 288 nm (13485).
- UV (CH3OH/NaOH) λmax 210 (12850), 290 (8930), 526 nm (1650).
- 1H NMR (600 MHz, CDCl3, 6, J in Hz): see [Table 6].
- 13C NMR (150.87 MHz, CDCl3): see [Table 6].
- HREIMS m/z 358.2151 [M+](12, calcd for C22H30O4, 358.2144), 191.1803 (15, calcd for C14H23, 191.1800), 168.0423 (41, calcd for C8H8O4, 168.0422), 121.1013 (12, calcd for C9H13, 121.1017), 107.0859 (30, calcd for C8H11, 107.0861), 95.0861 (100, calcd for C7H11, 95.0861).
-
TABLE 6 13C NMR position 1 H NMR carbon 1a 1 1c H2C-1 1.40, m C-1 17.7 19.9 20.6 1.97, m H2C-2 1.82, m C-2 27.1 27.1 27.8 1.93, m HC-3 5.06, bs C-3 121 121 121.6 H2C-6 0.96 (ax), m C-4 143.9 143.9 144.7 1.57 (eq), ddd, 13.0, 3.0, 3.0 H2C-7 1.25, m C-5 43.1 38.6 39.2 1.28, m HC-8 1.17, m C-6 36.1 36.1 36.7 HC-10 0.95, bd, 12.0 C-7 28.1 28.1 28.6 H2C-11 2.42, d, 14.0 C-8 38.1 38.1 38.6 2.55, d, 14.0 ABsystem H3C-12 0.77, s C-9 38.6 43.1 43.8 H3C-13 0.90, d, 6.0 C-10 48.2 48.2 48.6 H3C-14 0.94, s C-11 32.5 32.5 33 H3C-15 1.47, bs C-12 17.3 17.3 18 H3C-0 3.79, s C-13 18.1 17.7 18.4 HC-18 C-14 19.9 20.2 20.9 HC-19 5.77, s C-15 20.2 18.1 18.9 HC-21 C-16 117.8 117.8 118.3 C-17 182.4 182.4 183 C-18 161.8 161.8 162.5 C-19 102 102 102.7 C-20 182 182 182.8 C-21 153.4 153.4 154 C-22 56.8 56.8 57.5 indicates data missing or illegible when filed - A compound of Preparation Example 11 was prepared in the same manner as in Preparation Example 10. The obtained compound (Preparation Example 11) had the following physicochemical properties and was identified as ‘2-hydroxy-5-methoxy-3-[[(1R,2S)-1,2,5,5-tetramethyl-2,3,6,7,8,8a-hexahydronaphthalen-1-yl]methyl]cyclohexa-2,5-diene-1,4-dione’.
- Pale Yellow Feathery Solid.
- m.p. 108.5-109.5° C.
- C22H30O4 (high resolution FABMS (M+358.2146, Δ 0.2 mmu, C22H30O4; MH+ 359.2223, Δ 0.1 mmu, C22H31O4)).
- 1H NMR (500 MHz, CDCl3) δ: 0.73 (s, 3H), 0.90 (sh, 1H), 0.92 (s, 3H), 0.96 (d, J=7 Hz, 3H), 0.99 (s, 3H), 1.12 (ddd, J=13.5, 13.5, 4.3 Hz, 1H), 1.33-1.45 (complex mult., 4H), 1.73 (mult, 1H), 1.79 (br d, 1H), 1.95 (ddd, J=18, 17.5, 4.5 Hz, 1H), 2.08 (br d, J=13 Hz, 1H), 2.45 (d, cJ=13.0 HZ, 1H), 2.58 (d, J=13.0 Hz, 1H), 3.84 (s, 3H), 5.35 (br s, 1H), 5.84 (s, 1H), 7.45 (s, 1H); 13C NMR (500 MHz, CDCl3), δ (mult., proton assignments): 16.0 (q, 0.73, C-14), 16.5 (q, 0.92, C-11), 22.7 (t, 1.40, 1.46, C-2), 27.9 (q, 0.96, C-13), 29.7 (q, 0.99, C-12). 30.6 (t, 0.90, 1.79, C-l), 31.5 (t, 1.73, 1.95, C-7), 32.7 (t, 2.45, 2.58, C-15), 36.3 (s, C-4), 36.4 (d, 1.36, C-8), 40.9 (s, C-g), 41.2 (t, 1.13, 1.32, C-3), 41.7 (s, 2.08, C-10), 56.8 (q, 3.86, C-22), 102.0 (d, 5.85, C-19), 114.8 (d, 5.35, C-6), 118.3 (s, C-16), 146.3 (s, C-5), 152.8 (s, —OH, C-17), 161.5 (s, C-20), 182.0 (s, C-21), 182.4 (s, C-18).
- The
fraction 1 obtained in Preparation Example 10 was refractionated by Cis column (MeOH/H2O) and C18 HPLC (Wakosil-II 5C18AR, Wako Pure Chemical Industries, Ltd., 250×10 mm; eluent, MeCN/H2O/CF3CO2H, 90:10:0.05; flow rate, 2.0 mL/min; UV detection at 300 nm) to obtain a compound of Preparation Example 11 (2.8 mg, 0.00093% wet weight) and a compound of Preparation Example 12 (24.7 mg, 0.0082%). - The obtained Preparation Example 12 compound had the following physicochemical properties and was identified as ‘3-[[(1R,2S,8aS)-1,2,5,5-tetramethyl-2,3,6,7,8,8a-hexahydronaphthalen-1-yl]methyl]-4-hydroxy-5-(2-phenylethylamino)cyclohexa-3,5-diene-1,2-dione’.
- Purple-Red, Amorphous Solid.
- [α]23 D−14 (c 0.2, CHCl3).
- IR (film) νmax 3290, 1730, 1650, 1590, 1510, 1460, 1380, 1360, 1220 cm−1.
- UV (MeOH) λmax 336 (log 4.28), 507 nm (2.84).
- 1H NMR (CDCl3): see [Table 7].
- 13C NMR (CDCl3): see [Table 7].
- EIMS m/z (%) 447 (M+, 9), 257 (100), 191 (2), 166 (20), 152 (5), 105 (10), 95 (15); HREIMS m/z 447.2790 [M]+ (calcd for C29H37NO3, 447.2773).
-
TABLE 7 position δC δH (m, J in Hz) HMBC NOESY 1 30.5 CH2 1.85 (m) 1b, 2a, 10, 14, 15a 0.95 (m) 1a, 3b 2 22.8 CH2 1.49 (m) 1a, 1b, 2a, 3b 1.32 (m) 2a, 3a, 12 3 41.3 CH2 1.37 (m) 2, 11, 12 3b 1.16 (ddd, 13.5, 13.5, 4.1) 2, 4, 11, 12 2a, 3a, 11 4 36.4 C 5 146.5 C 6 114.8 CH 5.38 brs 4, 8, 7, 10 7a, 7b, 11 7 31.6 CH2 1.96 (ddd, 17.3, 5.2, 5.2) 5, 6, 8, 9, 13 7b, 8, 13 1.77 (dddd, 17.3, 9.5, 2.6, 2.6) 5, 6, 8, 13 7a, 8, 13, 14 8 36.3 CH 1.39 (m) 7, 9, 13 7a, 10, 13, 15b 9 40.6 C 10 41.6 CH 2.10 (m) 5 1a, 2b, 8, 12, 15b 11 29.7 CH3 1.03b (brs) 3, 4, 5, 12 3a, 3b 12 28.0 CH3 0.95b (s) 3, 4, 5, 11 2b, 10 13 16.5 CH3 0.99b (d, 6.7) 7, 8, 9 7a, 7b, 8, 14, 5a, 15b 14 15.9 CH3 0.74b (s) 8, 9, 10, 15 1a, 1b, 7b, 13, 15a, 15b 15 32.7 CH3 2.54 (d, 13.4) 8, 9, 10, 14, 16, 17, 21 1a, 13, 14, 15b 2.41 (d, 13.4) 8, 9, 10, 14, 16, 17, 21 8, 10, 13, 15a 16 114.7 C 17 156.5 C 18 178.5 C 19 91.8 CH 5.42 (s) 17, 21 22, 23 20 149.9 C 21 183.0 C 22 44.0 CH3 3.44a (td, 6.9, 6.1) 20, 23, 24 19, 23, 25 23 34.2 CH2 2.95a (t, 6.9) 22, 24, 25 19, 22, 25 24 137.4 C 25 128.5 CH 7.19 (d, 73) 23, 27 22, 23 26 128.9 CH 7.33 (dd, 7.3, 7.3) 24, 27 27 127.0 CH 7.26 (t, 7.3) 25 20-NH 6.54 (brs) 19, 21 H H C indicates data missing or illegible when filed - A compound of Preparation Example 13 was prepared in the same manner as in Preparation Example 12. The obtained compound (Preparation Example 13) had the following physicochemical properties and was identified as ‘3-[[(1R,2S,4aS,8aS)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]-4-hydroxy-5-(2-phenylethylamino)cyclohexa-3,5-diene-1,2-dione’.
- Purple-Red. Amorphous Solid.
- [α]25 D+180 (c 0.1, CHCl3).
- IR (film) λmax 3270, 1730, 1640, 1590, 1510, 1460, 1380, 1210 cm−1.
- UV (MeOH) λmax 335 (log 4.20), 502 nm (2.74).
- 1H NMR (CDCl3): see [Table 8].
- 13C NMR (CDCl3): see [Table 8].
- EIMS m/z (%) 447 (M+, 25), 257 (100), 209 (17), 191 (18), 168 (45), 166 (48), 152 (17), 119 (42), 105 (40);
- HREIMS m/z 447.2783 [M]+ (calcd for C29H37NO3, 447.2773).
-
TABLE 8 Pos. δC δH (m, J in Hz) HMBC NOESY 1 19.9 CH2 2.03 (m) 5 1b, 2b, 10, 14, 15a 1.45 (dddd, 12.0, 12.0, 12.0, 6.1) 1a, 2a, 12, 14 2 27.0 CH2 1.98 (m) 1b, 2a, 2b, 3, 10 1.81 (m) 1a, 2a, 3 3 120.8 CH 5.12 (brs) 2a, 2b, 11 4 144.1 C 5 38.5 C 6 36.0 C 1.62 (ddd, 12.2, 3.1, 3.1) 6b, 7 1.05 (ddd, 12.2, 12.2, 4.8) 6a, 7 7 28.0 CH2 1.32 (m) 6a, 6b, 8, 13, 14 8 37.7 CH 1.26 (m) 7, 10 9 42.7 C 10 47.6 CH 1.03 (overlapped) 1a, 2b, 8, 15a 11 18.2 CH3 1.54b (brs) 3, 4, 5 3, 12 12 20.1 CH3 1.00b (s) 4, 5, 6, 10 6a, 6b, 14 13 17.7 CH3 0.95b (d, 6.3) 7, 8, 9 7, 14 14 17.3 CH3 0.82b (s) 8, 9, 10, 15 1a, 1b, 8, 12, 13, 15a, 15b 15 32.4 CH2 2.56 (d, 13.9) 8, 9, 14, 16, 17, 21 1a, 10, 14, 15b 2.41 (d, 13.9) 9, 10, 14, 16, 17, 21 13, 14, 15a 16 113.9 C 17 156.9 C 18 178.3 C 19 91.8 CH 5.40 (s) 17, 21 22 20 150.9 C 21 182.8 C 22 44.0 CH3 3.42 (1d, 7.1, 6.7) 20, 23, 24 19, 23, 25, 20-NH 23 34.3 CH3 2.95 (t, 7.1) 22, 24, 25 19, 22, 25, 20-NH 24 137.4 C 25 128.6b CH 7.18 (d, 7.2) 23, 27 22, 23, 26 26 128.9c CH 7.33 (dd, 7.4, 7.2) 24, 25 25, 27 27 127.1 CH 7.26 (t, 7.4) 25 26 17-OH 8.36 (brs) 22, 23 20-NH 6.46 (brt, 6.7) 22, 23 a2H, b3H, c2C. indicates data missing or illegible when filed - The
fraction 2 obtained in Preparation Example 10 was subjected to C18 column (MeOH/H2O/CF3CO2H) and C18 HPLC (Luna 5u Phenyl-Hexyl, Phenomenex, 250×10 mm; eluent, MeCN/H2O/CF3CO2H, 80:20:0.05; flow rate, 2.0 mL/min; UV detection at 300 nm) to obtain a compound of Preparation Example 14 (0.9 mg, 0.00030%), a fraction y and afraction 6. - The obtained compound of Preparation Example 14 had the following physicochemical properties and was identified as ‘3-[[(1R,2S,4aS,8aS)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]-4-hydroxy-5-(2-methylpropylamino)cyclohexa-3,5-diene-1,2-dione’.
- Purple-Red, Amorphous Solid.
- [α]23 D+160 (c 0.1, CHCl3).
- IR (film) λmax 3270, 1730, 1640, 1590, 1510, 1380, 1210 cm1.
- UV (MeOH) λmax 334 (log 4.29), 509 nm (2.86).
- 1H NMR (CDCl3): see [Table 9].
- 13C NMR (CDCl3): see [Table 9].
- EIMS m/z (%) 399 (M+, 8), 209 (100), 191 (3), 166 (11), 152 (9), 107 (9), 95 (22).
- HREIMS m/z 399.2790 [M]+ (calcd for C25H37NO3, 399.2773).
-
TABLE 9 Pos. δC δH (m, J in Hz) HMBC NOESY 1 19.9 CH2 2.04 (m) 2, 3, 5, 9, 10 1b, 3, 10, 15a 1.45 (dddd, 12.0, 12.0, 12.0, 6.1) 2, 5, 10 1a, 14 2 27.1 CH2 1.99 (m) 1b, 2b 1.86 (m) 2a, 3, 10 3 120.8 CH 5.12 (brs) 12 1a, 2b, 11 4 144.1 C 5 38.5 C 6 36.0 CH2 1.61 (ddd, 12.7, 3.2, 3.2) 7 6b, 7 1.04 (m) 6a, 7 7 27.9 CH2 1.34 (m) 8 6a, 6b, 13, 14 8 37.7 CH 1.27 (m) 10, 13 9 42.6 C 10 47.6 CH 1.04 (m) 1, 2, 5, 9 1a, 2b, 8 11 18.1 CH3 1.53b (brs) 3, 4, 5, 6 3, 12 12 20.1 CH3 1.00b (s) 4, 5, 6, 10 11, 14 13 17.7 CH3 0.96b (d, 6.1) 7, 8, 9 7, 8, 15b 1b, 7, 12, 13, 15a 14 17.3 CH3 0.82b (s) 8, 9 10, 15 15b 15 32.4 CH2 2.56 (d, 13.9) 8, 9, 14, 16, 17, 21 1a, 14, 15b 2.42 (d, 13.9) 8, 9, 10, 14, 16, 17, 21 13, 14, 15a 16 113.9 C 17 157.1 C 18 178.1 C 19 91.6 CH 5.37 (s) 17, 21 22 20 150.5 C 21 182.9 C 22 50.3 CH2 2.97 (dd, 6.4, 6.4) 20, 23, 24 19, 23, 24, 20-NH 23 27.6 CH 1.96 (m) 22, 24 24 20.2d CH3 098c (d, 6.7) 22, 23 22, 23 20-NH 6.53 (brs) 22 a2H, b3H, c6H, d 2C. indicates data missing or illegible when filed - The fraction γ obtained in Preparation Example 14 was purified by C18 HPLC (Luna 5u C18(2), Phenomenex, 250×10 mm; MeOH/H2O/Et2NH, 70:30:0.1; flow rate, 2.0 mL/min; UV detection at 300 nm) to obtain a compound of Preparation Example 15 (1.4 mg, 0.00047%) and a compound of Preparation Example 16 (4.0 mg, 0.0013%).
- The compound of Preparation Example 15 had the following physicochemical properties and was identified as ‘3-[[(1R,2S,4aS,8aS)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]-4-hydroxy-5-[[(2S)-2-methylbutyl]amino]cyclohexa-3,5-diene-1,2-dione’.
- Purple-Red, Amorphous Solid.
- [α]21 D+136 (c 0.25, CHCl3).
- IR (film) νmax 3270, 1680, 1650, 1590, 1510, 1450, 1380, 1210 cm−1.
- UV (MeOH) λmax 336 (log 4.09), 505 nm (2.67).
- 1H NMR (CDCl3): see [Table 10].
- 13C NMR (CDCl3): see [Table 10].
- HREIMS m/z 413.2940 [M]+ (calcd for C26H39NO3, 413.2930).
-
TABLE 10 Pos. δC δH (m, J in Hz) HMBC NOESY 1 19.9 CH3 2.04 (m) 2, 3, 5, 10 1b, 10, 15a 1.47 (m) 12, 14 2 27.1 CH2 1.99 (m) 1b, 2b 1.85 (m) 2a, 10 3 120.8 CH 5.12 (brs) 2a, 2b, 11 4 144.1 C 5 38.5 C 6 36.0 CH2 1.62 (ddd, 12.7, 3.0, 3.0) 6b, 7, 11, 12 1.08 (m) 6a 7 27.9 CH2 1.35 (m) 6a, 6b 8 37.7 CH 1.27 (m) 10, 13 9 42.7 C 10 47.6 CH 1.04 (m) 2, 5, 9 1a, 2b, 8 11 18.1 CH3 1.53b (brs) 3, 4, 5 3, 6a 12 19.9 CH3 0.99b (s) 4, 5, 6 6a, 14 13 17.7 CH3 0.96b (d, 6, 8) 7, 8 8, 14, 15b 14 17.3 CH3 0.82b (s) 8, 9, 10, 15 1b, 7, 12, 13 15a, 15b 15 32.4 CH2 2.55 (d, 13.9) 8, 9, 14, 16, 17, 21 1a, 14, 15b 2.42 (d, 13.9) 8, 9, 10, 14, 16, 17, 21 13, 14, 15a 16 113.8 C 17 157.2 C 18 178.1 C 19 91.5 CH 5.37 (s) 17, 21 22a, 22b, 23 20 150.6 C 21 182.9 C 22 48.7 CH3 3.08 (ddd, 13.2, 6.5, 6.5) 20, 23, 24, 26 19, 26, 20-NH 2.95 (ddd, 13.2, 6.7, 6.7) 20, 23, 24, 26 19, 26, 20-NH 23 34.0 CH 1.74 (m) 22, 24 22a, 22b, 24a, 26 24 27.2 CH2 1.44 (m) 23, 26 23, 24b, 25 1.24 (m) 26 24a, 25 25 11.1 CH3 0.93 (t, 7.4) 23, 24 24a, 24b 26 17.4 CH3 0.96 (d, 6.8) 22, 23, 24 22a, 22b, 23 20-NH 6.53 (brs) 22a, 22b 2H, 3H. indicates data missing or illegible when filed - A compound of Preparation Example 16 was prepared in the same manner as in Preparation Example 15. It had the following physicochemical properties and was identified as ‘3-[[(1R,2S,4aS,8aS)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]-4-hydroxy-5-(3-methylbutylamino)cyclohexa-3,5-diene-1,2-dione’.
- Purple-Red, Amorphous Solid.
- [α]21 D+124 (c 0.25, CHCl3).
- IR (film) νmax 3270, 1680, 1640, 1590, 1510, 1380, 1210 cm−1.
- UV (MeOH) λmax 336 (log 4.17), 515 nm (2.55).
- 1H NMR (CDCl3): see [Table 11].
- 13C NMR (CDCl3): see [Table 11].
- EIMS m/z (%) 413 (M+, 7), 223 (100), 191 (3), 166 (8), 152 (9), 107 (8), 95 (18);
- HREIMS m/z 413.2947 [M]+ (calcd for C26H39NO3, 413.2930).
-
TABLE 11 Pos. δC δH (m, J in Hz) HMBC NOESY 1 20.1 CH2 2.03 (m) 2, 3, 5, 9, 10 1b, 15a 1.44 (dddd, 12.1, 12.1, 12.1, 6.2) 2, 5, 10 1a, 8 2 27.0 CH2 1.98 (ddd, 17.5, 5.3, 5.3) 2b, 3 1.85 (m) 2a, 3 3 120.7 CH 5.10 (brs) 11 2a, 2b, 11 4 144.0 C 5 38.4 C 6 35.9 CH2 1.60 (ddd, 12.8, 3.3, 3.3) 6b, 7 1.03 (m) 6a, 8 7 27.9 CH2 1.33 (m) 5, 6, 8, 9 8 37.6 CH 1.25 (m) 14 1b 9 42.6 C 10 47.5 CH 1.03 (m) 8 11 18.1 CH3 1.52b (brs) 3, 4, 5 3, 12 12 19.8 CH3 0.98b (s) 4, 5, 6, 10 1b, 6a, 14 13 17.7 CH3 0.94b (d, 6.2) 7, 9 7, 15b 14 17.2 CH3 0.81b (s) 8, 9, 10, 15 1b, 8, 12, 15a, 15b 15 32.4 CH2 2.54 (d, 14.0) 8, 9, 14, 16, 17, 21 1a, 14, 15a 2.41 (d, 14.0) 8, 9, 10, 14, 16, 17, 21 13, 14, 15b 16 113.8 C 17 157.2 C 18 178.0 C 19 91.5 CH 5.37 (s) 17, 21 22, 23, 25 20 150.3 C 21 182.8 C 22 41.1 CH2 3.15 (dt, 7.3, 6.6) 20, 23, 24 19, 23, 25 23 36.8 CH2 1.55b (td, 7.3, 6.7) 22, 24, 25 19, 22, 25 24 25.9 CH 1.66 (d sept, 6.7, 6.7) 23, 25 25 25 22.3d CH3 0.93c (d, 6.7) 23, 24 19, 23, 24 17-OH 7.92 (brs) 20-NH 6.46 (brs) 19, 21 22 a2H, b3H, c6H, d2C. indicates data missing or illegible when filed - The
fraction 6 obtained in Preparation Example 14 was refractionated by Cis HPLC (Luna 5u Phenyl-Hexyl, 250×10 mm; MeOH/H2O/Et2NH, 65:35:0.1; flow rate, 2.0 mL/min; UV detection at 300 nm) to obtain a compound of Preparation Example 17 (0.7 mg, 0.00023%) and a compound of Preparation Example 18 (1.6 mg, 0.00053%). - The obtained Preparation Example 17 compound had the following physicochemical properties and was identified as ‘3-[[(1R,2S,8aS)-1,2,5,5-tetramethyl-2,3,6,7,8,8a-hexahydronaphthalen-1-yl]methyl]-4-hydroxy-5-[[(2S)-2-methylbutyl]amino]cyclohexa-3,5-diene-1,2-dione’.
- Purple-Red, Amorphous Solid.
- [α]23 D−42 (c 0.25, CHCl3).
- IR (film) λmax 3290, 1680, 1650, 1590, 1520, 1460, 1390, 1200 cm−1.
- UV (MeOH) λmax 338 (log 4.06), 511 nm (2.63).
- 1H NMR (CDCl3): see [Table 12].
- 13C NMR (CDCl3): see [Table 12].
- EIMS m/z (%) 413 (M+, 15), 223 (100), 191 (10), 168 (15), 166 (14), 152 (16), 119 (18).
- HREIMS m/z 413.2916 [M]+ (calcd for C26H39NO3, 413.2930).
-
TABLE 12 Pos. δC δH (m, J in Hz) HMBC NOESY 1 30.6 CH2 1.87 (m) 1b, 2a, 2b, 10, 14, 15a 0.96 (m) 1a 2 22.8 CH2 1.50 (m) 1a, 1b, 2b 1.40 (m) 2a, 3a, 3b 3 41.4 CH2 1.38 (m) 2a, 2b, 3b 1.16 (ddd, 13.1, 13.1, 4.4) 2a, 2b, 3a 4 36.3 C 5 146.5 C 6 114.9 CH 5.40 (brs) 4, 7, 8, 10 7a, 7b, 11 7 31.6 CH2 1.97 (ddd, 17.6, 4.3, 4.3) 5 7b, 8, 13 1.78 (m) 5, 6 6, 7a 8 36.4 CH 1.40 (m) 7a, 10, 12 9 40.6 C 10 41.6 CH 2.11 (m) 1a, 8, 12, 15b 11 29.7 CH3 1.03b (brs) 3, 4, 5, 12 3a, 3b 12 28.0 CH3 0.96b (a) 3, 4, 5, 11 8, 10 13 16.6 CH3 1.00b (d, 6.7) 7, 8, 9 7a, 8, 14, 15a, 15b 14 15.9 CH3 0.74b (s) 8, 9, 10, 15 1a, 7b, 13, 15a, 15b 15 32.8 CH2 2.56 (d, 13.5) 8, 9, 10, 14, 16, 17, 21 1a, 13, 14, 15b 2.42 (d, 13.5) 8, 9, 10, 14, 16, 17, 21 8, 10, 13, 14, 15a 16 114.5 C 17 156.7 C 18 178.3 C 19 91.5 CH 5.40 (s) 17, 21 22a, 22b 20 150.5 C 21 183.1 C 22 48.7 CH2 3.11 (ddd, 13.1, 6.4, 6.4) 20, 23, 24, 26 19, 22b, 23, 26 3.00 (ddd, 13.1, 6.7, 6.7) 20, 23, 24, 26 19, 22a, 23, 26 23 34.0 CH2 1.76 (m) 22, 24, 25, 26 22a, 22b, 24a, 26 24 27.2 CH 1.44 (m) 22, 23, 25, 26 23, 24b, 25 1.23 (m) 22, 23, 25, 26 24a 25 11.1 CH3 0.93b (t, 7.5) 23, 24 24a 26 17.3 CH3 0.97b (d, 6.7) 22, 23, 24 22a, 22b, 23 20-NH 6.58 (brs) a2H. b3H. - A compound of Preparation Example 18 was prepared in the same manner as in Preparation Example 17. It had the following physicochemical properties and was identified as ‘3-[[(1R,2S,8aS)-1,2,5,5-tetramethyl-2,3,6,7,8,8a-hexahydronaphthalen-1-yl]methyl]-4-hydroxy-5-(3-methylbutylamino)cyclohexa-3,5-diene-1,2-dione’ Compound
- Purple-Red, Amorphous Solid.
- [α]21D-38 (c 0.2, CHCl3).
- IR (film) νmax 3270, 1680, 1650, 1590, 1510, 1460, 1380, 1200 cm−1.
- UV (MeOH) λmax 338 (log 4.21), 515 nm (2.63).
- 1H NMR (CDCl3): see [Table 13].
- 13C NMR (CDCl3): see [Table 13].
- EIMS m/z (%) 413 (M+, 24), 223 (100), 191 (13), 166 (20), 152 (17), 119 (20).
- HREIMS m/z 413.2947 [M]+ (calcd for C29H37NO3, 413.2930).
-
TABLE 13 Pos. δC δH (m, J in Hz) HMBC NOESY 1 30.6 CH2 1.87 (m) 1b, 2a, 2b, 10, 14, 15a 0.93 (m) 1a, 2a, 2b, 14 2 22.8 CH2 1.50 (m) 1a, 1b, 2b, 3a, 3b 1.38 (m) 3a, 3b, 12 3 41.4 CH2 1.38 (m) 2a, 2b 1.16 (ddd, 13.0, 13.0, 4.2) 2a, 2b 4 36.4 C 5 146.5 C 6 114.9 CH 5.39 (brs) 4, 7, 8, 10 7a, 7b, 11 7 31.6 CH2 1.98 (m) 6, 7b, 8, 13 1.77 (m) 8 6, 7a, 13, 14 8 36.3 CH 1.38 (m) 7a, 7b, 10, 15b 9 40.6 C 10 41.6 CH 2.11 (m) 1a, 8, 12, 15a 11 29.7 CH3 1.03b (brs) 3, 4, 5, 12 6 12 28.0 CH3 0.95b (s) 3, 4, 5, 11 2b, 10 13 16.6 CH3 0.99b (d, 6.7) 7, 8, 9 7a, 7b, 8, 14, 15a, 15b 14 16.0 CH3 0.74b (s) 8, 9, 10, 15 1a, 1b, 7b, 13, 15a, 15b 15 32.7 CH2 2.55 (d, 13.4) 8, 9, 10, 14, 16, 17, 21 1a, 13, 14, 15b 2.42 (d, 13.4) 8, 9, 10, 14, 16, 17, 21 8, 10, 13, 14, 15a 16 114.5 C 17 156.7 C 18 178.3 C 19 91.5 CH 5.39 (s) 17, 21 20 150.1 C 21 183.1 C 22 41.1 CH2 3.18a (td, 6.7, 6.3) 20, 23, 24 23, 25 23 36.9 CH2 1.57a (dt, 6.7, 6.7) 22, 24, 25 22, 25 24 25.9 CH 1.68 (d sept, 6.7, 6.7) 25 25 25 22.3d CH3 0.95c (d, overlapped) 23, 24 22, 23, 24 20-NH 6.43 (brs) a2H. b3H. c6H. d2C. - A sponge (Spongiidae SS-265) was obtained as described in the literature ‘Yohei Takahashi et al., 2010’ and extracted. Briefly, an extract was prepared by adding MeOH (4.3 and 3.2 L) to sponge SS-265 (1.4 kg, wet weight). The MeOH extract (68.4 g) was fractionated with CHCl3 and H2O. The CHCl3-soluble substances (2.3 g) were subjected to silica gel column (n-hexane/EtOAc), C18 column (MeOH/H2O), silica gel column (n-hexane/acetone) and C18 HPLC (Wakosil-II 5C18AR, 250×10 mm; eluent, MeCN/H2O/CF3CO2H, 90:10:0.1; flow rate, 2.0 mL/min; UV detection at 300 nm and Luna 5u C18(2), 250×10 mm; MeOH/H2O/Et2NH, 70:30:0.1; flow rate, 2.0 mL/min; UV detection at 300 nm) repeatedly to obtain a compound of Preparation Example 19 (1.8 mg, 0.00013%).
- The obtained Preparation Example 19 compound had the following physicochemical properties and was identified as ‘3-[[(1R,2S,4aS,8aS)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-4-hydroxy-5-[[(2S)-2-methylbutyl]amino]cyclohexa-3,5-diene-1,2-dione’.
- Purple-Red, Amorphous Solid.
- [α]22 D+33 (c 0.2, CHCl3).
- IR (film) λmax 3280, 1640, 1590, 1510, 1380, 1200 cm1.
- UV (MeOH) λmax 501 (log 2.88), 327 (4.17), 243 (3.86), 208 nm (4.25).
- 1H NMR (CDCl3): see [Table 14].
- 13C NMR (CDCl3): see [Table 14].
- EIMS m/z (%) 413 (M+, 15), 223 (100), 191 (3), 166 (10), 152 (10), 95 (10).
- HREIMS m/z 413.2934 [M]+ (calcd for C26H39NO3, 413.2930).
-
TABLE 14 Pos. δC δH (m, J in Hz) HMBC NOESY 1 23.2 CH2 2.09 (m) 3, 5 1b, 8, 10, 15a 1.43 (m) 1a, 2a, 3a 2 28.7 CH2 1.84 (m) 1b, 2b, 3a, 3b 1.14 (m) 2a, 3b 3 33.0 CH2 2.32 (ddd, 13.7, 13.7, 5.4) 2, 4, 11 1b, 2a, 3b, 12 2.05 (m) 1.5 2a, 2b, 3a, 11a 4 160.5 C 5 40.4 C 6 36.7 CH2 1.51 (m) 5, 7, 8, 10 6b, 11b 1.36 (m) 6a, 11b 7 28.0 CH2 1.39a (m) 12, 14 8 37.9 CH 1.18 (m) 10 9 42.9 C 10 50.0 CH 0.78 (dd, 11.6, 1.8) 1, 5, 8, 9, 12, 14, 15 1a, 2b, 6b, 8, 15a 11 102.5 CH2 4.43 (s) 3, 4, 5 3b 4.42 (s) 3, 4, 5 6a, 6b 12 20.5 CH3 1.04b (s) 4, 5, 6, 10 3a, 7, 14 13 17.9c CH3 0.96b,c (d, 6.4) 7, 8, 9 7, 15b 14 17.2 CH3 0.82b (s) 8, 9, 10, 15 7, 12, 15a, 15b 15 32.5 CH2 2.48 (d, 14.0) 8, 9, 10, 14, 16, 17, 21 1a, 10, 14, 15b 2.39 (d, 14.0) 8, 9, 10, 14, 16, 17, 21 8, 13, 14, 15a 16 113.5 C 17 157.3 C 18 178.1 C 19 91.6 CH 5.36 (s) 17, 21 22a, 22b, 23 20 150.5 C 21 182.9 C 22 48.7 CH2 3.08 (ddd, 13.2, 6.6, 6.6) 20, 23, 24, 26 19, 22b, 23, 24a, 20-NH 2.95 (ddd, 13.2, 6.7, 6.7) 20, 23, 24, 26 19, 22a, 23, 20-NH 23 34.0 CH2 1.75 (m) 22, 24, 25, 26 22a, 22b, 24a, 24b, 25, 26 24 27.2 CH 1.45 (m) 22, 23, 25, 26 22a, 23, 24b, 25 1.23 (m) 22, 23, 25, 26 23, 24a 25 11.1 CH3 0.93b (t, 7.4) 23, 24 23, 24a 26 17.4c CH3 0.96b,c (d, 6.8) 22, 23, 24 23 20-NH 6.51 (brs) 22a, 22b, 23, 26 a2H. b3H. cinterchangeable. - A sponge (Spongiidae SS-1208) was obtained as described in the literature ‘Yohei Takahashi et al., 2010’ and extracted. Briefly, an extract was prepared by adding MeOH (3×0.8 L) and MeOH/toluene (3:1, 1×0.8 L) to sponge SS-1208 (0.4 kg, wet weight). The extract mixture (15.9 g) was fractionated with CHCl3 and H2O (3×500 mL). The CHCl3-soluble fraction (2.7 g) was subjected to silica gel column (n-hexane/EtOAc and CHCl3/MeOH), C18 column (MeOH/H2O/CF3CO2H) and C18 HPLC (Luna 5u Phenyl-Hexyl, 250×10 mm; eluent, MeCN/H2O/CF3CO2H, 70:30:0.1; flow rate, 2.0 mL/min; UV detection at 300 nm and Wakosil-II 5C18AR, 250×10 mm; eluent, MeCN/H2O/CF3CO2H, 75:25:0.1; flow rate, 2.0 mL/min; UV detection at 300 nm) repeatedly to obtain a compound of Preparation Example 20 (0.8 mg, 0.00020%).
- The obtained Preparation Example 20 compound had the following physicochemical properties and was identified as ‘2-[[5-[[(1R,2S,4aS,8aS)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]-6-hydroxy-3,4-dioxocyclohexa-1,5-dien-1-yl]amino]ethanesulfonic acid’.
- Purple-Red, Amorphous Solid.
- [α]22 D+38 (c 0.2, MeOH).
- IR (KBr) νmax 3450, 1640, 1600, 1530, 1380, 1210 cm1.
- UV (MeOH) λmax 237 (log 2.8), 345 (4.00), 513 nm (2.47).
- 1H NMR (DMSO-d6): see [Table 15].
- 13C NMR (DMSO-d6): see [Table 15].
- ESIMS (neg) m/z 450 [M−H]−.
- HRESIMS (neg) m/z 450.1955 [M−H]− (calcd for C23H32NO6S, 450.1950).
-
TABLE 15 Pos. δC δH (m, J in Hz) HMBC NOESY 1 19.4 CH2 1.99 (m) 1b, 15a 1.33 (m) 1a, 2, 12, 14 2 26.3 CH2 1.88a (m) 1b, 10 3 120.8 CH 5.05 (brs) 12 2 4 143.1 C 5 37.8 C 6 35.4 C 1.53 (m) 6b, 7, 12 0.96 (m) 6a 7 27.5 CH2 1.27a (m) 6a, 13 8 37.1 CH 1.22 (m) 13, 14 9 41.8 C 10 47.0 CH 0.96 (m) 14 2, 15b 11 17.9 CH3 1.47b (brs) 3, 4, 5 12 19.9 CH3 0.93b (s) 4, 5, 6, 10 1b, 6a, 14 13 17.8 CH3 0.90b (d, 6.0) 7, 8, 9 7, 8 14 17.2 CH3 0.74b (s) 8, 9, 10, 15 1b, 8, 12, 15a 15 32.0 CH3 2.41 (d, 13.6) 16, 17, 21 1a, 15b 2.30 (d, 13.6) 9, 10, 16, 10, 15a 17, 21 16 113.6 C 17 158.8c C 18 178.0 C 19 91.6 CH 5.26 (s) 17, 21 22, 23 20 dC 21 182.7c C 22 39.2c CH2 3.33a (overlapped) 23 23 48.0 CH2 2.69a (brt, 6.4) 22 19, 20-NH 20-NH 7.96 (brs) 23 a2H, b3H. cassigned from HMBC spectrum. dnot observed. - After freeze-drying a sponge (Dactylospongia elegans), the freeze-dried sponge (2.6 kg, wet weight) was chopped and immersed in MeOH overnight to prepare an extract. The MeOH extract was fractionated with hexane, 90% methanol, n-BuOH and H2O. The 90% methanol fraction was evaporated under reduced pressure to obtain 12 g of a 90% MeOH extract. 2 g of the 90% MeOH extract was separated by SiO2 column (hexane-AcOEt-acetone-MeOH) to obtain three fractions, Fr. A (0.42 g), Fr. B (0.73 g) and Fr. C (0.83 g). Among the fractions, Fr. A and Fr. B were separated by ODS column (MeOH—H2O) or HPLC (Cosmosil 5SL, hexane-AcOEt=7:1) to obtain a compound of Preparation Example 21 (20 mg, 1%) and a compound of Preparation Example 22 (17 mg, 0.85%).
- The obtained Preparation Example 21 compound had the following physicochemical properties and was identified as ‘methyl 3-[[(1R,2S,4aS,8aS)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-4-hydroxybenzoate’.
- White Solid.
- [α]27D+17.3 (c 0.12, CHCl3).
- 1H NMR (500 MHz, CDCl3) δ: 7.77 (1H, s), 7.77-7.74 (1H, m), 6.77 (1H, d, J=8.0 Hz), 6.01 (1H, s), 4.41 (1H, s), 4.36 (1H, s), 3.87 (3H, s), 2.68 (1H, d, J=14.3 Hz), 2.64 (1H, d, J=14.3 Hz), 2.33 (1H, td, J=13.7, 5.2 Hz), 2.08 (2H, d, J=13.7 Hz), 1.93-1.89 (1H, m), 1.61-1.56 (1H, m), 1.47 (1H, dt, J=12.2, 3.2 Hz), 1.41-1.38 (3H, m), 1.31-1.27 (1H, m), 1.22-1.19 (1H, m), 1.06 (3H, s), 1.02 (3H, d, J=6.9 Hz), 0.96 (1H, dd, J=12.0, 1.7 Hz), 0.88 (3H, s).
- 13C NMR (125 MHz, CDCl3) δ: 167.6, 160.0, 159.2, 135.0, 129.3, 125.2, 121.6, 115.3, 102.8, 52.0, 48.0, 42.0, 40.2, 37.0, 36.5, 36.3, 33.0, 27.8, 27.7, 23.2, 20.5, 17.62, 17.59.
- IR (KBr): 3341, 1686, 1601, 1426, 1287 cm1′.
- MS (ESI-TOF) m/z: 379 [M+Na]+.
- HRMS (ESI-TOF) m/z: 379.2249 (calcd for C23H32O3Na; found: 379.2266).
- A compound of Preparation Example 22 was prepared in the same manner as in Preparation Example 21. It had the following physicochemical properties and was identified as ‘methyl 3-[[(1 S,2R,4aR,8aR)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-4,5-dihydroxybenzoate’.
- White Solid.
- [α]26: D+10.4 (c 0.19, CHCl3).
- 1H NMR (500 MHz, CDCl3) δ: 7.49 (1H, d, J=2.0 Hz), 7.40 (1H, d, J=2.0 Hz), 5.90 (2H, S), 4.41 (1H, s), 4.37 (1H, s), 3.87 (3H, s), 2.68 (1H, d, J=14.3 Hz), 2.65 (1H, d, J=14.3 Hz), 2.34 (1H, td, J=13.7, 5.0 Hz), 2.09 (2H, d, J=14.3 Hz), 1.93-1.91 (1H, m), 1.60-1.55 (1H, m), 1.47 (1H, dt, J=11.6, 2.7 Hz), 1.43-1.35 (3H, m), 1.33-1.19 (2H, m), 1.06 (3H, s), 1.03 (3H, d, J=6.3 Hz), 0.96 (1H, d, J=11.5 Hz), 0.88 (3H, s).
- 13C NMR (125 MHz, CDCl3) δ: 167.7, 160.1, 148.7, 142.3, 127.4, 125.2, 120.3, 114.0, 102.8, 52.1, 48.0, 42.1, 40.2, 37.0, 36.5, 36.3, 33.0, 27.9, 27.7, 23.2, 20.6, 17.64, 17.59.
- IR (KBr): 3341, 1686, 1601, 1426, 1287 cm1.
- MS (ESI-TOF) m/z: 395 [M+Na]+.
- HRMS (ESI-TOF) m/z: 395.2198 (calcd for C23H32O4Na; found: 395.2214).
- After adding anhydrous 95% potassium tert-butoxide (217 mg, 1.93 mmol) to 7.5 mL of benzene, a suspension was prepared by stirring the same. Then, 657 mg (0.62 mmol) of methyltriphenylphosphonium bromide was added. The prepared light yellow solution was heated for 30 minutes under reflux. A heated ylide solution was added dropwise to a solution of 212 mg (0.62 mmol) of the ketone (−)-(1R,4aS,8aS)-1β,2β, 4aβ-trimethyl-1α[(2′,5′-dimethoyphenyl)methyl]-1,2,3,4,4a,5,6,7,8,8aα-decahydronaphthalen-5-one dissolved in 3 mL of benzene. After heat-treating further for 22 hours, the reaction mixture was cooled and diluted by stirring fast while sequentially adding 10 mL of ether and 3 mL of H2O. After phase separation was completed, the organic phase was washed with 2 mL of H2O and 3 mL of saturated brine and then dried (MgSO4). An almost colorless oil obtained by concentrating under reduced pressure was separated by silica gel column (10×2.5 cm) chromatography using 5% EtOAc (in hexane) as an eluent to obtain a compound of Preparation Example 23 (180 mg, 85%).
- The obtained Preparation Example 23 compound had the following physicochemical properties and was identified as ‘(−)-(1R,4aS,8aS)-1β,2β,4β,-trimethyl-1α[(2′,5′-dimethoxyphenyl)methyl]-5-exo-methylene-(3H)-1, 4,4a,5,6,7,8,8aα-octahydronaphthalene’.
- [α]25 D−40.4° (c 0.5, CH2Cl2).
- m.p.: 77-78° C.
- Silica gel TLC Rf 0.70 (15% EtOAc in hexane).
- 1H NMR (CDCl3) δ 0.86 (s, 3H), 1.01 (d, 3H, J=5.5 Hz), 1.07 (s, 3H), 1.15-1.65 (m, 7H), 1.70-1.95 (m, 2H), 2.05-2.15 (m, 2H), 2.20-2.45 (m, 1H), 2.64 (AB q, 2H, J=14 Hz), 3.72 (s, 3H), 3.75 (s, 3H), 4.33-4.47 (m, 2H), 6.65-6.77 (m, 3H).
- Anal calcd for C23H34O2: C, 80.65; H, 10.00. found: C, 80.82; H, 10.04.
- The compound of Preparation Example 23 (108.5 mg, 0.317 mmol) and rhodium trichloride hydrate (16.7 mg, 0.06 mmol, 20 mol %) were added to 11 mL of EtOH solution and the prepared mixture was heated under reflux. After heat-treating for 20 hours, the reaction mixture was cooled and quenched by adding 5 mL of H2O. The aqueous phase was extracted three times with 10 mL of CH2Cl2 and the extract was combined, dried (MgSO4) and concentrated to obtain a faintly colored oil. The residue was purified with a silica gel (10% EtOAc in hexane) plug and concentrated to obtain a clear colorless oil. Then, a compound of Preparation Example 24 was obtained by slowly solidifying the same under a high-pressure condition. The obtained Preparation Example 24 compound had the following physicochemical properties and was identified as ‘dimethyl ether of 2-[[(1R,2S,4aS,8aS)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]benzene-1,4-diol’.
- [α]25 D+8.88° (c 0.18, CH2Cl2).
- m.p.: 63-68° C.
- Silica gel TLC Rf 0.71 (15% EtOAc in hexane), 0.37 (5% EtOAc in hexane).
- 1H NMR (CDCl3) δ 0.75-1.15 (m, 4H), 0.87 (s, 3H), 1.01 (s, 3H), 1.24-1.65 (m, 9H), 2.0-2.15 (br m, 3H), 2.70 (br s, 2H), 3.72 (s, 3H), 3.75 (s, 3H), 5.15 (br s, 1H), 6.65-6.85 (m, 3H).
- Mass spectrum (chemical ionization, negative ion), m/z 341 (M−1)−.
- A solution obtained by adding the compound of Preparation Example 24 (70.0 mg, 0.204 mmol) to 3.5 mL of THF was added dropwise to 448 mg (0.82 mmol) of a ceric ammonium nitrate solution (in 3.5 mL of H2O) under stirring. 15 minutes later, the reaction mixture was diluted sequentially with 3 mL of saturated brine and 10 mL of ethyl ether. After phase separation was completed, the aqueous phase fraction was extracted three times with 10 mL of CH2Cl2. The extracted solution was combined, dried (MgSO4), concentrated and purified by silica gel column (15×2 cm) chromatography to obtain an orange oil. It was eluted with 5% EtOAc (in hexane) to obtain a compound of Preparation Example 25 (25 mg, 40%). The obtained compound had the following physicochemical properties and was identified as ‘2-[[(1R,2S,4aS,8aS)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]cyclohexa-2,5-diene-1,4-dione’.
- [α]25 D+21° (c 0.02, CH2Cl2).
- Silica gel TLC Rf 0.55 (15% EtOAc in hexane); λmax (CH3OH) 292 nm.
- 1H NMR (CDCl3) δ 0.80-2.15 (m, 5H), 0.85 (s, 3H), 0.93 (d, 3H, J=6.5 Hz), 1.00 (s, 3H), 1.53 (br s, 1H), 2.45-2.67 (AB q, 2H, J=13.5 Hz), 5.14 (br s, 1H), 6.51 (br s, 1H), 6.71 (m, 2H).
- Mass spectrum (chemical ionization) m/z 312 [M+1]+; mass spectrum (electron impact), m/z 311.199 (C21H27O2 requires 311.201).
- 25 mg (0.08 mmol) of the compound of Preparation Example 25 was dissolved in 2 mL of ethyl ether and a Na2S2O4 solution (56 mg Na2S2O4 in 2 mL of H2O, 0.32 mol) was added dropwise to the resulting solution under vigorous stirring. 45 minutes later, the reaction mixture was diluted with 2 mL of saturated brine and 10 mL of ethyl ether. After phase separation was completed, the extracted aqueous phase fraction was further extracted three times with 10 mL of ethyl ether. The extracted ether solution was combined, dried (Na2SO4), concentrated and purified by silica gel column (18×1 cm) chromatography to obtain an oily residue. It was eluted with a 15% EtOAc (in hexane) solution to obtain a clear colorless oil. The oil was solidified in vacuo to obtain a compound of Preparation Example 26 (23 mg, 92%). The obtained compound had the following physicochemical properties and was identified as ‘2-[[(1R,2S,4aS,8aS)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]benzene-1,4-diol’.
- (+)-1: [α]25 D+22.0° (c 1.35, CDCl3).
- (−)-1: [α]25 D−19.5° (c 1.0, CKCl3).
- m.p.: 125-127° C.
- Silica gel TLC Rf 0.10 (15% EtOAc in hexane); λmax (DMSO) 305 nm.
- 1H NMR (CDCl3) δ 0.86 (s, 3H), 0.99 (d, 3H, J=8 Hz), 1.02 (s, 3H), 1.51 (br s, 3H), 1.2-1.65 (m, 7H), 1.9-2.15 (m, 3H), 2.54-2.70 (AB q, 2H, J=14 HZ), 4.38 (br s, 1H), 4.41 (br s, 1H), 5.14 (br s, 1H) and 6.59 (m, 3H); mass spectrum (chemical ionization), m/z 315 [M+1]+.
- Mass spectrum (electron impact), m/z 314.225 [M]+ (C21H30O2 requires 314.225).
- The compound of Preparation Example 10 (3.0 mg, 8.4 μmol) and glycine (0.8 mg, 10 mol) were added to EtOH (1 mL) and stirred for 24 hours at room temperature in the presence of NaHCO3 (11 mg, 130 μmol). A residue prepared through filtration and evaporation was subjected to C18 reversed-phase HPLC (YMC-Pack AM-323, 1.0×25 cm; flow rate 2.5 mL/min; UV detection at 300 nm; eluent CH3CN/H2O/CF3CO2H, 85:15:0.1) to obtain a compound of Preparation Example 27 (1.6 mg, 47%).
- The obtained Preparation Example 27 compound had the following physicochemical properties and was identified as ‘2-[[5-[[(1R,2S,4aS,8aS)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]-6-hydroxy-3,4-dioxocyclohexa-1,5-dien-1-yl]amino]acetic acid’.
- m.p.: 156-158° C.
- [α]20 D−71.7θ (C 1.0, MeOH).
- IR (KBr) νmax 3300, 1720, 1640, 1580, 1370, 1200 cm1.
- UV(MeOH) λmax 317 (c 11800) and 488 nm (860).
- ELMS m/z (%) 401 (M+, 1). 385(1), 357(4), 343(3), 211(20), 191(25) and 95(100).
- FABMS (positive) m/z 404 [M+2H+H]+; HRFABMS m/z 404.2461 [M+2H+H]+, calcd for C23H34NO5, 404.2437.
- 1H NMR (CD3OD): see [Table 16].
- 13C NMR (CD3OD): see [Table 16].
-
TABLE 16 position 1H a J(Hz) 13Ca H coupled with C b1 2.10 m 21.1 t 1.44 m 2 1.93c m 28.0 t H-10 3 5.08 brs 121.9 d H-11 4 144.9 s H-11, H-12 5 39.6 s H-10, H-11, H-12 6 1.63 m 37.4 t H-12 1.03 m 7 1.36c m 29.2 t H-13 8 1.32 m 39.0 d H-10, H-14, H-15 9 43.6 s H-10, H-13, H-14, H-15 10 1.10 m 49.9 d H-12, H-14, H-15 11 1.50 s 18.4 q 12 1.00 s 20.7 q H-10 13 0.97 d 7.0 18.4 q 14 0.82 s 17.8 q H-10, H-15 15 2.57 d 13.6 33.3 t H-14 2.42 d 13.6 16 115.9 s H-15 17 159.6 s H-15, H-19 18 180.8 s 19 5.28 s 93.8 d 20 151.5 s H-22 21 184.0 s H-15, H-19 22 3.96 s 44.9 t 23 171.9 s H-22 aδ in ppm bHMBC correlations c2H - The compound of Preparation Example 10 (3.0 mg, 8.4 μmol) and L-serine (1.3 mg, 10 μmol) were added to EtOH (1 mL) and stirred for 24 hours at 40° C. in the presence of NaHCO3 (27 mg, 34 μmol). A residue prepared through filtration and evaporation was subjected to C18 reversed-phase HPLC (YMC-Pack AM-323, 1.0×25 cm; flow rate 2.5 mL/min; UV detection at 300 nm; eluent CH3CN/H2O/CF3CO2H, 85:15:0.1) to obtain a compound of Preparation Example 28 (1.7 mg, 46%).
- The obtained Preparation Example 28 compound had the following physicochemical properties and was identified as ‘(2S)-2-[[5-[[(1R,2S,4aS,8aS)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a hexahydronaphthalen-1-yl]methyl]-6-hydroxy-3,4-dioxocyclohexa-1,5-dien-1-yl]amino]-3-hydroxypropanoic acid’.
- m.p.: 198-200° C.
- [α]17 D−71° (c 0.73, EtOH).
- IR (K Br) νmax 3400, 1670, 1630, 1590, 1540, 1380, 1200 cm1.
- UV (MeOH) λmax 321 (c 12100) and 498 nm (920).
- FABMS (negative, diethanolamine matrix) m/z 432 [M+2H−H]−.
- HRFABMS m/z 432.2381 [M+2H−H]−, calcd for C24H34NO6 432.2386.
- 1H NMR (DMSO-d6): see [Table 17].
- 13C NMR (DMSO-d6): see [Table 17].
-
TABLE 17 position 1H a J(Hz) 13Ca H coupled with Cb 1 2.01 m 18.9 t H-10 1.39 m H-10 2 1.92c m 25.8 t 3 5.05 brs 121.0 d H3-11 4 142.8 s H3-11, H3-12 5 37.2 s H-3, H3-11, H3-12 6 1.53 m 34.9 t H3-12 0.98 m 7 1.33c m 26.9 t H3-13 8 1.30 m 36.8 d H-6, H-10, H3-14, H2-15 9 41.2 s H-10, H3-13, H3-14, H2-15 10 1.02 m 46.5 d H3-12, H3-14, H2-15 11 1.48 s 17.5 q H-3 12 0.93 s 19.3 q 13 0.90 d 7.0 17.2 q 14 0.78 s 16.5 q H-10, H2-15 15 2.43 d 13.6 31.4 t H3-14 2.32 d 13.6 16 113.5 s H2-15 17 158.5 s H2-15, H-19 18 178.8 s H-19, NH-20 19 5.35 s 93.1 d NH-20 20 147.1 s 20-NH 7.15 d 8.0 21 182.0 s H2-15, H-19, NH-20 22 4.20 m 56.5 d 23 171.9 s H2-24 24 3.78 dd 11.4, 2.9 59.8 t 3.82 dd 11.4, 2.9 aδ in ppm bHMBC correlations c2H - The compound of Preparation Example 10 (3.0 mg, 8.4 μmol) and L-threonine (1.3 mg, 13 μmol) were added to EtOH (1 mL) and stirred for 24 hours at 40° C. in the presence of NaHCO3 (11 mg, 130 μmol). A residue prepared through filtration and evaporation was subjected to C18 reversed-phase HPLC (YMC-Pack AM-323, 1.0×25 cm; flow rate 2.5 mL/min; UV detection at 300 nm; eluent CH3CN/H2O/CF3CO2H, 85:15:0.1) to obtain a compound of Preparation Example 29 (1.3 mg, 35%).
- The obtained Preparation Example 29 compound had the following physicochemical properties and was identified as ‘(2S)-2-[[5-[[(1R,2S,4aS,8aS)-1,2,4a,5-tetramethyl-2,3,4,7,8,8a-hexahydronaphthalen-1-yl]methyl]-6-hydroxy-3,4-dioxocyclohexa-1,5-dien-1-yl]amino]-3-hydroxybutanoic acid’.
- m.p.: 188-191° C.
- [α]17 D−183° (c 1.0, EtOH).
- IR (K Br) νmax 3400, 1670, 1630, 1590, 1540, 1380, 1200 cm−1.
- UV (MeOH) λmax 317 (c 12600) and 490 nm (1000).
- FABMS (negative, diethanolamine matrix) m/z 446 [M+2H+H]−.
- HRFABMS m/z 446.2524 [M+2H−H]−, calcd for C25H36NO6, 446.2906.
- 1H NMR (DMSO-d6): see [Table 18].
- 13C NMR (DMSO-d6): see [Table 18].
-
TABLE 18 position 1H a J(Hz) 13Ca H coupled with C b1 1.99 m 19.9 t H-10 1.35 m H-10 2 1.88c m 26.2 t 3 5.05 brs 120.5 d H3-11 4 143.5 s H3-11, H3-12 5 37.5 s H-3, H3-11, H3-12 6 1.56 m 35.7 t H3-12 0.95 m 7 1.28c m 28.5 t H3-13 8 1.25 m 37.2 d H-10, H3-13, H3-14, H2-15 9 41.9 s H 10, H3 13, H3 14, H2 1510 0.98 m 46.9 d H3-12, H3-14, H2-15 11 1.48 s 17.9 q H-3 12 0.94 s 20.0 q 13 0.92 d 7.0 18.0 q 14 0.78 s 17.1 q H-10 15 2.47 d 13.7 31.7 t H3-14 2.32 d 13.7 16 114.1 s H2-15 17 158.1 s H2-15 18 179.1 s H-19 19 5.33 s 93.0 d 20 149.5 s 20-NH 6.95 brd 7.0 21 183.1 s H2-15, H-19 22 4.07 m 60.2 d NH-20, H3-25 23 171.0 s 24 4.27 m 66.5 d H-22 25 1.09 d 7.0 20.8 q aδ in ppm bHMBC correlations c2H - Smenospongia aurea and Smenospongia cerebriformis were homogenized and incubated with Verongula rigida in ethanol for a week. A dried ethanol extract (3.6 kg) of the mixture of the three sponge species was subjected to silica gel VLC (36 kg, 14 (H)×17.5 (D) cm) and eluted sequentially with hexane (100%), hexane-acetone (80:20, 60:40, 50:50, 40:60, 20:80), acetone (100%), acetone-MeOH (80:20, 60:40, 50:50), MeOH (100%), MeOH—H2O (50:50) and H2O (100%) to obtain 13 fractions (Fr. 1-13). The fraction 10 (39.3 g) was fractionated further with hexane-acetone mixtures (95:5, 90:10, 85:15, 80:20), MeOH (100%) and MeOH—H2O (50:50) using a silica gel VLC (12 (H)×17.5 (D) cm) into 9 fractions (Fr. 10-1 to 10-9). The fraction 10-7 (3.7 g) was subjected to C18 MPLC (15.5×4 cm) under an isocratic condition of MeOH—H2O (85:15) to prepare 6 subfractions (Fr. 10-7-1 to 10-7-6). The fraction 10-7-3 (115.8 mg) was subjected to C18 HPLC (250×21.20 mm, 10 μm) chromatography using MeOH—H2O (83:17) to prepare 3 fractions (Fr. 10-7-3-1 to 10-7-3-3). The fraction 10-7-3-2 (12.4 mg) was subjected to C18 HPLC (250×4.60 mm and 150×4.60 mm, 5 μm, connected in line) using MeOH—H2O (75:25) to obtain a compound of Preparation Example 30 and an epimer mixture thereof.
- The obtained substance had the following physicochemical properties and was identified as ‘18-methoxy-22,22-dimethyl-16-[{(5R,8S,9R,10S)-5,8,9-trimethyl-4-methylenedecahydronaphthalen-9-yl}methyl]benzo[d]-oxazol-17(2H)-one’.
- Yellow, amorphous solid.
- [α]25 D+21 (c 0.1, MeOH).
- UV (MeOH) λmax 297 nm.
- 1H NMR (150 MHz, CDCl3): see [Table 19];
- 13C NMR (150 MHz, CDCl3): see [Table 19].
- HRFABMS m/z 398.2696 [M+H]+ (calcd for C25H36NO3, 398.2695), 420.2509 [M+Na]+ (calcd for C25H35NO3Na, 420.2515).
-
TABLE 19 position δH, mult. (J in Hz) δ C1 ax 1.42, m 23 eq 2.13, m 2 ax 1.20, m 28.8 eq 1.84, m 3 ax 2.29, dt (14, 5.2) 33.2 eq 2.04, m 4 161 5 40.5 6 ax 1.30, m 36.9 eq 1.47, m 7 ax 1.36, m 28.1 eq 8 1.22, m 38.1 9 42.9 10 0.80, m 50 11 a 4.40, br s 102.4 b 4.38, br s 12 1.01, s 20.7 13 0.97, d (6.6) 18 14 0.81, s 17.5 15 2.37, d (14) 32.7 2.53, d (14) 16 110.3 17 181.6 18 158.9 19 6.14, s 96.9 20 155.6 21 161.4 22 116.2 23 1.58, s 25.9 24 1.60, s 26 OH OCH3 3.83, s 56.4 - During the procedure of Preparation Example 30, the fraction 10-7-3-3 (9.7 mg) was subjected to C18 HPLC (250×4.60 mm and 150×4.60 mm, 5 μm, connected in line) using MeOH—H2O (78:22) and then to C18 HPLC (250×4.60 mm, 5 μm) for 120 minutes with varying concentrations of MeOH—H2O (80:20-100:0) to obtain a compound of Preparation Example 31 (1.8 mg).
- The obtained compound (Preparation Example 31) had the following physicochemical properties and was identified as ‘18-methoxy-22-methyl-16-[{(5S,8S,9R,10S)-5,8,9-trimethyl-4-methylenedecahydronaphthalen-9-yl}methyl]benzo[d]-oxazol-17-ol’.
- White, Amorphous Solid.
- [α]25 D−29 (c 0.1, MeOH).
- UV (MeOH) λmax 295 nm.
- 1H NMR (150 MHz, CDCl3): see [Table 20].
- 13C NMR (150 MHz, CDCl3): see [Table 20].
- HRFABMS m/z 384.2540 [M+H]+ (calcd for C24H34NO3, 384.2539), 406.2357 [M+Na]+ (calcd for C24H33NO3Na, 406.2358).
-
TABLE 20 δH, mult. (J in position Hz) δ C1 ax 1.51, m 23.4 eq 2.27, m 2 ax 1.22, m 28.9 eq 1.87, m 3 ax 2.33, t (7.5) 33.2 eq 2.02, m 4 160.5 5 40.6 6 ax 1.19, m 36.5 eq 1.43, m 7 ax 1.39, m 28.2 eq 8 1.40, m 37.4 9 43.1 10 0.92, m 49.4 11 a 4.36, br s 102.7 b 4.32, br s 12 1.04, s 20.7 13 1.04, d 18.5 14 0.91, s 17.7 15 2.80, d (14) 34.6 2.89, d (14) 16 109.2 17 143.7 18 144.6 19 6.98, s 98.8 20 132.3 21 146.6 22 162 23 2.54, s 14.6 24 OH 5.87, s OCH3 3.90, s 56.6 - After preparing subfractions Fr. 10-7-1 to 10-7-6 according to the same method as in Preparation Example 30, Fr. 10-7-4 (53 mg) was subjected to C18 HPLC (25×2.1 cm, 10 m) repeatedly under an isocratic condition of MeOH—H2O (87:13) to obtain a compound of Preparation Example 32 (tR=113 min).
- The obtained compound had the following physicochemical properties and was identified as ‘3-[[(1R,2S,4aS,8aS)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-4-hydroxy-5-(2-phenylethylamino)cyclohexa-3,5-diene-1,2-dione’.
- C29H37NO3.
- m.p.: 168-170° C.
- SM m/e (%): 447 (7), 257 (64), 191 (11), 166 (59), 152 (25), 135 (16), 121 (23), 109 (23), 107 (20), 95 (100).
- m/e 166.0495. calc. 166.0504 for C8H8NO3; m/e 191.1795. calc. 191.1799 for C14H23; m/e 257.104, calc. 257.105 for C15H15NO3.
- IR (KBr) ν cm−1: 3265, 1600, 1395.
- 1H NMR (CDCl3, 250 MHz) δ ppm: 6.47 (1H exch., s), 5.41 (1H, s), 4.45 (2H, br s). 3.43 (2H, q), 2.87 (2H, t), 2.52-2.51 (dd, AB syst., J=14 and 2 Hz), 1.05 (3H, s), 0.98 (3H, d, J=7.5 Hz), 0.84 (3H, s), 0.79 (1H, dd, J=11.2 and 2 Hz).
- 13C NMR (ppm; CDCl3): see [Table 21].
-
TABLE 21 Preparation Example 32 Carbon (δ ppm) C-1 22.5 C-2 25.0 C-3 32.8 C-4 153.6 C-5 39.5 C-6 37.9 C-7 27.9 C-8 39.3 C-9 44.5 C-10 48.3 C-11 105.7 C-12 33.2 C-13 18.7 C-14 18.4 C-15 32.0 C-16 114.0 C-17 157.0 C-18 178.4 C-19 91.9 C-20 150.1 C-21 182.8 - Three sponge species Smenospongia aurea, Smenospongia cerebriformis and Verongula rigida were mixed and an ethanol extract was prepared by adding ethanol (98%). The ethanol extract was separated with a silica gel column using hexane, acetone, methanol, water, etc. to obtain a total of 13 fractions. Among them,
fractions - The obtained compound had the following physicochemical properties and was identified as ‘3-[[(1R,2S,4aS,8aS)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-2-hydroxy-5-methoxycyclohexa-2,5-diene-1,4-dione’.
- Yellow Solid.
- C22H30O4.
- Molecular weight: 358.47.
- m.p.: 72.5° C.
- IT-TOF/MS: m/z 381.1972 [M+Na]+.
- 1H-NMR (CDCl3, 600 MHz): 2.08, 1.42 (each 1H, m, H2-1), 1.84, 1.16 (each 1H, m, H2-2), 2.29, 2.05 (each 1H, ddd, J=13.7, 8.6, 5.4, H2-3), 1.49, 1.32 (each 1H, m, H2-6), 1.37 (2H, m, H2-7), 1.14 (1H, m, H-8), 0.74 (1H, d, J=12.0, H-10), 4.43, 4.41 (each 1H, s, H2-11), 1.02 (3H, s, H3-12), 0.96 (3H, d, J=6.4, H3-13), 0.82 (3H, s, H3-14), 2.51, 2.45 (each 1H, d, J=13.7, H2-15), 5.83 (1H, s, H-19), 3.84 (3H, s, H3-22).
- 13C NMR (CDCl3, 150 MHz): 23.34 (C-1), 28.11 (C-2), 33.13 (C-3), 160.69 (C-4), 40.63 (C-5), 36.82 (C-6), 28.80 (C-7), 38.25 (C-8), 43.50 (C-9), 50.30 (C-10), 102.66 (C-11), 20.73 (C-12), 18.01 (C-13), 17.52 (C-14), 32.52 (C-15), 117.49 (C-16), 153.49 (C-17), 182.51 (C-18), 102.17 (C-19), 161.90 (C-20), 182.20 (C-21), 57.01 (C-22).
- 400 mg of the compound of Preparation Example 33 was dissolved in 20 mL of ethanol in a round flask. After adding 10.5 mL of a 1 M potassium hydroxide (KOH) solution, the reaction mixture was stirred at 70° C. for an hour. After adding a 1 M hydrochloric acid solution to the stirred reaction mixture and concentrating under reduced pressure, the mixture was transferred to a separation funnel and fractionated by dissolving in ethyl acetate and distilled water. The ethyl acetate layer was combined, dehydrated with magnesium sulfate, filtered and then concentrated under reduced pressure. In order to obtain a pure reaction product, the resulting concentrate was separated by silica gel column chromatography using a mobile phase (n-hexane:ethyl acetate=10:1) to obtain the final compound (Preparation Example 34).
- The obtained final compound (Preparation Example 34) had the following physicochemical properties and was identified as ‘3-[[(1S,2R,4aR,8aR)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-5-ethoxy-2-hydroxycyclohexa-2,5-diene-1,4-dione’.
- Yellow Semi-Solid.
- C23H32O4.
- Molecular weight: 372.5.
- IT-TOF/MS: m/z 395.2146 [M+Na]+.
- 1H NMR (CDCl3, 600 MHz): 7.47 (1H, s), 5.83 (1H, s), 4.46, 4.44 (each 1H, s), 4.06 (2H, q, J=7.2 Hz), 2.50 (2H, dd, J=12, 6.0 Hz), 2.33 (1H, dt, J=12, 6.0 Hz), 2.17-1.66 (4H, m), 1.49 (3H, t, J=7.2 Hz), 1.46-1.09 (7H, m), 1.04 (3H, m), 0.98 (3H, d, J=6 Hz), 0.84 (3H, s).
- 13C NMR (CDCl3, 150 MHz): 182.68, 182.26, 161.19, 160.75, 153.35, 117.45, 102.63, 102.40, 66.10, 50.35, 43.45, 40.63, 38.29, 36.82, 33.14, 32.63, 28.79, 28.12, 23.32, 20.73, 18.46, 18.05, 13.97.
- It was investigated whether the prepared compounds inhibit Wnt/3-catenin for some structurally representative compounds.
- <1-1> Wnt/β-catenin pathway inhibitory activity of compounds of Preparation Examples 30 and 31
- HEK293 cells (human embryonic kidney cells) and Wnt3a-secreting L cells were obtained from the ATCC (American Type Culture Collection, USA) and were cultured in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10% FBS (fetal bovine serum), 120 λg/mL penicillin and 200 λg/mL streptomycin.
- Wnt3a-CM (Wnt3a-conditioned medium) was prepared by culturing Wnt3a-secreting L cells in DMEM supplemented with 10% [v/v] FBS (fetal bovine serum) for 4 days and recovering the DMEM medium and sterilizing by filtering through a 0.22-μm filter. Then, after adding a fresh DMEM (supplemented with 10% [v/v] FBS) medium to the cells and culturing for 3 days, the medium was recovered by the same method and then combined with the previously prepared Wnt3a-CM.
- After treating HEK293 cells with the Wnt3a-CM, the compound of Preparation Example 30 or the compound of Preparation Example 31 (10, 20 or 40 μM) for 15 hours and extracting cytoplasmic proteins from the cells, the amount of β-catenin regulating the CRT (β-catenin response transcription) of the Wnt/β-catenin pathway in the cells was investigated by western blot using a β-catenin antibody (BD Transduction Laboratories, USA) and the ECL system (Santa Cruz Biotechnology). The result is shown in
FIG. 1 . - As seen from the western blot result of
FIG. 1 , the cells treated with the Wnt3a-CM showed increased 3-catenin expression in the cytoplasm but the cells treated with the Preparation Example 30 compound or the Preparation Example 31 compound of the present disclosure showed decreased level of β-catenin. - <1-2> Wnt/3-Catenin Pathway Inhibitory Activity of Preparation Example 32 Compound
- The Wnt/1-Catenin Pathway Inhibitory Activity of the Preparation Example 32 Compound was evaluated in the same manner as in Example <1-1>. Briefly, after treating HEK293 cells with the Wnt3a-CM or the compound of Preparation Example 32 (10 or 20 μM) for 15 hours and extracting cytoplasmic proteins from the cells, the amount of β-catenin regulating the CRT (β-catenin response transcription) of the Wnt/β-catenin pathway in the cells was investigated by western blot using a β-catenin antibody (BD Transduction Laboratories, USA) and the ECL system (Santa Cruz Biotechnology). The result is shown in
FIG. 2 . - As seen from the western blot result of
FIG. 2 , the cells treated with the Wnt3a-CM showed increased 3-catenin expression in the cytoplasm but the cells treated with the Preparation Example 32 compound of the present disclosure showed decreased level of β-catenin. - <1-3> Wnt/3-catenin pathway inhibitory activity of Preparation Example 33 and 34 compounds
- ARPE-19 cells (human retinal epithelial cells) and Wnt3a-secreting L cells were obtained from the ATCC (American Type Culture Collection, USA) and were cultured in DMEM (Dulbecco's modified Eagle's medium) supplemented with 10% FBS, 120 λg/mL penicillin and 200 λg/mL streptomycin. Wnt3a-CM (Wnt3a-conditioned medium) was prepared by culturing Wnt3a-secreting L cells in DMEM supplemented with 10% [v/v] FBS (fetal bovine serum) for 4 days and recovering the DMEM medium and sterilizing by filtering through a 0.22-μm filter. Then, after adding fresh DMEM (supplemented with 10% [v/v] FBS) to the cells and culturing for 3 days, Wnt3a-CM was recovered.
- After treating ARPE-19 cells with the Wnt3a-CM, the compound of Preparation Example 33 or the compound of Preparation Example 34 (3 or 6 μM) for 24 hours and extracting cytoplasmic proteins from the cells, the amount of β-catenin regulating the CRT (β-catenin response transcription) of the Wnt/3-catenin pathway in the cells was investigated by western blot using a β-catenin antibody (BD Transduction Laboratories, USA) and the ECL system (Santa Cruz Biotechnology). The result is shown in
FIG. 3 . - As seen from
FIG. 3 , the cells treated with the Wnt3a-CM showed increased 3-catenin expression in the cytoplasm but the cells treated with the Preparation Example 33 compound or Preparation Example 34 compound of the present disclosure showed decreased level of β-catenin, suggesting that the compounds inhibit the Wnt/0-catenin pathway in the human retinal epithelial cells. Meanwhile, this activity was not identified in the sponge ethanol extract used to isolate the compound of Preparation Example 33 (data not shown). - <2-1> Intravitreal Administration
- For the compound of Preparation Example 33 which showed good activity in Example 1, the inhibitory activity on vascular leakage, which is a cause of macular degeneration or macular edema, was investigated in a macular edema-induced mouse model. Macular edema was induced in a 10-week-old C57BL/6 mouse by irradiating a laser. After anesthetizing the mouse with ketamine (70 mg/kg) and xylazine (30 mg/kg), the pupil was dilated with 1% tropicamide. Hydroxypropylmethyl cellulose was dropped onto the eye and a microscope cover glass was used as a contact lens. Then, five laser burns were made in the space between the blood vessels around the optic disc (Zeiss 1149-630, laser power 180 mW, duration 0.1 s, spot size 50 μm). In this state, the blood vessel size and permeability were investigated by fluorescein angiography (FA) and optical coherence tomography (OCT). 24 hours after the laser irradiation, 0.5 μL of DMSO (dimethyl sulfoxide) was injected to a control group and 100 ng/0.5 μL of the Preparation Example 33 compound dissolved in DMSO was injected to a test group, into the vitreous cavity of the mouse. One week later, fluorescein angiography and optical coherence tomography were conducted again.
FIG. 4 shows the images of the control group and the compound-treated group. - As seen from the fluorescein angiography and optical coherence tomography results of
FIG. 4 , the test group (FIG. 4 , C, D) showed distinctly decreased vascular leakage, which is a cause of macular degeneration or macular edema, as compared to the control group (FIG. 4 , A, B). - <2-2> Intraperitoneal Administration After inducing macular edema in a C57BL/6 mouse and intraperitoneally administering the compound of Preparation Example 33, vascular leakage in the retina was investigated.
- Briefly, after anesthetizing an 8-to-12-week-old C57BL/6 mouse with Zoletil (40 mg/kg) and xylazine (5 mg/kg), the pupil was dilated with 1% tropicamide. Hydroxypropylmethyl cellulose was dropped onto the eye and a microscope cover glass was used as a contact lens. Then, 3-5 laser burns were made in the space between the retinal blood vessels around the optic disc (Zeiss 1149-630, laser power 200 mW, duration 0.05 s, spot size 50 m).
- After the laser irradiation, 10 mL/kg of distilled water as a vehicle was intraperitoneally administered to a control group (
FIG. 5 , A) and 1 mg/kg of the compound of Preparation Example 33 (dissolved distilled water) was intraperitoneally administered to a test group (FIG. 5 , B) every day for 7 days. Onday - As seen from
FIG. 5 , it was confirmed that the compound of the present disclosure inhibited vascular leakage, which is a cause of macular degeneration or macular edema, even when it was injected intraperitoneally. - Male ICR mice (8 weeks, 30-35 g) were purchased from Samtako Co. (Osan, Korea). The test animals were acclimatized for a week under the following conditions: temperature 23±2° C., relative humidity 55±10%, illumination intensity 150-300 lux, ventilation frequency 15-20 times/h, illumination cycle 12 h (07:00-19:00). All the animal experiments were approved by the Animal Care and Use Committee of Kyungpook National University (Study No. 2016-0043).
- The mice were fasted for 12 hours before drug administration. Feed and water were supplied ad libitum. The compound of Preparation Example 33 was dissolved in DW:PEG 400 (=60:40 (v/v)) and administered by oral gavage at a dose of 10 mg/kg.
- 0.5 hour and 2 hours after the oral administration, blood samples were taken from the abdominal artery. 50 mL of a plasma sample obtained after centrifuging the blood sample at 13,000 rpm for 5 minutes was stored at −80° C. until use for analysis. An eye sample taken from the mouse was homogenized with 9-fold saline to obtain a 10% cell homogenate. The obtained 50-mL aliquots were stored at −80° C. until use for analysis.
- 50 μL of the aliquot was added to 200 μL of an acetonitrile solution containing 0.5 ng/mL propranolol. After vortex mixing for 10 minutes, followed by centrifugation at 13,000 rpm for 10 minutes, the supernatant was transferred to a fresh tube and evaporated under nitrogen gas flow. The residue was added to 150 μL of a mobile phase and a 5-μL aliquot was injected directly into the LC-MS/MS system for analysis.
- In order to investigate the distribution of the compound of the present disclosure in the target tissue, the compound was orally administered at a dose of 10 mg/kg and the concentration of the compound in the blood plasma and eye was measured. The sampling times were determined as 0.5 hour and 2 hours based on the peak plasma concentration and the distribution phase. As seen from
FIG. 6 , the compound of the present disclosure (particularly, the compound of Preparation Example 33) showed high permeability for the target tissue and was found to be highly targeted in the eye even when it was administered orally. Through this result, it was confirmed that the compound of Preparation Example 33 of the present disclosure can exhibit therapeutic effect even when it is administered via different administration routes (oral administration, intraperitoneal injection, intravenous injection, etc.) other than being administered directly into the vitreous cavity. That is to say, whereas the currently available eye disease-related therapeutic agents cause inconvenience, pain and side effects because they have to be administered directly into the vitreous cavity, it was confirmed that the compound of the present disclosure can be administered orally. - <4-1> Evaluation of Acute Toxicity
- This experiment was conducted to determine acute (within 24 hours) toxicity and lethality when the compound of Preparation Example 33 was administered in excessive amounts in a short period of time. 20 normal ICR mice were divided into a control group and a test group, with 10 mice per each. The control group was administered with PEG 400:Tween 80:ethanol (8:1:1, v:v:v) only and the test group was orally administered with the compound of Preparation Example 33 dissolved in PEG 400:Tween 80:ethanol (8:1:1, v:v:v). When lethality was investigated 24 hours after the administration, all the mice in the control group and the mice in the test group administered with the Preparation Example 33 compound at a dose of 2 g/kg/day survived.
- <4-2> Evaluation of Tissue Toxicity
- A long-term toxicity test was conducted by administering the compound of Preparation Example 33 at different doses to C57BL/6J mice (10 mice per group) for 8 weeks. In order to investigate the effect on different organs (tissues) of the animals, blood was taken from the animals of the test group to which the compound of Preparation Example 33 was administered and the control group to which only PEG 400:Tween 80:ethanol (8:1:1, v:v:v) was administered 8 weeks later and the level of GPT (glutamate-pyruvate transferase) and BUN (blood urea nitrogen) in the blood was measured using Select E (Vital Scientific NV, Netherlands). As a result, there was no significant difference between the control group and the test group in GPT, which is known to be related with liver toxicity, and BUN, which is known to be related with kidney toxicity. In addition, no special abnormality was observed in the liver and kidney tissues taken from the animals when they were prepared into tissue sections and observed under an optical microscope according to the common method.
- <Formulation Examples> Preparation of Pharmaceutical Formulations
- <Formulation Example 1> Preparation of Tablet
- 200 g of the compound of the present disclosure was mixed with 175.9 g of lactose, 180 g of potato starch and 32 g of colloidal silicate. After adding a 10% gelatin solution, the mixture was pulverized and passed through a 14-mesh sieve. A mixture obtained by drying the same and adding 160 g of potato starch, 50 g of talc and 5 g of magnesium stearate thereto was prepared into a tablet.
- <Formulation Example 2> Preparation of Injection 1 g of the compound of the present disclosure, 0.6 g of sodium chloride and 0.1 g of ascorbic acid were dissolved in distilled water to make 100 mL. The resulting solution was put in a bottle and sterilized by heating at 20° C. for 30 minutes.
- As described above, the present disclosure relates to a novel use of a sesquiterpene derivative, more particularly to a composition for preventing, improving or treating macular degeneration or macular edema caused by vascular leakage in the eye, which contains the sesquiterpene derivative compound represented by
Chemical Formula 1 of the present disclosure or a pharmaceutically acceptable salt thereof as an active ingredient. - The compound of the present disclosure of
Chemical Formula 1 has therapeutic effect for a disease caused by vascular leakage in the eye, such as macular edema, macular degeneration, etc., by inhibiting the vascular leakage in the eye, particularly in the retina. In addition, whereas the intraocular disease-related treating agents available in the market should be injected directly into the vitreous cavity, thus causing pain and side effects, the sesquiterpene derivative compound of the present disclosure is delivered to the target tissue (eye) via different administration routes (oral, intraperitoneal, etc.) other than the intravitreal route. Accordingly, the sesquiterpene derivative compound provides excellent therapeutic effect without being restricted by the administration routes. Accordingly, it is highly industrially applicable. - The compound of the present disclosure of
Chemical Formula 1 has therapeutic effect for a disease caused by vascular leakage in the eye, such as macular edema, macular degeneration, etc., by inhibiting the vascular leakage in the eye, particularly in the retina. Whereas the intraocular disease-related treating agents available in the market should be injected directly into the vitreous cavity, thus causing pain and side effects, the sesquiterpene derivative compound of the present disclosure is delivered to the target tissue (eye) via different administration routes (oral, intraperitoneal, etc.) other than the intravitreal route. Accordingly, the sesquiterpene derivative compound provides excellent therapeutic effect without being restricted by the administration routes. - Those skilled in the art will appreciate that the conceptions and specific embodiments disclosed in the foregoing description may be readily utilized as a basis for modifying or designing other embodiments for carrying out the same purposes of the present disclosure. Those skilled in the art will also appreciate that such equivalent embodiments do not depart from the spirit and scope of the disclosure as set forth in the appended claims.
Claims (13)
1. A pharmaceutical composition for preventing or treating macular degeneration or macular edema, comprising a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient:
wherein
the broken line denotes a single bond or a double bond, wherein
i) if the bond between C-3 and C-4 and the bond between C-5 and C-6 are single bonds, R2b is nonexistent and R2a is CH2;
ii) if the bond between C-3 and C-4 is a double bond, the bond between C-5 and C-6 is a single bond, R2b is nonexistent and R2a is CH3; or
iii) if the bond between C-5 and C-6 is a double bond, the bond between C-3 and C-4 is a single bond and R2a and R2b are CH3,
R1 is H or CH3,
R3 is a functional group selected from a group consisting of R3a through R3d,
in R3a,
i) each of R4 and R7 is OH or OCH3 and R5, R6 and R8 are H; or
ii) R5 is COOCH3, R is H or OH, R8 is OH and R4 and R are H,
in R3b,
R9 is a functional group selected from a group consisting of H, NH2, C1-C8 alkoxy and R9a through R9j and R10 is H or OH,
2. The pharmaceutical composition according to claim 1 , wherein, if the bond between C-3 and C-4 and the bond between C-5 and C-6 are single bonds, R2b is nonexistent, R2a is CH2 and R3 is a functional group selected from a group consisting of R3b through R3d.
3. The pharmaceutical composition according to claim 2 , wherein, in the functional group selected from a group consisting of R3b through R3d,
in R3b, R9 is selected from a group consisting of ethoxy, methoxy and R9a;
in R3c, R11 is OH, R12 is OCH3 and R13 is CH3; or
in R3d, R14 is OCH3 and R15 and R16 are CH3.
4. The pharmaceutical composition according to claim 3 , wherein the compound of Chemical Formula 1 is a compound selected from a group consisting of:
3-[[(1R,2S,4aS,8aS)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-4-hydroxy-5-(2-phenylethylamino)cyclohexa-3,5-diene-1,2-dione;
3-[[(1R,2S,4aS,8aS)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-2-hydroxy-5-methoxycyclohexa-2,5-diene-1,4-dione;
3-[[(1 S,2R,4aR,8aR)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-5-ethoxy-2-hydroxycyclohexa-2,5-diene-1,4-dione;
18-methoxy-22-methyl-16-[{(5 S,8S,9R,10S)-5,8,9-trimethyl-4-methylenedecahydronaphthalen-9-yl}methyl]benzo[d]-oxazol-17-ol; and
18-methoxy-22,22-dimethyl-16-[{(5R,8S,9R,10S)-5,8,9-trimethyl-4-methylenedecahydronaphthalen-9-yl}methyl]benzo[d]-oxazol-17(2H)-one.
5. The pharmaceutical composition according to claim 1 , wherein the composition is prepared into a formulation selected from a group consisting of an oral medication, an injection, an eye drop and an ointment.
6. A pharmaceutical composition for inhibiting vascular leakage in the eye, comprising a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient:
wherein
the broken line denotes a single bond or a double bond,
wherein
i) if the bond between C-3 and C-4 and the bond between C-5 and C-6 are single bonds, R2b is nonexistent and R2a is CH2;
ii) if the bond between C-3 and C-4 is a double bond, the bond between C-5 and C-6 is a single bond, R2b is nonexistent and R2a is CH3; or
iii) if the bond between C-5 and C-6 is a double bond, the bond between C-3 and C-4 is a single bond and R2a and R2b are CH3,
R1 is H or CH3,
R3 is a functional group selected from a group consisting of R3a through R3d,
in R3a,
i) each of R4 and R7 is OH or OCH3 and R5, R6 and R8 are H; or
ii) R5 is COOCH3, R7 is H or OH, R8 is OH and R4 and R6 are H,
in R3b,
R9 is a functional group selected from a group consisting of H, NH2, C1-C8 alkoxy and R9a through R9j and R10 is H or OH,
7. The pharmaceutical composition according to claim 6 , wherein, if the bond between C-3 and C-4 and the bond between C-5 and C-6 are single bonds, R2b is nonexistent, R2a is CH2 and R3 is a functional group selected from a group consisting of R3b through R3d.
8. The pharmaceutical composition according to claim 7 , wherein, in the functional group selected from a group consisting of R3b through R3d,
in R3b, R9 is selected from a group consisting of ethoxy, methoxy and R9a;
in R3c, R11 is OH, R12 is OCH3 and R13 is CH3; or
in R3d, R14 is OCH3 and R15 and R16 are CH3.
9. The pharmaceutical composition according to claim 8 , wherein the compound of Chemical Formula 1 is a compound selected from a group consisting of:
3-[[(1R,2S,4aS,8aS)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-4-hydroxy-5-(2-phenylethylamino)cyclohexa-3,5-diene-1,2-dione;
3-[[(1R,2S,4aS,8aS)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-2-hydroxy-5-methoxycyclohexa-2,5-diene-1,4-dione;
3-[[(1 S,2R,4aR,8aR)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-5-ethoxy-2-hydroxycyclohexa-2,5-diene-1,4-dione;
18-methoxy-22-methyl-16-[{(5 S,8S,9R,10S)-5,8,9-trimethyl-4-methylenedecahydronaphthalen-9-yl}methyl]benzo[d]-oxazol-17-ol; and
18-methoxy-22,22-dimethyl-16-[{(5R,8S,9R,10S)-5,8,9-trimethyl-4-methylenedecahydronaphthalen-9-yl}methyl]benzo[d]-oxazol-17(2H)-one.
10. A food composition for preventing or improving macular degeneration or macular edema, comprising a compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient:
wherein
the broken line denotes a single bond or a double bond, wherein
i) if the bond between C-3 and C-4 and the bond between C-5 and C-6 are single bonds, R2b is nonexistent and R2a is CH2;
ii) if the bond between C-3 and C-4 is a double bond, the bond between C-5 and C-6 is a single bond, R2b is nonexistent and R2a is CH3; and
iii) if the bond between C-5 and C-6 is a double bond, the bond between C-3 and C-4 is a single bond and R2a and R2b are CH3,
R1 is H or CH3,
R3 is a functional group selected from a group consisting of R3a through R3d,
in R3a,
i) each of R4 and R7 is OH or OCH3 and R5, R6 and R8 are H; or
ii) R5 is COOCH3, R7 is H or OH, R8 is OH and R4 and R6 are H,
in R3b,
R9 is a functional group selected from a group consisting of H, NH2, C1-C8 alkoxy and R9a through R9j and R10 is H or OH,
11. The food composition according to claim 10 , wherein, if the bond between C-3 and C-4 and the bond between C-5 and C-6 are single bonds, R2b is nonexistent, R2a is CH2 and R3 is a functional group selected from a group consisting of R3b through R3d.
12. The food composition according to claim 11 , wherein, in the functional group selected from a group consisting of R3b through R3d,
in R3b, R9 is selected from a group consisting of ethoxy, methoxy and R9a;
in R3c, R11 is OH, R12 is OCH3 and R13 is CH3; or
in R3d, R14 is OCH3 and R15 and R16 are CH3.
13. The food composition according to claim 12 , wherein the compound of Chemical Formula 1 is a compound selected from a group consisting of:
3-[[(1R,2S,4aS,8aS)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-4-hydroxy-5-(2-phenylethylamino)cyclohexa-3,5-diene-1,2-dione;
3-[[(1R,2S,4aS,8aS)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-2-hydroxy-5-methoxycyclohexa-2,5-diene-1,4-dione;
3-[[(1 S,2R,4aR,8aR)-1,2,4a-trimethyl-5-methylidene-3,4,6,7,8,8a-hexahydro-2H-naphthalen-1-yl]methyl]-5-ethoxy-2-hydroxycyclohexa-2,5-diene-1,4-dione;
18-methoxy-22-methyl-16-[{(5 S,8S,9R,10S)-5,8,9-trimethyl-4-methylenedecahydronaphthalen-9-yl}methyl]benzo[d]-oxazol-17-ol; and
18-methoxy-22,22-dimethyl-16-[{(5R,8S,9R,10S)-5,8,9-trimethyl-4-methylenedecahydronaphthalen-9-yl}methyl]benzo[d]-oxazol-17(2H)-one.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2016-0086331 | 2016-07-07 | ||
KR1020160086331A KR101674622B1 (en) | 2016-07-07 | 2016-07-07 | Novel Use of Sesquiterpene Derivatives |
PCT/KR2016/011558 WO2018008803A1 (en) | 2016-07-07 | 2016-10-14 | Novel use of sesquiterpene derivative |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2016/011558 A-371-Of-International WO2018008803A1 (en) | 2016-07-07 | 2016-10-14 | Novel use of sesquiterpene derivative |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/686,940 Continuation US10918625B2 (en) | 2016-07-07 | 2019-11-18 | Use of sesquiterpene derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190290617A1 true US20190290617A1 (en) | 2019-09-26 |
Family
ID=57528861
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/301,583 Abandoned US20190290617A1 (en) | 2016-07-07 | 2016-10-14 | Novel use of sesquiterpene derivative |
US16/686,940 Active US10918625B2 (en) | 2016-07-07 | 2019-11-18 | Use of sesquiterpene derivative |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/686,940 Active US10918625B2 (en) | 2016-07-07 | 2019-11-18 | Use of sesquiterpene derivative |
Country Status (8)
Country | Link |
---|---|
US (2) | US20190290617A1 (en) |
EP (1) | EP3482750B1 (en) |
JP (1) | JP6667681B2 (en) |
KR (1) | KR101674622B1 (en) |
CN (1) | CN109414416B (en) |
AU (1) | AU2016413709B2 (en) |
ES (1) | ES2929708T3 (en) |
WO (1) | WO2018008803A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101674622B1 (en) * | 2016-07-07 | 2016-11-09 | 국민대학교산학협력단 | Novel Use of Sesquiterpene Derivatives |
KR101800346B1 (en) | 2016-08-30 | 2017-11-22 | 국민대학교산학협력단 | Composition for Inhibiting Vascular Leakage in Retina |
TWI723344B (en) * | 2019-02-20 | 2021-04-01 | 安益藥業股份有限公司 | Uses of picrotoxane-type sesquiterpenes for preparing pharmaceutical composition with eye care effect |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2100124B1 (en) | 1994-08-01 | 1998-04-01 | Pharma Mar Sa | IMPROVEMENTS INTRODUCED IN IP 9401697 FOR TERPENO-QUINONAS WITH ANTITUMORAL ACTIVITY. |
WO2000015766A1 (en) * | 1998-09-16 | 2000-03-23 | Oncopharmaceutical, Inc. | Treatment of oncologic tumors with an injectable formulation of a golgi apparatus disturbing agent |
US20040072831A1 (en) * | 2001-10-12 | 2004-04-15 | Choongwae Pharma Corporation | Reverse-turn mimetics and method relating thereto |
US20090074668A1 (en) * | 2007-09-14 | 2009-03-19 | Farjo Rafal A | Vldlr-/- mouse models and related methods |
KR100905419B1 (en) * | 2008-09-11 | 2009-07-02 | 연세대학교 산학협력단 | Uses of sesquiterpene derivatives |
KR101059321B1 (en) * | 2008-11-07 | 2011-08-24 | 영남대학교 산학협력단 | Composition for the prevention and treatment of diseases caused by overexpression of MPM-X or MMP-2 containing sponge extract fraction as an active ingredient |
WO2012033353A2 (en) * | 2010-09-07 | 2012-03-15 | 서울대학교 산학협력단 | Sesterterpene compounds and use thereof |
EP2554662A1 (en) * | 2011-08-05 | 2013-02-06 | M Maria Pia Cosma | Methods of treatment of retinal degeneration diseases |
US10010610B2 (en) | 2014-01-16 | 2018-07-03 | Retinal Therapies, LLC | Compositions and methods for the treatment of intraocular neovascularization and/or leakage |
KR101674622B1 (en) * | 2016-07-07 | 2016-11-09 | 국민대학교산학협력단 | Novel Use of Sesquiterpene Derivatives |
KR101800346B1 (en) * | 2016-08-30 | 2017-11-22 | 국민대학교산학협력단 | Composition for Inhibiting Vascular Leakage in Retina |
KR101692378B1 (en) * | 2016-09-20 | 2017-01-03 | 국민대학교산학협력단 | Novel Use of Sesquiterpene Derivatives |
-
2016
- 2016-07-07 KR KR1020160086331A patent/KR101674622B1/en active IP Right Grant
- 2016-10-14 CN CN201680087442.1A patent/CN109414416B/en active Active
- 2016-10-14 ES ES16908245T patent/ES2929708T3/en active Active
- 2016-10-14 EP EP16908245.0A patent/EP3482750B1/en active Active
- 2016-10-14 WO PCT/KR2016/011558 patent/WO2018008803A1/en unknown
- 2016-10-14 AU AU2016413709A patent/AU2016413709B2/en active Active
- 2016-10-14 JP JP2018568856A patent/JP6667681B2/en active Active
- 2016-10-14 US US16/301,583 patent/US20190290617A1/en not_active Abandoned
-
2019
- 2019-11-18 US US16/686,940 patent/US10918625B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3482750A4 (en) | 2020-04-15 |
EP3482750B1 (en) | 2022-09-28 |
KR101674622B1 (en) | 2016-11-09 |
JP6667681B2 (en) | 2020-03-18 |
CN109414416B (en) | 2021-03-26 |
US10918625B2 (en) | 2021-02-16 |
CN109414416A (en) | 2019-03-01 |
JP2019524686A (en) | 2019-09-05 |
US20200078338A1 (en) | 2020-03-12 |
WO2018008803A1 (en) | 2018-01-11 |
ES2929708T3 (en) | 2022-12-01 |
AU2016413709A1 (en) | 2019-01-17 |
AU2016413709B2 (en) | 2019-07-11 |
EP3482750A1 (en) | 2019-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10918625B2 (en) | Use of sesquiterpene derivative | |
KR102338093B1 (en) | Composition for preventing, improving or treating eye diseases comprising (7S)-(+)-cyclopentyl carbamic acid, 8,8-dimethyl-2-oxo-6,7-dihydro-2H,8H-pyrano[3,2-g]chromen-7-yl-ester as an active ingredient | |
US20160067209A1 (en) | Pterocarpan compound or pharmaceutically acceptable salt thereof and pharmaceutical composition for prevention or treatment of metabolic disease or complication thereof, or for antioxidant containing the same as an active ingredient | |
WO1999064424A1 (en) | Therapeutic agents | |
KR101800346B1 (en) | Composition for Inhibiting Vascular Leakage in Retina | |
KR100704299B1 (en) | Novel quinoline compound, and composition containing centipede extract or compounds isolated therefrom for prevention and treatment of cardiovascular disease | |
KR101692378B1 (en) | Novel Use of Sesquiterpene Derivatives | |
WO2021025103A1 (en) | Composition for inhibiting reduction of testosterone and/or dihydrotestosterone | |
US20130041023A1 (en) | Composition for Preventing or Treating Rotavirus Infection Comprising Licorice Extract | |
TW518221B (en) | Antiallergic agent and antiallergic foods or drinks comprising 4,5-dihydroxy-2-cyclopenten-1-one or its optical activators or their salts | |
KR20160137808A (en) | Anti-cancer adjuvant comprising panaxadiols compound | |
JPWO2006030907A1 (en) | Retinal protective agent | |
KR101051085B1 (en) | Parkinson's disease prevention and treatment composition containing cinnamon extract, fractions thereof or trans-cinnaaldehyde isolated from cinnamon as an active ingredient | |
US8785503B2 (en) | Biphenyl compound or pharmaceutically acceptable salt thereof, method for preparing novel biphenyl compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient for preventing or treating diabetes complications | |
KR101642291B1 (en) | Composition for Preventing or Treating Breast Cancer Diseases Comprising Ramalin | |
US8686031B2 (en) | Flavonoids and uses thereof | |
US11168092B2 (en) | Compounds and method of preventing or treating cancer using the same | |
CA2862807A1 (en) | Opsin-binding ligands, compositions and methods of use | |
US20240216462A1 (en) | Pharmaceutical composition for enhancing immunity or anti-cancer activity including extract of pseudolysimachion nakaianum (ohwi) t.yamaz as active ingredient | |
KR101448116B1 (en) | Composition comprising DDMP group soyasaponin for preventing or treating obesity or lipid related metabolic disease | |
KR20140018706A (en) | Composition comprising extract of fermented curcuma longa by natural fermented soybean and curcuminoid derivatives isolated therefrom for treating or preventing liver disease | |
KR20230073533A (en) | Composition containing red ginseng saponin extract for preventing or treating age-related macular degeneration | |
KR100806226B1 (en) | A composition for the prevention and treatment of cardiovascular disease containing extract of Glycine max Roots or polypenol compounds isolated thereof | |
US20210299103A1 (en) | Composition for preventing or treating cancer, comprising sulfonamide derivative as active ingredient | |
KR101677083B1 (en) | Anti-inflammatory active composition and pharmaceutical composition comprising the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: KOOKMIN UNIVERSITY INDUSTRY ACADEMY COOPERATION FO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:OH, SANGTAEK;REEL/FRAME:047499/0927 Effective date: 20181114 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |